CURRICULUM VITAE

Hagop M. Kantarjian, M. D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Vice President for Global Academic Programs, The University of Texas MD Anderson Cancer Center, Houston, TX

Kelcie Margaret Kana - Research Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1515 Holcome Blvd.
Unit Number: 428
Houston, TX 77030
Room Number: FC4.3042
Phone: (713) 792 7026
Fax: (713) 792 2031
Email: hkantarj@mdanderson.org

EDUCATION

Degree-Granting Education

American University of Beirut, Beirut, Lebanon, BaccalaureateII, 1972

American University of Beirut, Beirut, Lebanon, BS, 1975, Science

American University of Beirut, Beirut, Lebanon, MD, 1979, Medicine

American University of Beirut, Beirut, Lebanon, Internal Medicine, 1981, Internal Medicine

The University of Texas MD Anderson Cancer Center, Houston, TX, Medical Oncology Subspecialty, 1983, Hematology/Oncology

Postgraduate Training

Straight Intern, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon, 1978−1979

Junior Resident, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon, 1979−1980

Senior Resident, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon, 1980−1981

CREDENTIALS

Board Certification

American Board of Internal Medicine Certification, 1983

American Board of Medical Oncology Certification, 1985

American Board of Hematology Certification, 1990

Licensures

Active

TX, G5239, 2011−2013

Inactive

N/A

EXPERIENCE/SERVICE

Academic Appointments

Fellow, Department of Developmental Therapeutics, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1981−1983

Faculty Associate, Department of Hematology, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1983−1984

Assistant Professor, Department of Hematology, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1984−1988

Associate Professor, Department of Hematology, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1988−1993

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993−present

Administrative Appointments/Responsibilities

Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1995−present

Other Appointments/Responsibilities

Associate Vice President for Global Academic Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2010−present

Non-resident Scholar for Healthcare Policies, Rice University's Baker Institute for Public Policy, Houston, TX, 11/2013−12/2015

Endowed Positions

Kelcie Margaret Kana - Research Chair, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998−present

Consultantships

N/A

Military or Other Governmental Service

N/A

Institutional Committee Activities

Infection Control Committee, Committee Member, 1985−1986

Research Committee, Committee Member, 1986−1987

Medical Record Committee, Alternate Member, 1987−1988

Nursing Liaison Committee, Committee Member, 1987−1988

Medical Record Committee, Committee Member, 1988−1991

Surveillance Committee, Alternate Member, 1991

Surveillance Committee, Committee Member, 1992−1996

Search Committee for Chairman, Department of Hematology, Committee Member, 1993

Clinical Research Committee, Committee Member, 1994−present

Search Committee for Director of Hematopathology, Committee Member, 1994

Surveillance Committee, Vice Chairman, 1995−1996

Executive Committee of the Faculty Senate, Committee Member, 1995−present

Credentials Committee of the Medical Staff, Committee Member, 1997−1998

Promotion and Tenure Committee, Co-Chair, 1999−2000

Search Committee, Department of Melanoma, Chair, 1999−2000

Physicians Referral Service Executive Council, Committee Member, 1999−present

Subcommittee of the Faculty Achievement Award Parent Committee, Chair, 2000

Chair Search, Department of Laboratory Medicine, Committee Member, 9/2007−9/2008

Global Academic Programs Steering Committee, Committee Member, 1/2010−present

HONORS AND AWARDS

Lange Award, 1976

Alpha Omega Alpha Honor Medical Society, American University of Beirut Chapter,Beirut, Lebanon, 1979

Penrose Award, 1979

Fellow Research Award, UT M.D. Anderson Cancer Center, 1982, 1983

Fellow, Leukemia Society of America, 1984

Special Fellow, Leukemia Society of America, 1985−1987

Scholar, Leukemia Society of America, 1989−1994

First Emil J Freireich Award for Outstanding Clinical Research, UT M.D. Anderson Cancer Center, 1997

Outstanding Service to Mankind Award, Leukemia Society of America, 1997

Kelcie Margaret Kana Research Chair, UT M.D. Anderson Cancer Center, 1998

AUB Medical Alumni Gold Metal Award, The American University of Beirut Medical Center, 1999

Faculty Achievement Award for Clinical Research, UT M.D. Anderson Cancer Center, 1999

America’s Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011

The Division of Cancer Medicine, MD Anderson Cancer Center "John Mendelsohn Lifetime Scientific Achievement Award," MD Anderson Cancer Center, 2008

The Division of Cancer Medicine, MD Anderson Cancer Center 'Waun Ki Hong Award for Excellence in Team Science," MD Anderson Cancer Center, 2008

Best Doctors in America 2009-2010, Best Doctors, 2009−2010

Ben Qurrah Award, 2010

Robert A. Kyle Award for Outstanding Clinician Scientist, Mayo Clinic, 2011

37th Jeffrey A Gottlieb Memorial Award, 2012

AAAS Fellow, AAAS Council, 2012

Grinberg-Wisch Lecture Award, Mount Sinai School of Medicine, 2012

Hematologic Malignancies 2012 Distinguished Lecturer Award, Houston, Texas, October, 2012

Top 1% of Physicians, US News and World Report, 2012

WAAAUB Distinguished Alumni Award, American University of Beirut, 2012

2013 Joseph H. Burchenal Memorial Award, American Association for Cancer Research, 2013

RESEARCH

Grants and Contracts (past 5 years)

Funded

Consultant, Phase I Studies of Targeted Anti-Cancer Therapies; Clinical Core, 5 U01 CA062461-16, NIH/NCI, PI - Razelle Kurzrock, M.D., 3/1/1994−2/28/2013, $1,430,020 ($286,004/year)

Mentor, Research Training in Academic Medical Oncology, 5 T32 CA009666-17, NIH/NCI, PI - Waun K. Hong, M.D., 9/30/1994−4/30/2015, $1,860,692 ($331,789/year)

Principal Investigator, 27%, The University of Texas MD Anderson Cancer Center SPORE in Leukemia, 5 P50 CA100632-10, NIH/NCI, 8/1/2003−4/30/2014, NCE, $5,972,800 ($1,194,560/year)

Co-Investigator, 1%, Full Member Application Affiliated with SWOG, 5 U10 CA105409-08, NIH/NCI, PI - Edward Kim, M.D., 7/26/2004−12/31/2015, $1,311,848 ($206,130/year)

Principal Investigator, 1%, 2005-0048: Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Oral AMN107, CS2005 - 13985, Novartis, 2/11/2005−12/31/2013, $400,200 ($88,933/year)

Principal Investigator, 1%, 2004-0817: Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical CMML, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk AML-MDS, Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With BMS-354825, CS2005-14875, Bristol-Myers Squibb, 11/2/2005−12/31/2014, $960,200 ($86,418/year)

Principal Investigator, 1%, 2005-0647: Randomized Phase 3 Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia, CS2006-15536, MGI, 11/11/2005−12/31/2014, $576,500 ($64,056/year)

Principal Investigator, 1%, 2006-0686: Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) with or without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia, CS2007-19450, MGI, 2/7/2007−7/18/2016, $480,500 ($53,389/year)

Co-Project Leader, 5%, Therapy of AML: Project 4: Clinical Trials in AML, 5P01 CA55164-19, NIH/NCI, PI - Michael Andreeff, M.D., Ph.D., 9/20/2007−8/31/2013, NCE, $939,310 ($181,633/year)

Principal Investigator, 1%, 2007-0727: A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, CS2008-22450, Cyclacel, 12/1/2007−12/31/2014, $736,680 ($105,240/year)

Principal Investigator-MDACC, 1%, 2008-0249: A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS), CS2008-24075, Amgen, 8/7/2008−8/31/2016, $486,718 ($96,817/year)

Program Leader, 1%, SPORE in Leukemia Career Development Program, 5 P50 CA100632-10, NIH/NCI, 9/1/2008−4/30/2014, NCE, $468,665 ($93,733/year)

Core Leader, 5%, SPORE in Leukemia Core A: Administrative Core, 5 P50 CA100632-10, NIH/NCI, 9/1/2008−4/30/2014, NCE, $482,280 ($96,456/year)

Program Leader, 1%, SPORE in Leukemia Developmental Research Program, 5 P50 CA100632-10, NIH/NCI, 9/1/2008−4/30/2014, NCE, $497,975 ($99,595/year)

Project Leader, 10%, SPORE in Leukemia Project 1: Epigenetics and Epigenetic Therapy in AML, 5 P50 CA100632-10, NIH/NCI, 9/1/2008−4/30/2014, NCE, $1,420,130 ($284,026/year)

Project Leader, 10%, SPORE in Leukemia Project 5: Development of Sapacitabine Therapy in Leukemias, 5 P50 CA100632-10, NIH/NCI, 9/1/2008−4/30/2014, NCE, $862,380 ($172,476/year)

Principal Investigator-MDACC, 1%, 2009-0046: Study PMA112509, a Phase I/II CT Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia after MDS (sAML/MDS), CS2009-27020, Glaxo Smith-Kline, 2/16/2009−2/28/2014, $226,793 ($45,359/year)

Internal Advisory Board Member, Lymphoma SPORE, 5 P50 CA136411-02, NIH/NCI, PI - Larry Kwak, M.D., 9/1/2009−8/31/2013, NCE, $145,794 ($48,598/year)

Principal Investigator-MDACC, 1%, 2009-1002: A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia, CS2010-31386, Cyclacel, 1/1/2010−1/31/2015, $278,980 ($130,120/year)

Principal Investigator-MDACC, 1%, 2009-0872: Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) with CMC-544 (Inotuzumab Ozogamycin), with or without Later Addition of Rituximab, CS2010-31381, Pfizer, 4/1/2010−3/31/2015, $241,200 ($81,061/year)

Co-Program Leader, 5%, The Therapy of CML Core A: Administrative Core, 5 P01 CA049639-22, NIH/NCI, PI - Richard Champlin, M.D., 7/1/2010−6/30/2015, $1,169,020 ($233,804/year)

Co-Investigator, 5%, The Therapy of CML: Project 1: Improving Cytogenetic and Molecular Complete Responses Using High Dose Imatinib Meyslate (Gleevec; ST1571) with or without PEG-Interferon Alpha 2B and GM-CSF, 5 P01CA049639-22, NIH/NCI, PI - Richard Champlin, M.D., 7/1/2010−6/30/2015, $893,700 ($176,027/year)

Principal Investigator, 1%, 2009-1000: Phase I Study of 4'-Thio-araC in Patients with Advanced Hematologic Malignancies, CS2010-31396, Access, 7/13/2010−6/30/2016, $561,200 ($282,906/year)

Principal Investigator-MDACC, 1%, 2010-0727: A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia, CS2011-33864, Cyclacel, 10/1/2010−9/30/2015, $211,500 ($425,569/year)

Principal Investigator, 1%, 2010-0615: A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), CS2011-33711, Supergen, 11/17/2010−11/16/2015, $789,729 ($394,864/year)

Principal Investigator, 1%, 2010-0736: A Phase II Study of Omacetaxine (OM) and Low Dose Cytarabine (LDAC) in Older Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS), CS2011-34261, ChemGenex, 2/25/2011−8/31/2016, $81,200 ($40,600/year)

Principal Investigator, 1%, 2010-0991: Treatment of Acute Lymphoblastic Leukemia (ALL) in Patients with Low-Intensity Chemotherapy and Inotuzumab Ozogamycin (CMC-544), CS2011-00034843, Pfizer, 7/25/2011−7/24/2014, $385,200 ($128,400/year)

Principal Investigator, 1%, 2011-0369: A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Acute Leukemias and Related Disorders, CS2011-35150, Amgen, 8/19/2011−8/18/2016, $319,654 ($63,931/year)

Principal Investigator-MDACC, 1%, 2011-0287: Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) with SAR3419 (CD19 Monoclonal Antibody Conjugated to Maytansine), CS2011-35139, Sanofi-Aventis, 9/9/2011−9/8/2016, $841,894 ($168,389/year)

Principal Investigator, 1%, 2011-0784: An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), CS2012-35820, Micromet, 12/15/2011−12/14/2016, $652,540 ($130,508/year)

Principal Investigator, 1%, 2012-0151: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22- Positive Acute Lymphoblastic Leukemia (ALL), CS2012-36507, Pfizer, 8/1/2012−7/31/2017, $429,868 ($85,974/year)

Principal Investigator, 1%, 2012-0262: A Phase I/II Study of DFP-10917 Given by Continuous Infusion in Patients with Relapsed or Refractory Acute Leukemia, CS2012-36689, Delta Fly, 8/9/2012−8/8/2017, $286,940 ($57,388/year)

Co-Principal Investigator, 1%, 2012-0534: Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis and Anemia, CS2012-37069, Celgene, PI - Srdan Verstovsek, MD, PhD, 10/10/2012−10/9/2017, $257,200 ($51,440/year)

Co-Program Leader, 5%, Cancer Center Support Grant: Hematologic Malignancies Program, 2 P30 CA016672-37, NIH/NCI, PI - Ronald dePinho, M.D., 7/1/2013−6/30/2018, $77,530 ($15,506/year)

Principal Investigator, 1%, 2013-0144: An Open-Label, Phase 1 Study of Inotuzumab Ozogamicin in Subjects with Relapsed or Refractory CD22-Positive Acute Lymphocytic Leukemia, 8186, Pfizer, 7/5/2013−7/4/2018, $511,356 ($102,271/year)

Pending

Program Leader, 3.3%, SPORE in Leukemia Career Development Program, 2P50 CA100632-11, NIH/NCI, 5/1/2013−4/30/2018, $500,000 ($100,000/year)

Core Leader, 5%, SPORE in Leukemia Core A: Administration, 2P50 CA100632-11, NIH/NCI, 5/1/2013−4/30/2018, $607,330 ($121,466/year)

Program Leader, 1%, SPORE in Leukemia Developmental Research Program, 2 P50CA100632-11, NIH/NCI, 5/1/2013−4/30/2018, $500,000 ($100,000/year)

Program Leader, 10%, SPORE in Leukemia Project 1: Epigenetics and Epigenetic Therapy in AML, 2P50 CA100632-11, NIH/NCI, 5/1/2013−4/30/2018, $1,710,395 ($342,079/year)

Principal Investigator, 1%, 2012-1090: Phase I Study of Imetelstat (GRN163L) in Patients with Advanced Hematologic Malignancies, 7420, Pfizer

Other

Principal Investigator-MDACC, 1%, 2008-0519: A Phase I Study of DT2219ARL (IND# 100780), a Bispecific Single Chain Immunotoxin for the Treatment of CD19 (+), CD 22 (+) B-Lineage Acute Lymphoblastic Leukemia, drug only, CS2009-26017, University of Minnesota, 1/10/2009−12/31/2010

Completed

Co-Investigator, 5%, Therapy of CML - Project 1: Improving Cytogenetic and Molecular Complete Responses Using High-Dose Imatinib Mesylate with or without PEG-Interferon

Alpha 2B and GM-CSF, 5P01 CA49639-19, NIH/NCI, PI - Richard Champlin, M.D., 12/1/1998−6/30/2010 ($169,994/year)

Principal Investigator, 1%, DM02-089: An open-label, randomized phase II (proof of concept) trial of PKC412 monotherapy in patients with acute myeloid leukemia (AML) and patients with high-risk myelodysplastic syndrome (MDS) with either wild type or mutated FLT3, CS2002-6899, Novartis, 3/22/2002−6/30/2013, $185,417 ($19,181/year)

Principal Investigator, 1%, 2004-0251: A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec®-resistant CML in accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hematologic malignancies, CS2004-11619, Novartis, 6/1/2004−8/31/2013, $3,449,532 ($684,328/year)

Principal Investigator, 2004-0675 “Phase II Study of Liposomal Annamycin in Patients with Refractory or Relapsed Acute Lymphocytic Leukemia (ALL)”, CS2005-13599, Callisto, 4/6/2005−4/8/2009, $288,200

Principal Investigator, 20%, New Approaches to the Biology and Treatment of MDS, P01 CA108631, NIH/NCI, 6/21/2005−5/31/2011, $76,747,870 ($1,534,956/year)

Principal Investigator, 2005-0295 "Phase 1B open-label, multicenter clinical study of the safety and activity of intravenous administration of SNS-595 in patients with advanced hematologic malignancies”, CS2005 - 14689, Sunesis, 8/8/2005−4/14/2010 ($26,933/year)

Principal Investigator, 2004-0817: Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical CMML, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk AML-MDS, Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis with BMS-354825, CS2005-14879, Bristol-Meyers Squibb, 11/2/2005−11/2/2008, $960,200

Principal Investigator, 1%, 2005-0768: A Phase I Pharmacologic Study of Oral Sapacitabine in Patients with Advanced Leukemias or Myelodysplastic Syndromes, CS2006-15918, Cyclacel, 12/20/2005−12/20/2014, $272,500 ($30,278/year)

Co-Investigator, 5%, Early Therapeutics Development with Phase II Emphasis, N01 CM 62202, NIH/NCI, PI - David Stewart, M.D., 1/1/2006−12/31/2011

Principal Investigator, 2005-0941: Phase 2 Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Advanced-Stage Myelodysplastic Syndromes (The ADOPT [Alternative Dosing for Outpatient Treatment] Trial), CS2006-16305, MGI, 1/3/2006−6/30/2011, $104,500 ($23,463/year)

Principal Investigator, 1%, 2005-0535: Phase II Randomized Study of Two Different Schedules of Intravenous Clofarabine in Myelodysplastic Syndrome (MDS)”, CS2005-15736, Genzyme, 1/3/2006−1/3/2012, $271,124 ($54,641/year)

Principal Investigator, 2005-0721: A Multicenter, Open-Label, Phase 2 Study of the Efficacy of FG-2216 in Subjects with Lower-Risk Myelodysplastic Syndromes (MDS), CS2005-15622, Fibrogen, 1/15/2006−1/31/2009, $117,500

Principal Investigator, 1%, 2005-0536: Phase II Study of Oral Clofarabine in Myelodysplastic Syndrome (MDS), CS2005-15737, Genzyme, 2/16/2006−12/6/2012, $338,280 ($38,722/year)

Principal Investigator, 2005-0577: An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Subjects with Thrombocytopenia and Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS), CS2006-16203, Amgen, 3/3/2006−11/25/2009, $230,960 ($45,843/year)

Principal Investigator, 1%, Genzyme Clinical Fellowship in Leukemia, CS2006-16368, Genzyme, 5/31/2006−5/31/2011, $50,000 ($10,077/year)

Principal Investigator, 1%, 2006-0278: A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INNO-406 in Adult Patients with

Imatinib-resistant or intolerant Philadelphia Chromosome-positive (Ph+) Leukemias, CS2006-17379, Innovive, 6/1/2006−6/30/2013, $876,978 ($145,307/year)

Principal Investigator, 1%, 2006-0177: A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and preliminary efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients with Relapsed or Refractory Acute Leukaemias, Chronic Myeloid Leukaemia or High-Risk Myelodysplastic Syndromes, CS2006-16460, Astex, 6/22/2006−1/31/2013, $808,236 ($134,706/year)

Principal Investigator, 1%, 2006-0654: A Phase II Study of Single Agent Clofarabine In Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit, CS2006-18553, Genzyme, 9/27/2006−11/27/2011, $395,300 ($79,666/year)

Co-Investigator, 5%, Biomarkers of CDDO Efficacy in Leukemia, R6149-07 01, Leukemia and Lymphoma Society, PI - Marina Konopleva, M.D., 10/1/2006−9/30/2009 ($180,018/year)

Principal Investigator, 1%, 2006-0285: A Phase I/II, Open-Label, Multi-centre, 2-part study to assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1152 in Patients with Relapsed Acute Myeloid Leukaemia, CS2006-17416, AstraZeneca, 10/1/2006−12/2/2009, $141,260

Co-Investigator, 1%, 2006-0796: A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide, CS2007-19075, AstraZeneca, 12/14/2006−7/7/2010, $386,000

Principal Investigator, 1%, 2007-0287:A Phase I/II, Open-Label, Multi-Center, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD4877 Administered on Days 1, 2 and 3 in Adult Patients with Recurrent or Refractory Acute Myelogenous Leukemia (AML), CS2007-20819, AstraZeneca, 7/1/2007−2/1/2010, $250,500 ($70,414/year)

Principal Investigator, 1%, 2007-0410: A Phase IIa, Open-label, Randomized Dose Confirmation Study of Oral Clofarabine in Previously Treated Adult Patients with Myelodysplastic Syndromes (MDS), CS2007-21405, Genzyme, 8/20/2007−11/30/2011, $207,700 ($41,858/year)

Co-Investigator, 1%, Randomized study of combined epigenetic therapy, 5R01 CA121104-05, NIH/NCI, PI - Jean-Pierre Issa, M.D., 9/1/2007−7/31/2012 ($192,000/year)

Consultant, Phase I Study of 5-Aza-2'-Deoxycitidine in Acute Lymphocytic Leukemia, R21 CA126457, NIH/NCI, PI - Guillermo Garcia-Manero, M.D., 9/12/2007−8/31/2010, $380,000 ($190,000/year)

Principal Investigator, 1%, 2007-0634: Phase I-II Study of Bendamustine in Patients with Acute Leukemia and High-Risk Myelodysplastic Syndrome (MDS), CS2008-21995, Cephalon, 11/27/2007−11/30/2014, $582,900 ($83,271/year)

Principal Investigator, 1%, ID03-0180: Data sharing agreement "Phase II Randomized Study of Three Different Schedules of Low-Dose Decitabine (5-AZA-2-Deoxycytidine) in Myelodysplastic Syndrome (MDS), CS2008-22448, Johnson & Johnson, 12/4/2007−12/31/2008, $102,400

Principal Investigator, 1%, Data sharing agreement 2004-0468 "Phase II Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) Post Azacytidine (AZA) Failure," CS2008-22984, Johnson & Johnson, 12/11/2007−12/31/2008, $38,400

Principal Investigator-MDACC, 1%, 2007-0879: A Phase 1/2 Study of ARRY-520 in Patients with Advanced Myeloid Leukemia, CS2008-22793, Array Pharmaceuticals, 1/28/2008−12/31/2011, $405,021 ($123,567/year)

Principal Investigator, 1%, 2007-0264: An Open Label Extension Study Evaluating the Safety of Long Term Dosing of AMG 531 in Thrombocytopenic Subjects with Myelodysplastic

Syndromes (MDS), CS2007-20650, Amgen, 11/27/2008−11/30/2012, $246,201 ($57,126/year)

Principal Investigator-MDACC, 1%, 2009-0172: A Phase I CT, open-label, multi-centre, multiple ascending dose study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML), CS2009-28065, Astrazenaca, 5/6/2009−2/1/2012, $161,200 ($108,054/year)

Principal Investigator-MDACC, 1%, 2009-0217: A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in patients aged >/= 60 with newly diagnosed acute myeloid leukaemia (AML) who are considered unsuitable to receive intensive induction chemotherapy regimens, CS2009-28299, Astrazeneca, 6/1/2009−5/31/2014, $439,120 ($88,546/year)

Principal Investigator, 1%, 2009-0539: A Phase 1, Open-Label, Multi-Center, Multi-Dose Study of MDX-1342 Monotherapy in Subjects with CD19-Positive Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Medarex, 4/27/2010−4/30/2011, $9,200 ($9,200/year)

Principal Investigator-MDACC, 1%, 2009-0791: Phase IV Randomized Open-Label Two-Arm Study Comparing the Efficacy and Safety of DACOGEN® (Decitabine) for Injection and VIDAZA® (Azacitidine) among Subjects with Intermediate or High Risk MDS, CS2010-31119, Eisai, 8/20/2010−12/17/2010, $140,017 ($28,234/year)

Not Funded

Co-Investigator, 5%, Clinical Studies of Safety and Effectiveness of Orphan Products; Research Project Grant (R01) “DT2219ARL Bispecific Immunotoxin Treatment of Relapsed Acute Lymphoblastic Leukemia”, 1 R01 FD003750-01, Food and Drug Administration (FDA), PI - Stanley R. Frankel, M.D., Scott & White, 11/1/2009−10/31/2012, $170,954 ($55,309/year)

Principal Investigator, 30%, Identifying Mechanisms of Resistance and Overcoming Resistance in ALL, RP101320, Cancer Prevention & Research Institute of Texas (CPRIT), 8/1/2010−7/31/2015, $10,273,459 ($1,977,688/year)

Principal Investigator, Identifying Mechanisms of Resistance and Overcoming Resistance in ALL, RP101320, Cancer Prevention & Research Institute of Texas (CPRIT), 5/1/2011−4/30/2016, $9,569,525 ($1,813,080/year)

Principal Investigator, 15%, Identifying Mechanisms of Resistance and Overcoming Resistance in ALL; Administration Core, RP110597/RP110613, Cancer Prevention & Research Institute of Texas (CPRIT), 5/1/2011−4/30/2016, $786,100 ($148,064/year)

Principal Investigator, 15%, Identifying Mechanisms of Resistance and Overcoming Resistance in ALL; C1 Clinical Core, RP110597/RP110610, Cancer Prevention & Research Institute of Texas (CPRIT), 5/1/2011−4/30/2016, $697,625 ($131,400/year)

Other Significant Contributor, The Effect of Hypoxia and Stroma on Resistance in Acute Myelogenous Leukemia Stem Cells, 1R21CA161675-01, NIH/NCI, PI - Steven Kornblau, M.D., 7/1/2011−6/30/2013, $275,000 ($150,000/year)

Co-Investigator, 5%, Optimal personalized dynamic treatment regimes for recurrent diseases, 1R01 CA163717-01, NIH/NCI, PI - Xuelin Huang, PhD, 9/1/2011−8/31/2016, $1,326,176 ($264,383/year)

Co-Investigator, 5%, A new analytic approach to optimal personalized treatments for recurrent diseases, 01, Patient-Centered Outcomes Research Institute, PI - Xuelin Huang, Ph.D, 6/1/2012−5/31/2014, $491,763 ($245,882/year)

Co-Investigator, 5%, A new analytic approach to optimal personalized treatments for recurrent diseases, 01, Patient-Centered Outcomes Research Institute, PI - Xuelin Huang, PhD, 6/1/2012−5/31/2014, $491,673 ($245,837/year)

Co-Investigator, 5%, Optimal personalized dynamic treatment regimes for recurrent diseases, 1R01 CA163717-01A1, NIH/NCI, PI - Xuelin Huang, Ph.D., 7/1/2012−6/30/2017, $1,000,000 ($200,000/year)

Co-Investigator, 5%, Optimal personalized dynamic treatment regimes for recurrent diseases, RP130021, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Xuelin Huang, PhD, 12/1/2012−11/30/2015, $915,721 ($305,240/year)

Co-Investigator, 5%, Optimal personalized dynamic treatment regimes for recurrent diseases, 1R01 CA163717-01A1, NIH/NCI, PI - Xuelin Huang, Ph.D., 4/1/2013−3/31/2015, $250,000 ($125,000/year)

Co-Investigator, 5%, Statistical methods for optimizing multi-stage cancer treatments, 1R21 CA176508-01, NIH/NCI, PI - Xuelin Huang, PhD, 4/1/2013−3/31/2015, $250,000 ($125,000/year)

Co-Investigator, 3%, The Therapy of AML Core A: Clinical Trials Core, 2P01 CA055614-20, NIH/NCI, PI - Michael Andreeff, MD, PhD, 4/1/2013−3/31/2018, $998,890 ($199,778/year)

Co-Investigator, 1%, A TP53/miR-155/BCL2/miR-181 circuitry controlling resistance to therapy in adult B-cell acute lymphoblastic leukemia, 01, Elsa Pardee Foundation, PI - George Calin, PhD, 12/1/2013−11/30/2014, $119,456 ($119,456/year)

Protocols

Funded

Principal Investigator, A Phase II Study of FMdC in Patients with Hematologic Malignancies, DM99-209, 1999−2001, Matrix

Principal Investigator, Phase I Study of 2-Chloro-2' -Fluoro-Deoxy-9-B-D Arabinofuranosyladenine (CL-F-ARA-A) in Solid and Hematologic Malignancies, DM93-036, 1999−2001, FDA

Principal Investigator, Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Oral-9-Nitro-20-(S)-Camptothecin (9NC), DM99-087, 2000, Supergen

Principal Investigator, Tiazofurin Phase III Study in Patients with CML in Accelerated Phase or Blast Crisis, DM00-102, 2000−2001, ICN

Principal Investigator, Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Refractory Hematologic Cancers, DM00-349, 2000−2003, Janssen

Principal Investigator, A Phase I/II Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635) Salvage Therapy for the Treatment of Refractory Acute Promeylocytic Leukemia, DM01-265, 2001−2003, ChemGenex

Principal Investigator, Phase II Study of Clofarabine in Acute Leukemia and Myelodysplastic syndrome (MDS) Refractory to Therapy or in Relapse, ID00-038, 2001−2003, Ilex

Principal Investigator, Phase I Study of Clofarabine in Solid and Hematologic Malignancies, ID99-031, 2001−2004, Oncopharm

Co-Principal Investigator, Total Salvage Therapy for Refractory Acute Promyelocytic Leukemia (APL) including Arsenic Trioxide (As2O3), All-Trans Retinoic Acid (ATRA), and Mylotarg, ID00-424, PI - Cortes, 2001−2008, CTI

Co-Principal Investigator, Therapy for Frontline Acute Promyelocytic Leukemia (APL) with All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3), ID01-014, PI - Ravandi, 2001−present, CTI

Principal Investigator, Prospective Clinical Study of Patients Who Have Received and Discontinued Investigational Treatment on Protocol DM97-229 "Therapy of Early Chronic PH Chronic Myleogenous Leukemia (CML) Alpha Interferon, Low-Dose Cytosine Arabinoside and Homoharringtonine, DM02-362, 2002−2004, FDA

Principal Investigator, An Open-Label, Randomized Phase II (Proof of Concept) Trial of PKC412 Monotherapy in Patients with Acute Myeloid Leukemia (AML) and Patients with High Risk Myelodysplastic Syndrome (MDS) with Either Wild Type or Mutated FLT3 (Novartis Trial PKC412 2104), DM02-089, 2002−2007, Novartis

Principal Investigator, Phase I Dose-Escalation Study to Determine Safety, Pharmacokinetics & Pharmacodynamics of BMS-354825 in Treatment of Pts w/Chronic Accelerated or Blast Phase CML or Philadelphia Chromosome + ALL w/Hematologic Resistance to Imatinib Mesylate (Gleevec), ID03-240, 2003−2006, Bristol Myers Squibb

Principal Investigator, Phase II Randomized Study of Three Different Schedules of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS), ID03-0180, 2003−2009, MGI

Collaborator, Phase I-II study of idarubicin, cytarabine and R115777 (tipifarnib, zarnestra; 702818; IND 58359), a farnesyltransferase inhibitor, in patients with high-risk myelodysplastic syndromes and acute myeloid leukemias, 2003-0563, PI - Jorge Cortes, MD, 2003−2010, NCI

Principal Investigator, A Phase I/II Study of ALIMTA (pemetrexed) in Patients With Relapsed or Refractory Acute Leukemia or Lymphoid Blast Phase CML, 2004-0873, 2004−2007, Eli Lilly

Principal Investigator, A Randomized, Multicenter, Open-Label, Modified Dose-Ascension, Parallel Study of the Safety, Tolerability, and Efficacy of Oral SCIO-469 in Patients with Myelodysplastic Syndromes, 2004-0790, 2004−2007, Scios

Principal Investigator, Phase II Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) Post Azacytidine (AZA) Failure, 2004-0468, 2004−2008, MGI

Principal Investigator, Phase II Study of Liposomal Annamycin in Patients with Refractory or Relapsed Acute Lymphocytic Leukemia (ALL), 2004-0675, 2004−2009, Callisto

Principal Investigator, A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec®-resistant CML in accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hematologic malignancies, 2004-0251, 2004−present, Novartis

Collaborator, The effect of interleukin 11 on thrombocytopenia associated with imatinib therapy in patients with chronic myelogenous leukemia, 2004-0113, PI - Jorge Cortes, MD, 2004−present, Wyeth

Principal Investigator, Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid Or Myelomonocytic Leukemia, C-kit Positive Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, And Mastocytosis With BMS-354825, 2004-0817, 2004−present, Bristol-Myers Squibb

Principal Investigator, A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate, 2004-0811, 2005−2006, Bristol Myers Squibb

Principal Investigator, A Multicenter, Open-Label, Phase 2 Study of the Efficacy of FG-2216 in Subjects with Lower-Risk Myelodysplastic Syndromes (MDS), 2005-0721, 2005−2007, Fibrogen

Principal Investigator, A Phase I Dose-finding and Pharmacokinetic Study of RTA401 (CDDO) Administered as a 5-day Continuous Intravenous Infusion in Patients with Relapsed

or Refractory Leukemias or High-risk Myelodysplastic Syndromes, 2005-0469, 2005−2007, Reata

Principal Investigator, A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who are Resistant or Intolerant to Imatinib Mesylate (Gleevec®), 2005-0428, 2005−2007, Bristol-Myers Squibb

Principal Investigator, Phase II Study to Determine Activity of BMS-354825 in Subjects w/ Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Imatinib Mesylate (Gleevac) or Who are Intolerant of Imatinib, 2005-0003, 2005−2008, Bristol Myers Squibb

Principal Investigator, An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Subjects with Thrombocytopenia and Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS), 2005-0577, 2005−2009, Amgen

Principal Investigator, Phase 1B open-label, multicenter clinical study of the safety and activity of intravenous administration of SNS-595 in patients with advanced hematologic malignancies (SPO- 595-0004), 2005-0295, 2005−2010, Sunesis

Principal Investigator, A Phase I Pharmacologic Study of Oral Sapacitabine in Patients with Advanced Leukemias or Myelodysplastic Syndromes, 2005-0768, 2005−present, Cyclacel

Principal Investigator, Phase 2 Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Advanced-Stage Myelodysplastic Syndromes (The ADOPT [Alternative Dosing for Outpatient Treatment] Trial), 2005-0941, 2005−present, MGI

Principal Investigator, Phase II Randomized Study of Two Different Schedules of Intravenous Clofarabine in Myelodysplastic Syndrome (MDS), 2005-0535, 2005−present, Genzyme

Principal Investigator, Phase II Study of Oral Clofarabine in Myelodysplastic Syndrome (MDS), 2005-0536, 2005−present, Genzyme

Principal Investigator, Randomized Phase 3 Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia, 2005-0647, 2005−present, MGI

Principal Investigator, Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Oral AMN107, 2005-0048, 2005−present, Novartis

Principal Investigator, A Phase I Trial of AVN-944 in Patients with Advanced Hematologic Malignancies, 2005-0609, 2006−2008, Avalon

Principal Investigator, Phase II Study of Perifosine in Patients with Refractory and Relapsed Leukemia, 2005-0793, 2006−2008, AOI

Principal Investigator, A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INNO-406 in Adult Patients with Imatinib-resistant or intolerant Philadelphia Chromosome-positive (Ph+) Leukemias, 2006-0278, 2006−2009, Innovive

Principal Investigator, A Phase I/II, Open-Label, Multi-centre, 2-part study to assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1152 in Patients with Acute Myeloid Leukaemia, 2006-0285, 2006−2009, Astra Zeneca

Principal Investigator, A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and preliminary efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients with Relapsed or Refractory Acute Leukaemias, Chronic Myeloid Leukaemia or High-Risk Myelodysplastic Syndromes, 2006-0177, 2006−present, Astex

Principal Investigator, A Phase II Study of Single Agent Clofarabine In Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit, 2006-0654, 2006−present, Genzyme

Principal Investigator, A Phase I/II, Open-Label, Multi-Center, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD4877 Administered on Days 1, 2 and 3 in Adult Patients with Recurrent or Refractory Acute Myelogenous Leukemia (AML) Excluding Promyelocytic Leukemia, 2007-0287, 2007−2010, Astra Zeneca

Principal Investigator, A Phase 1/2 Study of ARRY-520 in Patients with Advanced Myeloid Leukemia, 2007-0879, 2007−present, Array BioPharma

Principal Investigator, A Phase IIa, Open-label, Randomized Dose Confirmation Study of Oral Clofarabine in Previously Treated Adult Patients with Myelodysplastic Syndromes (MDS), 2007-0410, 2007−present, Genzyme

Principal Investigator, A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, 2007-0727, 2007−present, Cyclacel

Principal Investigator, An Open Label Extension Study Evaluating the Safety of Long Term Dosing of AMG 531 in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS), 2007-0264, 2007−present, Amgen

Principal Investigator, Phase I-II Study of Bendamustine in Patients with Acute Leukemia and High-Risk Myelodysplastic Syndrome (MDS), 2007-0634, 2008−2012, Cephalon

Principal Investigator, A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS), 2008-0249, 2008−present, Amgen

Principal Investigator, A Phase I, open-label, multi-centre, multiple ascending dose study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML), 2009-0172, 2009−2012, $386,000, Astra Zeneca

Principal Investigator, A Phase I Study of DT2219ARL (Ind# 100780), a Bispecific Single Chain Immunotoxin For The Treatment of CD19 (+), CD 22 (+) B-Lineage Acute Lymphoblastic Leukemia or Lymphoma, 2008-0519, 2009−present, University of Minnesota Cancer Center

Principal Investigator, A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in patients aged >/= 60 with newly diagnosed acute myeloid leukaemia (AML) who are considered unsuitable to receive intensive induction chemotherapy regimens, 2009-0217, 2009−present, Astra Zeneca

Principal Investigator, Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia after MDS (sAML/MDS), 2009-0046, 2009−present, GlaxoSmithKline

Principal Investigator, Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) with CMC-544 (Inotuzumab Ozogamycin), with or without Later Addition of Rituximab, 2009-0872, 2009−present, Wyeth

Principal Investigator, Phase IV Randomized Open-Label Two-Arm Study Comparing the Efficacy and Safety of DACOGEN® (Decitabine) for Injection and VIDAZA® (Azacitidine) among Subjects with Intermediate or High Risk MDS, 2009-0791, 2010, Eisai

Principal Investigator, A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia, 2009-1002, 2010−present, Cyclacel Ltd.

Principal Investigator, A Phase II Study of Omacetaxine (OM) and Low Dose Cytarabine (LDAC) in Older Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS), 2010-0736, 2010−present, $27,633, ChemGenex

Principal Investigator, Phase I Study of 4'-Thio-araC in Patients with Advanced Hematologic Malignancies, 2009-1000, 2010−present, Access Pharmaceuticals

Principal Investigator, A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with, 2010-0727, 2010, Cyclacel Ltd

Principal Investigator, A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Acute Leukemias and Related Disorders, 2011-0369, 2011−present, $26,069, Amgen

Principal Investigator, A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), 2010-0615, 2011−present

Principal Investigator, Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) with Low-intensity Chemotherapy in Elderly Patients with Acute Lymphoblastic Leukemia (ALL), 2010-0991, 2011−present, $201,339, Pfizer

Principal Investigator, single agent by intravenous infusion in patients with relapsed or Refractory Acute Lymphoblastic Leukemia (ALL), 2011-0287, 2011−present, $67,460, sanofi-aventis

Principal Investigator, An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), 2011-0784, 2012−present, Micromet

Unfunded

Co-Investigator, The effect of interleukin 11 on thrombocytopenia associated with imatinib therapy in patients with chronic myelogenous leukemia, 2004-0113

Principal Investigator, Phase II Study of Intravenous Homoharringtonine in CML, ID99-031, 1999−2001, Oncopharm

Principal Investigator, Pilot Study of Reverse Transcriptase Inhibitors in Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), and Other Lymphoproliferative Disorders (LPD), IDP00-268, 2000−2001

Principal Investigator, Pilot Study of Reverse Transcriptase Inhibitors in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Myeloproliferative Disorder (MPD), IDP00-269, 2000−2001

Collaborator, Treatment of Myelodysplastic Syndrome (MDS) with Cytokine-Immunotherapy for Low-Risk MDS, 2004-0253, PI - Gautam Borthakur, MD, 2004−2009

Patents and Technology Licenses

Patents

Shire BioChem Inc., Giles F, Kantarjian H, Jolivet J. Pharmaceutical combination for the treatment of cancer, United States, 10/104,067/6,800,639, 3/25/2002, Issued

Shire BioChem Inc., Jolivet J, Giles F, Kantarjian H. Methods of treating leukemia, United States, 10/286,960/6,645,972, 11/7/2002, Issued

The Texas A&M University System; Board of Regents, The University of Texas System, Zingaro R, Freireich E, Duzkale H, Kantarjian H, Verstovsek S, Sotelo-Lerma M. S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer, United States, 6,911,471, 1/7/2003, Issued

Board of Regents, The University of Texas System, Albitar M, Estey E, Kantarjian H, Giles F, Keating M. Using plasma proteomic pattern for diagnosis, classification, prediction of

response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies, United States, 60563873/7,622,306, 4/2004, Issued

Board of Regents, The University of Texas System;The Texas A&M University System, Zingaro R, Freireich E, Duzkale H, Kantarjian H, Verstovsek S, Sotelo-Lerma M. S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer, United States, 6,995,188, 1/13/2005, Issued

The Texas A&M University System;Board of Regents, The University of Texas System, Zingaro R, Duzkale H, Freireich E, Kantarjian H, Sotelo-Lerma M, Verstovsek S, Gao M. Compounds and methods for the treatment of cancer, United States, 7,405,314, 10/17/2005, Issued

The Texas A&M University System; Board of Regents, The University of Texas System, Zingaro R, Freireich E, Duzkale H, Kantarjian H, Verstovsek S, Sotelo-Lerma M. S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer, United States, 7,619,000, 2/2006, Issued

MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Giles F, Kantarjian H, Jolivet J. Pharmaceutical combinations for the treatment of cancer, United States, 20050004081, 5/26/2004, Filed

Board of Regents, The University of Texas System, Albitar M, Kantarjian H, Goldknopf IL, Sheta E. Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity, United States, 20060029574, 8/5/2004, Filed

Power3 Medical Products, Inc., Goldknopf IL, Sheta EA, Kantarjian HM. Actin proteins as biomarkers for indication and targeting of resistance and sensitivity to an Abl kinase inhibitor in patients with chronic myelogenous leukemia, United States, 20080108549, 3/29/2007, Filed

U.S. Patent Office, Albitar M, Estey E, Kantarjian H, Giles F, Keating M. Using plasma proteomic patttern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies, United States, 12/582,998, 10/21/2009, Filed

and Adress: University of Texas M.D. Anderson Cancer Center, Albitar M, Kantarjian H, Giles F, Jilani I. Quantification of fusion proteins and their activity from chromosomal translocation, United States, 20090226933, 11/14/2006, Pending

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

AML P012002, NIH, Grant Reviewer, 2002

CALGB 2002, NIH, Grant Reviewer, 2002

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Bedikian AY, Kantarjian H, Young SE, Bodey GP. Prognosis in metastatic choroidal melanoma. South Med J 74(5):574-7, 5/1981.
2. Bedikian AY, Kantarjian H, Nelson RS, Stroehlein JR, Bodey GP. Colorectal cancer in young adults. South Med J 74(8):920-4, 8/1981.
3. Bledin AG, Kantarjian HM, Kim EE, Wallace S, Chuang VP, Patt YZ, Haynie TP. 99mTc-labeled macroaggregated albumin in intrahepatic arterial chemotherapy. AJR Am J Roentgenol 139(4):711-5, 10/1982.
4. Uwaydah M, Kantarjian H, Osseiran M, Bal'a F. Cefamandole bile levels in patients with hepatobiliary disease. Antimicrob Agents Chemother 22(6):1087-9, 12/1982.
5. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 143(2):237-40, 2/1983.

6. Uwaydah M, Tannir N, Kantarjian H, Osseiran M, Bal'a F. Moxalactam therapy of bacterial meningitis in adults. Antimicrob Agents Chemother 23(2):289-92, 2/1983.
7. Kantarjian HM, Bledin AG, Kim EE, Cogan BM, Chuang VP, Wallace S, Haynie TP. Arterial perfusion with Tc-99m macroaggregated albumin (MAAAP) in monitoring intra-arterial chemotherapy of sarcomas. J Nucl Med 24(4):297-301, 4/1983.
8. Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S, Cabanillas F. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1(11):689-94, 11/1983.
9. Kanojia M, Kantarjian H, Ajani J, Barlogie B. High-dose cytosine arabinoside (Ara-C) in colorectal cancer. Br J Cancer 48(6):869-71, 12/1983.
10. Kantarjian H, Dreicer R, Barlogie B, Plunkett W, Alexanian R. High-dose cytosine arabinoside in multiple myeloma. Eur J Cancer Clin Oncol 20(2):227-31, 2/1984.
11. Kantarjian H, Farha PA, Spitzer G, Murphy WK, Valdivieso M. Systemic combination chemotherapy as primary treatment of brain metastasis from lung cancer. South Med J 77(4):426-30, 4/1984.
12. Kantarjian HM, McLaughlin P, Fuller LM, Dixon DO, Osborne BM, Cabanillas FF. Follicular large cell lymphoma: analysis and prognostic factors in 62 patients. J Clin Oncol 2(7):811-9, 7/1984.
13. Uwaydah M, Nassar NT, Harakeh H, Vartivarian S, Talhouk A, Kantarjian H. Treatment of typhoid fever with cefamandole. Antimicrob Agents Chemother 26(3):426-7, 9/1984.
14. Kantarjian HM, Hortobagyi GN, Smith TL, Blumenschein GR, Montague E, Buzdar AU, Martin RG. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol 20(11):1353-61, 11/1984.
15. Kantarjian HM, Vellekoop L, McCredie KB, Keating MJ, Hester J, Smith T, Barlogie B, Trujillo J, Freireich EJ. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 3(2):192-200, 2/1985.
16. Srigley J, Barlogie B, Butler JJ, Osborne B, Blick M, Johnston D, Kantarjian H, Reuben J, Batsakis J, Freireich EJ. Heterogeneity of non-Hodgkin's lymphoma probed by nucleic acid cytometry. Blood 65(5):1090-6, 5/1985.
17. Kantarjian HM, Keating MJ, McCredie KB, Beran M, Walters R, Dalton WT, Jr, Hittleman W, Freireich EJ. A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J Clin Oncol 3(6):793-8, 6/1985.
18. Kantarjian HM, Barlogie B, Pershouse M, Swartzendruber D, Keating MJ, McCredie KB, Freireich EJ. Preferential expression of double-stranded ribonucleic acid in tumor versus normal cells: biological and clinical implications. Blood 66(1):39-46, 7/1985.
19. Kantarjian HM, Barlogie B, Keating MJ, Hall RR, Smith TL, McCredie KB, Freireich EJ. Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications. J Clin Invest 76(1):319-24, 7/1985.
20. Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 66(6):1326-35, 12/1985.
21. Kantarjian H, Ajani JA, Karlin DA. Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 42(2):69-71, 1985.
22. McCredie KB, Kantarjian H, Keating MJ, Hester JP, Freireich EJ. New approaches to the treatment of chronic myelogenous leukemia. Haematol Blood Transfus 29:51-2, 1985.
23. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314(17):1065-9, 4/1986.
24. Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, Dalton WT, Jr, Cork A, Trujillo JM, Freireich EJ. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med 80(5):789-97, 5/1986.
25. Talpaz M, Plager C, Quesada J, Benjamin R, Kantarjian H, Gutterman J. Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients. Eur J Cancer Clin Oncol 22(6):685-9, 6/1986.
26. Anaissie E, Kantarjian H, Jones P, Barlogie B, Luna M, Lopez-Berestein G, Bodey GP. Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer 57(11):2141-5, 6/1986.

27. Vellekoop L, Zander AR, Kantarjian HM, Jagannath S, Hester JP, Trujillo J, McCredie KB, Zagars G, Spitzer G, Dicke KA. Piperazinedione, total body irradiation, and autologous bone marrow transplantation in chronic myelogenous leukemia. J Clin Oncol 4(6):906-11, 6/1986.
28. Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, McCredie KB, Freireich EJ. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4(7):1079-88, 7/1986.
29. Talpaz M, Spitzer G, Hittelman W, Kantarjian H, Gutterman J. Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients. Exp Hematol 14(7):668-71, 8/1986.
30. Kantarjian HM, Keating MJ, Walters RS, Beran M, McLaughlin P, McCredie KB, Freireich EJ. The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. Cancer 58(4):924-7, 8/1986.
31. Talpaz M, McCredie K, Kantarjian H, Trujillo J, Keating M, Gutterman J. Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br J Haematol 64(1):87-95, 9/1986.
32. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81(3):387-94, 9/1986.
33. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Bodey GP, Freireich EJ. Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia. Cancer 58(8):1603-8, 10/1986.
34. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Smith TL, Talpaz M, Beran M, Cork A, Trujillo JM, Freireich EJ. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 58(9):2023-30, 11/1986.
35. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 4(12):1748-57, 12/1986.
36. Nogueira-Costa R, Spitzer G, Khorana S, Pham Q, Kantarjian HM, Manning JT, Ordonez NG, Dicke KA. T-cell involvement in benign phase chronic myelogenous leukemia. Leuk Res 10(12):1433-9, 1986.
37. Terjanian T, Kantarjian H, Keating M, Talpaz M, McCredie K, Freireich EJ. Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. Cancer 59(2):297-300, 1/1987.
38. Anaissie E, Kantarjian H, Jones P. Fungal infection caused by Fusarium in cancer patients. Am J Clin Oncol 10(1):86-8, 2/1987.
39. Talpaz M, Kantarjian H, McCredie K, Trujillo J, Keating M, Gutterman JU. Therapy of chronic myelogenous leukemia. Cancer 59(3 Suppl):664-7, 2/1987.
40. Yoffe G, Blick M, Kantarjian H, Spitzer G, Gutterman J, Talpaz M. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 69(3):961-3, 3/1987.
41. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 69(3):929-36, 3/1987.
42. Talpaz M, Rosenblum M, Kurzrock R, Reuben J, Kantarjian H, Gutterman J. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia--a pilot study. Am J Hematol 24(4):341-50, 4/1987.
43. Kantarjian HM, Keating MJ, Walters RS, Smith TL, McCredie KB, Freireich EJ. Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 59(7):1258-63, 4/1987.
44. Keating MJ, Gehan EA, Smith TL, Estey EH, Walters RS, Kantarjian HM, McCredie KB, Freireich EJ. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol 5(5):710-21, 5/1987.
45. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69(5):1280-8, 5/1987.
46. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 59(10):1739-43, 5/1987.

47. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 47(11):3005-11, 6/1987.
48. Walters RS, Kantarjian HM, Keating MJ, Estey EH, McCredie KB, Freireich EJ. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 60(2):149-55, 7/1987.
49. Yoffe G, Chinault AC, Talpaz M, Blick MB, Kantarjian HM, Taylor K, Spitzer G. Clonal nature of Philadelphia chromosome-positive and -negative chronic myelogenous leukemia by DNA hybridization analyses. Exp Hematol 15(7):725-8, 8/1987.
50. Kantarjian HM, Talpaz M, Gutterman J. Biologic therapy of chronic myelogenous leukemia. Oncology (Williston Park) 1(7):35-40, 48-9, 52, 9/1987.
51. Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83(3):445-54, 9/1987.
52. Kassamali H, Anaissie E, Ro J, Rolston K, Kantarjian H, Fainstein V, Bodey GP. Disseminated Geotrichum candidum infection. J Clin Microbiol 25(9):1782-3, 9/1987.
53. Kantarjian H, Walters R. Implications of cytogenetic findings in secondary leukemia. Am J Clin Oncol 10(5):453-6, 10/1987.
54. Kantarjian HM, Keating MJ, McCredie KB, Walters R, Talpaz M, Smith TL, Freireich EJ. Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia. South Med J 80(10):1228-32, 10/1987.
55. O'Brien S, Kantarjian HM, Anaissie E, Dodd G, Bodey GP. Successful medical management of neutropenic enterocolitis in adults with acute leukemia. South Med J 80(10):1233-5, 10/1987.
56. Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 70(4):943-7, 10/1987.
57. Walters RS, Kantarjian HM, Keating MJ, Talpaz M, Childs CC, McCredie KB, Freireich EJ. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer 60(8):1708-12, 10/1987.
58. Beran M, Andersson B, Kantarjian H, Keating M, Rios A, McCredie KB, Freireich EJ, Gutterman J. Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. Leukemia 1(1):52-7, 1987.
59. O'Brien S, Kantarjian HM, Talpaz M, Cork A, Trujillo J, Beran M. The effect of long-term marrow culture on the nonadherent Philadelphia chromosome-positive clone in chronic myelogenous leukemia: preliminary observations. Hematol Pathol 1(3):167-72, 1987.
60. Amato R, Kantarjian H, Walters R, Keating M. Rebound peripheral blastosis with subsequent remission during remission induction in a patient with acute promyelocytic leukemia. Cancer 61(4):650-3, 2/1988.
61. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 6(2):232-8, 2/1988.
62. Keating MJ, Scouros M, Murphy S, Kantarjian H, Hester J, McCredie KB, Hersh EM, Freireich EJ. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 2(3):157-64, 3/1988.
63. Anaissie EJ, Fainstein V, Bodey GP, Rolston K, Elting L, Kantarjian H, Cabanillas F, McCredie KB. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. Am J Med 84(3 Pt 2):581-9, 3/1988.
64. Anaissie E, Kantarjian H, Ro J, Hopfer R, Rolston K, Fainstein V, Bodey G. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 67:77-83, 3/1988.
65. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61(7):1441-6, 4/1988.
66. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 2(7):403-12, 7/1988.

67. Shtalrid M, Talpaz M, Kurzrock R, Kantarjian H, Trujillo J, Gutterman J, Yoffe G, Blick M. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood 72(2):485-90, 8/1988.
68. Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 62(4):677-82, 8/1988.
69. Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 62(4):672-6, 8/1988.
70. Lee MS, Chang KS, Freireich EJ, Kantarjian HM, Talpaz M, Trujillo JM, Stass SA. Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. Blood 72(3):893-7, 9/1988.
71. Schachner J, Kantarjian H, Dalton W, McCredie K, Keating M, Freireich EJ. Cytogenetic association and prognostic significance of bone marrow blast cell terminal transferase in patients with acute myeloblastic leukemia. Leukemia 2(10):667-71, 10/1988.
72. Shtalrid M, Talpaz M, Blick M, Romero P, Kantarjian H, Taylor K, Trujillo J, Schachner J, Gutterman JU, Kurzrock R. Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. J Clin Oncol 6(10):1569-75, 10/1988.
73. Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 72(5):1784-9, 11/1988.
74. Kantarjian HM, Shtalrid M, Kurzrock R, Blick M, Dalton WT, LeMaistre A, Stass SA, McCredie KB, Gutterman J, Freireich EJ, et al. Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Am J Med 85(5):639-44, 11/1988.
75. Hittelman WN, Agbor P, Petkovic I, Andersson B, Kantarjian H, Walters R, Koller C, Beran M. Detection of leukemic clone maturation in vivo by premature chromosome condensation. Blood 72(6):1950-60, 12/1988.
76. Zander, AR, Keating M, Dicke K, Dixon D, Pierce S, Jagannath S, Peters L, Horwitz L, Cockerill K, Spitzer G, Vellekoop L, Kantarjian H, Walters R, McCredie K, Freireich EJ:. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. . J Clin Oncol 6:1548 1557, 1988.
77. Keating MJ, Kantarjian H, Talpaz M, Redman J, McCredie KB. Fludarabine therapy in chronic lymphocytic leukemia (CLL). Nouv Rev Fr Hematol 30(5-6):461-6, 1988.
78. O'Brien S, Kantarjian H, Shtalrid M, Blick M, Beran M, Talpaz M. Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Hematol Pathol 2(1):25-9, 1988.
79. Talpaz M, Kantarjian HM, Kurzrock R, Gutterman J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol 25(1):62-73, 1988.
80. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63(5):813-7, 3/1989.
81. LeMaistre A, Lee MS, Talpaz M, Kantarjian HM, Freireich EJ, Deisseroth AB, Trujillo JM, Stass SA. Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood 73(4):889-91, 3/1989.
82. Anaissie E, Bodey GP, Kantarjian H, Ro J, Vartivarian SE, Hopfer R, Hoy J, Rolston K. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 11(3):369-78, 5/1989.
83. Talpaz M, Kurzrock R, Kantarjian H, O'Brien S, Gutterman JU. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med 86(5):554-8, 5/1989.
84. Lee MS, LeMaistre A, Kantarjian HM, Talpaz M, Freireich EJ, Trujillo JM, Stass SA. Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood 73(8):2165-70, 6/1989.

85. Taylor KM, Shetta M, Talpaz M, Kantarjian HM, Hardikar S, Chinault AC, McCredie KB, Spitzer G. Myeloproliferative disorders: usefulness of X-linked probes in diagnosis. Leukemia 3(6):419-22, 6/1989.
86. Kantarjian HM, Walters RS, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer 64(1):16-22, 7/1989.
87. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74(1):19-25, 7/1989.
88. O'Brien S, Kantarjian HM, Keating M, Gagnon G, Cork A, Trujillo J, McCredie KB. Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21. J Clin Oncol 7(8):1081-6, 8/1989.
89. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7(8):1071-80, 8/1989.
90. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia. Bone Marrow Transplant 4 Suppl 1:63, 1989.
91. Horwitz LJ, Kantarjian HM, Jagannath S, Keating MJ, McCredie KB, Spitzer G, Vellekoop L, Zander AR, Dicke KA. Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia. Bone Marrow Transplant 4(1):101-5, 1989.
92. Talpaz M, Kurzrock R, Kantarjian H, Gutterman J. Therapy of chronic myelogenous leukaemia with interferons. Cancer Surv 8(4):793-8, 1989.
93. Kurzrock R, Gutterman JU, Kantarjian H, Talpaz M. Therapy of chronic myelogenous leukemia with interferon. Cancer Invest 7(1):83-91, 1989.
94. Kurzrock R, Kantarjian HM, Shtalrid M, Gutterman JU, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood 75(2):445-52, 1/1990.
95. Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Fludarabine therapy in macroglobulinemic lymphoma. Blood 75(10):1928-31, 5/1990.
96. Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB, et al. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 75(9):1766-9, 5/1990.
97. Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B, McCredie K, Freireich E. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 8(6):994-1004, 6/1990.
98. Dicke KA, Dicke-Evinger MJ, Spinolo JA, Estey EH, Kantarjian HM, Spitzer GS. Double intensification including autologous bone marrow transplantation (ABMT) in AML: long term follow-up and detection of residual disease. Bone Marrow Transplant 6 Suppl 1:27-34, 7/1990.
99. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Update on therapeutic options for chronic myelogenous leukemia. Semin Hematol 27(3 Suppl 4):31-6, 7/1990.
100. Spinolo JA, Dicke KA, Horwitz LJ, Jagannath S, McCredie K, Estey E, Kantarjian H, Zander AR, Keating M, Spitzer G. High-dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission. Cancer 66(4):619-26, 8/1990.
101. Kantarjian HM, Hirsch-Ginsberg C, Yee G, Huh Y, Freireich EJ, Stass S. Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. Blood 76(4):808-13, 8/1990.
102. Wetzler M, Kurzrock R, Taylor K, Spitzer G, Kantarjian H, Baiocchi G, Ku S, Gutterman JU, Talpaz M. Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma. Cancer Res 50(18):5801-5, 9/1990.

103. Howard OM, Talpaz M, Kantarjian H, Seong D, Wedrychowski A, Paslidis N, Hester J, Cork A, Turpin J, Lopez-Berestein G, et al. Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients. Blood 76(6):1117-30, 9/1990.
104. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ, Trujillo JM, Lee MS, Stass SA. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76(6):1214-9, 9/1990.
105. Kantarjian HM, Redman JR, Keating MJ. Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol 17(5 Suppl 8):66-70, 10/1990.
106. Seong DC, Sims S, Johnson E, Howard OM, Reiter B, Hester J, Talpaz M, Kantarjian H, Deisseroth A. A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genes. J Clin Invest 86(5):1664-70, 11/1990.
107. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50(21):6823-6, 11/1990.
108. Walters R, Kantarjian HM, Keating MJ, Estey EH, Trujillo J, Cork A, McCredie KB, Freireich EJ. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am J Med 89(5):579-87, 11/1990.
109. Wedrychowski A, Seong D, Paslidis N, Johnson E, Howard OM, Sims S, Talpaz M, Kantarjian H, Hester J, Turpin J, et al. Characterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cells. J Biol Chem 265(35):21433-40, 12/1990.
110. Haber LM, Childs CC, Hirsch-Ginsberg C, Nellis K, Kantarjian HM, Cork A, Trujillo JM, Stass SA. Strategy for breakpoint cluster region analysis in chronic myelocytic leukemia in a routine clinical laboratory. Am J Clin Pathol 94(6):762-7, 12/1990.
111. Claxton D, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU, Talpaz M. Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. Acta Haematol 83(3):149-51, 1990.
112. Bodey GP, Fainstein V, Elting LS, Anaissie E, Rolston K, Khardori N, Kantarjian H, Plager C, Murphy WK, Holmes F, et al. Beta-lactam regimens for the febrile neutropenic patient. Cancer 65(1):9-16, 1990.
113. Kantarjian HM, Walters RL, Keating MJ, Estey EH, O'Brien S, Schachner J, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65(1):5-8, 1990.
114. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 88(1):1-8, 1990.
115. Mashal R, Shtalrid M, Talpaz M, Kantarjian H, Smith L, Beran M, Cork A, Trujillo J, Gutterman J, Deisseroth A. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 75(1):180-9, 1990.
116. Seong D, Sims SS, Johnson E, Swan F, Lyding J, Lopez A, Talpaz M, Kantarjian H, Emerson S, Lopez-Berestein G, et al. Regulation of gene expression by tumor necrosis factor-alpha and interferon-gamma in chronic myelogenous leukemia. Trans Assoc Am Physicians 103:236-41, 1990.
117. Estey, E, McCredie K, Keating MJ, Kantarjian HM, Kurzrock R, Talpaz M, Gutterman JU, Deisseroth AB. Treatment of acute myelogenous leukemia with chemotherapy and hematopoietic growth factorsv. Cancer Bulletin 42(3):162, 1990.
118. Kantarjian HM, Childs C, O'Brien S, Huh Y, Beran M, Schachner J, Koller C, Keating MJ. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med 90(2):223-8, 2/1991.
119. Dhingra K, Talpaz M, Kantarjian H, Ku S, Rothberg J, Gutterman JU, Kurzrock R. Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. Leukemia 5(3):191-5, 3/1991.
120. Estey EH, Kurzrock R, Talpaz M, McCredie KB, O'Brien S, Kantarjian HM, Keating MJ, Deisseroth AB, Gutterman JU. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 77(3):291-5, 3/1991.

121. Kantarjian HM, Schachner J, Keating MJ. Fludarabine therapy in hairy cell leukemia. Cancer 67(5):1291-3, 3/1991.
122. O'Brien S, Witt R, Talpaz M, Kantarjian H. Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission. Cancer 67(7):1946-9, 4/1991.
123. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114(7):532-8, 4/1991.
124. Kantarjian HM, Talpaz M, LeMaistre CF, Spinolo J, Spitzer G, Yau J, Dicke K, Jagannath S, Deisseroth AB. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. Cancer 67(12):2959-65, 6/1991.
125. Seong D, Sims S, Johnson E, Lyding J, Lopez A, Garovoy M, Talpaz M, Kantarjian H, Lopez-Berestein G, Reading C, et al. Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines. Br J Haematol 78(3):359-67, 7/1991.
126. Bodey G, Reuben A, Elting L, Kantarjian H, Keating M, Hagemeister F, Koller C, Velasquez W, Papadopoulos N. Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J Clin Microbiol Infect Dis 10(7):551-8, 7/1991.
127. Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, Defelice R, Downs N, File T, Karam G, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91(2):142-50, 8/1991.
128. O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer 68(4):691-4, 8/1991.
129. Kantarjian HM, Talpaz M, Keating MJ, Estey EH, O'Brien S, Beran M, McCredie KB, Gutterman J, Freireich EJ. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 68(6):1201-7, 9/1991.
130. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood 78(6):1476-84, 9/1991.
131. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68(7):1536-7, 10/1991.
132. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Interferon alpha in the therapy of CML. Br J Haematol 79 Suppl 1:38-41, 10/1991.
133. Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. Cancer 68(10):2125-30, 11/1991.
134. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood 78(9):2400-6, 11/1991.
135. Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo J, Huh Y, Stass S, Kurzrock R. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 78(9):2411-8, 11/1991.
136. Upadhyaya G, Guba SC, Sih SA, Feinberg AP, Talpaz M, Kantarjian HM, Deisseroth AB, Emerson SG. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 88(6):2131-6, 12/1991.
137. Keating, MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukemia 6:78-80, 1991.

138. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9(1):44-9, 1991.
139. Claxton, D, Suh S-P, Filaccio M, Ellerson D, Gaozza E, Andersson B, Brenner M, Reading C,Feinberg A, Moen R, Belmont J, Moore K, Talpaz M, Kantarjian, H, Deisseroth A. Molecular analysis of retroviral transduction in chronic myelogenous leukemia. . Human Gene Therapy 2:317-321, 1991.
140. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer 69(2):410-2, 1/1992.
141. Kantarjian HM, Estey EH, O'Brien S, Anaissie E, Beran M, Rios MB, Keating MJ, Gutterman J. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood 79(4):876-81, 2/1992.
142. Claxton D, Deisseroth A, Talpaz M, Reading C, Kantarjian H, Trujillo J, Stass S, Gooch G, Spitzer G. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. Blood 79(4):997-1002, 2/1992.
143. Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79(4):882-7, 2/1992.
144. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10(3):406-13, 3/1992.
145. Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R. Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. Cancer Res 52(5):1087-90, 3/1992.
146. Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios MB, Beran M, Deisseroth A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 10(3):398-405, 3/1992.
147. Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 79(8):1920-3, 4/1992.
148. Saunders PP, Alvarez E, Kantarjian HM. Determination of nicotinamide-adenine dinucleotide and thiazole-4-carboxamide-adenine dinucleotide in human leukocytes by reversed-phase high-performance liquid chromatography. J Chromatogr 577(1):37-41, 5/1992.
149. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 10(5):772-8, 5/1992.
150. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79(9):2246-55, 5/1992.
151. Freireich EJ, Cork A, Stass SA, McCredie KB, Keating MJ, Estey EH, Kantarjian HM, Trujillo JM. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 6(6):500-6, 6/1992.
152. Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S, Kantarjian H, Keating MJ. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 80(1):29-36, 7/1992.
153. O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. CI-973, a new platinum derivative with potential antileukemic activity. Cancer Res 52(15):4130-4, 8/1992.
154. Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. Leukemia 6(8):754-60, 8/1992.
155. Marin T, Butturini A, Kantarjian H, Sokal J, Mickey MR, Gale R. Survival of children with chronic myeloid leukemia. Am J Pediatr Hematol Oncol 14(3):229-32, 8/1992.

156. Dimopoulos MA, Kantarjian HM, Estey EH, Alexanian R. 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 80(6):1626, 9/1992.
157. Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 117(6):466-9, 9/1992.
158. Seong DC, Gottlieb K, Suh SP, Sims S, Talpaz M, Kantarjian H, Deisseroth A. Identification of a complex formed between nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the peripheral blood myeloid cells of CML but not normal individuals. J Interferon Res 12(5):323-7, 10/1992.
159. Lee M, Khouri I, Champlin R, Kantarjian H, Talpaz M, Trujillo J, Freireich E, Deisseroth A, Stass S. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. Br J Haematol 82(4):708-14, 12/1992.
160. Kantarjian HM, Smith T, Estey E, Polyzos A, O'Brien S, Pierce S, Beran M, Feldman E, Keating MJ. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med 93(6):599-604, 12/1992.
161. Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol 6(1):43-8, 1992.
162. Kantarjian, H, Talpaz M, Wetzler M, Estey E, O'Brien S, Plunkett W, Keating M, Deisseroth A:. Chronic myelogenous leukemia in blastic phase (CML-BP): A model of heterogeneity and resistance in acute leukemia. . Haematology and Blood Transfusion 34:214-221, 1992.
163. Estey, EH, Kurzrock R, Talpaz M, McCredie KB, O'Brien S, Kantarjian HM, Keating MJ, Deisseroth AB, Gutterman JU. Effects of low-doses of recombinant human granulocyte - macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. . Haematology and Blood Transfusion 34:97-107, 1992.
164. Yuan T, Zhou YQ, Herst CV, Reading C, Ellersen D, Etkin M, Khouri I, Kantarjian H, Talpaz M, Deisseroth A. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation. Prog Clin Biol Res 377:227-30, 1992.
165. Plunkett, W, Gandhi V, Kantarjian H, Keating MJ:. Pharmacologically guided leukemia therapy. . Haematology and Blood Transfusion 34:253-257, 1992.
166. Etkin, M, Filaccio M, Ellerson D, Suh S-P, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA, Moseley AM, Reading C, Khouri I, Talpaz M, Kantarjian H, Deisseroth A. Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. . Human Gene Therapy 3:137-145, 1992.
167. Zhao L, Kantarjian HM, Van Oort J, Cork A, Trujillo JM, Liang JC. Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment. Leukemia 7(2):168-71, 2/1993.
168. Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia 7(2):214-20, 2/1993.
169. Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, Freireich EJ, Alexanian R. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 118(3):195-8, 2/1993.
170. Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Andersson B, Claxton D. Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine. Hum Gene Ther 4(1):71-85, 2/1993.
171. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9(4-5):343-50, 3/1993.
172. Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med 177(3):763-74, 3/1993.

173. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81(5):1146-51, 3/1993.
174. Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma 10(1-2):43-8, 5/1993.
175. Ross DW, Brunning RD, Kantarjian HM, Koeffler HP, Ozer H. A proposed staging system for chronic myeloid leukemia. Cancer 71(11):3788-91, 6/1993.
176. Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, Przepiorka D, Deisseroth AB, Champlin RE. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11(6):1055-61, 6/1993.
177. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81(11):2878-84, 6/1993.
178. Kemena A, O'Brien S, Kantarjian H, Robertson L, Koller C, Beran M, Estey E, Plunkett W, Lerner S, Keating MJ. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma 10(3):187-93, 6/1993.
179. Jaiyesimi IA, Kantarjian HM, Estey EH. Advances in therapy for hairy cell leukemia. A review. Cancer 72(1):5-16, 7/1993.
180. Dimopoulos MA, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B, Alexanian R, Keating MJ. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med 95(1):49-52, 7/1993.
181. Estrov Z, Talpaz M, Kantarjian HM, Zipf TF, McClain KL, Kurzrock R. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res 53(14):3289-93, 7/1993.
182. Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohli V, Kantarjian H. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 53(15):3603-10, 8/1993.
183. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 82(3):691-703, 8/1993.
184. Di Raimondo F, Giustolisi R, Cacciola E, O'Brien S, Kantarjian H, Robertson LB, Keating MJ. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 11(1-2):63-8, 9/1993.
185. Giralt S, Escudier S, Kantarjian H, Deisseroth A, Freireich EJ, Andersson BS, O'Brien S, Andreeff M, Fisher H, Cork A, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 329(11):757-61, 9/1993.
186. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82(6):1695-700, 9/1993.
187. Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 72(7):2155-60, 10/1993.
188. Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Hanania EG, Fu S, Randhawa GS, Cha Y, Fang X, et al. Molecular approaches to the diagnosis and treatment of cancer. Stem Cells 11 Suppl 3:129-30, 10/1993.
189. Robertson LE, Pugh W, O'Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, McLaughlin P, Cabanillas F, Keating MJ. Richter's syndrome: a report on 39 patients. J Clin Oncol 11(10):1985-9, 10/1993.
190. Gutierrez de Guzman J, Kantarjian H. Role of retinoic acid in the treatment of acute promyelocytic leukemia. Sangre (Barc) 38:375-8, 10/1993.
191. Kantarjian HM, Talpaz M. Therapy of chronic myelogenous leukemia. Stem Cells 11 Suppl 3:8-9, 10/1993.

192. Kantarjian HM, Estey E, O'Brien S, Anaissie E, Beran M, Pierce S, Robertson L, Keating MJ. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer 72(10):2950-5, 11/1993.
193. Anaissie EJ, Kontoyiannis DP, Vartivarian S, Kantarjian HM, O'Brien S, Giralt SA, Andersson BS, Karl C, Champlin RE, Bodey GP. Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. Clin Infect Dis 17(6):1022-31, 12/1993.
194. Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, Bauters F, Fenaux P. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 11(12):2370-9, 12/1993.
195. Keating MJ, O'Brien S, Robertson L, Huh Y, Kantarjian H, Plunkett W. Chronic lymphocytic leukemia--correlation of response and survival. Leuk Lymphoma 11 Suppl 2:167-75, 1993.
196. Derderian PM, Kantarjian HM, Talpaz M, O'Brien S, Cork A, Estey E, Pierce S, Keating M. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 94(1):69-74, 1993.
197. Kantarjian HM, Talpaz M. Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center. Leuk Lymphoma 11 Suppl 1:169-74, 1993.
198. Keating MJ, O'Brien S, Kantarjian H, Robertson LB, Koller C, Beran M, Estey E. Nucleoside analogs in treatment of chronic lymphocytic leukemia. Leuk Lymphoma 10 Suppl:139-45, 1993.
199. Dimopoulos MA, O'Brien S, Kantarjian H, Estey EE, Keating MJ, Alexanian R. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues. Leuk Lymphoma 11 Suppl 2:105-8, 1993.
200. Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K, Gutterman JU, Talpaz M. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol 21(1):80-5, 1993.
201. O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 330(5):319-22, 2/1994.
202. Kantarjian H, Talpaz M, Estey E, Ku S, Kurzrock R. What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia? Am J Med 96(2):133-8, 2/1994.
203. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. Ann Oncol 5(3):288-9, 3/1994.
204. Huh YO, Pugh WC, Kantarjian HM, Stass SA, Cork A, Trujillo JM, Keating MJ. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol 101(3):283-9, 3/1994.
205. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 73(8):2099-106, 4/1994.
206. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierce S, Freireich E, Deisseroth A, Keiting M. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12(4):671-8, 4/1994.
207. Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 8(5):823-6, 5/1994.
208. Cortes JE, Kantarjian H, O'Brien S, Robertson LE, Koller C, Hirsh-Ginsberg C, Stass S, Keating M, Estey E. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 73(12):2946-52, 6/1994.
209. Preti A, Kantarjian HM. Management of adult acute lymphocytic leukemia: present issues and key challenges. J Clin Oncol 12(6):1312-22, 6/1994.

210. Kantarjian HM, Talpaz M, Andersson B, Khouri I, Giralt S, Rios MB, Champlin R, Hester J, Deisseroth AB. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant 14(1):57-61, 7/1994.
211. Preti HA, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med 97(1):60-5, 7/1994.
212. O'Brien S, Kurzrock R, Duvic M, Kantarjian H, Stass S, Robertson LE, Estey E, Pierce S, Keating MJ. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 84(3):733-8, 8/1994.
213. Kantarjian HM. Adult acute lymphocytic leukemia: critical review of current knowledge. Am J Med 97(2):176-84, 8/1994.
214. Giralt S, O'Brien S, Weeks E, Luna M, Kantarjian H. Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid. Leuk Lymphoma 14(5-6):453-6, 8/1994.
215. Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 8(8):1269-74, 8/1994.
216. Kantarjian HM, O'Brien S, Smith T, Estey EH, Beran M, Preti A, Pierce S, Keating MJ. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol 88(1):94-100, 9/1994.
217. Gandhi V, Du M, Kantarjian HM, Plunkett W. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia 8(9):1463-8, 9/1994.
218. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 94(4):1383-9, 10/1994.
219. Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink MP, Talpaz M. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood 84(9):3142-7, 11/1994.
220. Cortes J, O'Brien S, Kantarjian H, Cork A, Stass S, Freireich EJ, Keating M, Pierce S, Estey E. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia 8(12):2174-8, 12/1994.
221. Kantarjian HM, Talpaz M. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia. Semin Oncol 21(6 Suppl 14):8-13, 12/1994.
222. Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff M. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia. Leuk Lymphoma 16(1-2):79-88, 12/1994.
223. Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12(12):2694-8, 12/1994.
224. Robertson LE, Estey E, Kantarjian H, Koller C, O'Brien S, Brown B, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia. Leukemia 8(12):2047-51, 12/1994.
225. Preti HA, Kantarjian HM. Acute lymphocytic leukemia in adults: an update. Tex Med 90(1):52-9, 1994.
226. Preti A, Kantarjian HM, Estey E, Huh Y, Keating M, Pierce S, Hirsch-Ginsberg C, Yee G, Stass SA. Characteristics and outcome of patients with acute lymphocytic leukemia and myeloperoxidase-positive blasts by electron microscopy. Hematol Pathol 8(4):155-67, 1994.
227. Yang, L-Y, Liu Y-Z, Kantarjian, H, Keating MJ. DNA cross-linking and repair in cisplatin-resistant human tumor cells following exposure to a new cisplatin analogue, CI-973. Intl J Oncol 5:597-602, 1994.
228. Giralt, SA, LeMaistre CF, Vriesendorp HM, Andersson BS, Dimopoulos M, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri I, Yau J, Kantarjian, H, Deisseroth AB, Champlin RE:.

Etoposoide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol 12:1923-1930, 1994.
229. Beran M, Pisa P, Kantarjian H, Porwit A, Bjorkholm M. Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice. Hematol Pathol 8(4):135-54, 1994.
230. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V, et al. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma 14 Suppl 2:11-6, 1994.
231. Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer 75(2):464-70, 1/1995.
232. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 122(4):254-61, 2/1995.
233. Kantarjian HM, Talpaz M, Hester J, Feldman E, Korbling M, Liang J, Rios MB, Smith TL, Calvert L, Deisseroth AB. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J Clin Oncol 13(3):553-9, 3/1995.
234. Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther 1(1):21-8, 3/1995.
235. O'Brien S, Kantarjian H, Ellis A, Zwelling L, Estey E, Keating M. Topotecan in chronic lymphocytic leukemia. Cancer 75(5):1104-8, 3/1995.
236. Giralt S, Kantarjian H, Talpaz M. The natural history of chronic myelogenous leukemia in the interferon era. Semin Hematol 32(2):152-8, 4/1995.
237. Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, Pherwani R, Rios MB, Stass SA, Kantarjian HM. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 85(10):2705-10, 5/1995.
238. Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ, Estey E. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 9(6):965-71, 6/1995.
239. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 9(6):943-5, 6/1995.
240. Talpaz M, Kantarjian H, Liang J, Calvert L, Hamer J, Tibbits P, Durett A, Claxton D, Giralt S, Khouri I, et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood 85(11):3257-63, 6/1995.
241. Haidar MA, Cao XB, Manshouri T, Chan LL, Glassman A, Kantarjian HM, Keating MJ, Beran MS, Albitar M. p16INK4A and p15INK4B gene deletions in primary leukemias. Blood 86(1):311-5, 7/1995.
242. O'Brien S, Kantarjian H, Beran M, Robertson LE, Koller C, Lerner S, Keating MJ. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood 86(4):1298-300, 8/1995.
243. Giralt S, Kantarjian H, Talpaz M. Treatment of chronic myelogenous leukemia. Semin Oncol 22(4):396-404, 8/1995.
244. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 9(9):1444-9, 9/1995.
245. Chucrallah AE, Stass SA, Huh YO, Albitar M, Kantarjian HM. Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes. Cancer 76(6):985-91, 9/1995.
246. Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xu J, Robinson JR, Deisseroth AB, Champlin RE, Siciliano MJ. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of

Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 86(6):2343-9, 9/1995.
247. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13(9):2401-7, 9/1995.
248. Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, Lee MS, O'Brien S, Rios MB, Stass SA, Keating M, Talpaz M. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. Cancer 76(6):992-7, 9/1995.
249. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 86(6):2091-7, 9/1995.
250. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M. Interferon-alpha therapy for chronic myelogenous leukemia. Am J Med 99(4):402-11, 10/1995.
251. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86(9):3322-6, 11/1995.
252. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13(11):2827-34, 11/1995.
253. Preti HA, Huh YO, O'Brien SM, Andreeff M, Pierce ST, Keating M, Kantarjian HM. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer 76(9):1564-70, 11/1995.
254. Cortes JE, Kantarjian HM. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer 76(12):2393-417, 12/1995.
255. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86(11):4337-43, 12/1995.
256. Jeha S, Kantarjian H, O'Brien S, Huh Y, Pisa P, Ordonez N, Beran M. Growth and biologic properties of karyotypically defined subcategories of adult acute lymphocytic leukemia in mice with severe combined immunodeficiency. Blood 86(11):4278-85, 12/1995.
257. Licht JD, Chomienne C, Goy An Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH, Zelenetz AD, Willman CL, Chen Z, Chen S-J, MacIntyre E, Veil A, Cortes J, Kantarjian H, and Waxman S. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85:1083-94, 1995.
258. Cortes JE, Kantarjian H, O'Brien S, Keating M, Pierce S, Freireich EJ, Estey E. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia 9(1):115-7, 1995.
259. Hester JP, Dignani MC, Anaissie EJ, Kantarjian HM, O'Brien S, Freireich EJ. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apher 10(4):188-93, 1995.
260. Wright S, Chucrallah A, Chong YY, Kantarjian H, Keating M, Albitar M. Acute lymphoblastic leukemia with myeloperoxidase activity. Am J Hematol 51(2):147-51, 2/1996.
261. O'Brien S, Jeha S, Kantarjian H, Pisa P, Jin G, Keating M, Beran M. Engraftment of chronic prolymphocytic and T cell leukemia in SCID mice. Leukemia 10(2):338-44, 2/1996.
262. Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma 20(5-6):435-9, 2/1996.
263. Escudier SM, Albitar M, Robertson LE, Andreeff M, Pierce S, Kantarjian HM. Acute lymphoblastic leukemia following preleukemic syndromes in adults. Leukemia 10(3):473-7, 3/1996.
264. van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Champlin R. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 100(3):299-307, 3/1996.

265. Jeha S, Luo XN, Beran M, Kantarjian H, Atweh GF. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res 56(6):1445-50, 3/1996.
266. Sarris A, Cortes J, Kantarjian H, Pierce S, Smith T, Keating M, Koller C, Kornblau S, O'Brien S, Andreeff M. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma 21(1-2):85-92, 3/1996.
267. Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M, et al. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia. Leukemia 10(3):396-401, 3/1996.
268. Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol 166(3):618-30, 3/1996.
269. Anderlini P, Pierce S, Kantarjian H, Estey E. Acute myeloid leukemia-type chemotherapy for myelodysplasia. J Clin Oncol 14(4):1404-5, 4/1996.
270. Anderlini P, Luna M, Kantarjian HM, O'Brien S, Pierce S, Keating MJ, Estey EH. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia 10(4):600-8, 4/1996.
271. Kantarjian HM, Estey EH, Keating MA. New chemotherapeutic agents in acute myeloid leukemia. Leukemia 10 Suppl 1:S4-6, 4/1996.
272. Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 100(4):452-5, 4/1996.
273. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of myelogenous leukemia: current status and investigational options. Blood 87(8):3069-81, 4/1996.
274. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med 100(5):555-70, 5/1996.
275. Khouri IF, Kantarjian HM, Talpaz M, Giralt S, Rios MO, Hester JP, Champlin RE, Deisseroth AB. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant 17(5):775-9, 5/1996.
276. Ghaddar HM, Pierce S, Kantarjian HM, Freireich EJ, Keating MJ, Estey EH. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Leuk Lymphoma 22(1-2):71-6, 6/1996.
277. Anderlini P, Ghaddar HM, Smith TL, Pierce S, Kantarjian HM, O'Brien S, Keating MJ, Freireich EJ, Estey EH. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 10(6):964-9, 6/1996.
278. Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol 52(2):77-81, 6/1996.
279. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 88(2):756, 7/1996.
280. Patmasiriwat P, Fraizer GC, Claxton D, Kantarjian H, Saunders GF. Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities. Leukemia 10(7):1127-33, 7/1996.
281. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10(10):1563-9, 10/1996.
282. Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, Arlinghaus RB. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. Am J Clin Pathol 106(4):442-8, 10/1996.
283. O'Brien S, Kantarjian H, Talpaz M. Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. Leuk Lymphoma 23(3-4):247-52, 10/1996.
284. Beran M, Kantarjian H, O'Brien S, Koller C, al-Bitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreeff M, Keating M, Estey E. Topotecan, a topoisomerase I inhibitor, is active in the

treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88(7):2473-9, 10/1996.
285. Wilhelm M, Kantarjian HM, O'Brien S, Pierce S, Keating MJ, Freireich EJ, Estey EH. Pneumonia during remission induction chemotherapy in patients with AML or MDS. Leukemia 10(12):1870-3, 12/1996.
286. Cortes JE, Kantarjian H, Freireich EJ. Acute lymphocytic leukemia: a comprehensive review with emphasis on biology and therapy. Cancer Treat Res 84:291-323, 1996.
287. Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN. Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol 14(1):287-95, 1996.
288. Anaissie EJ, Vartivarian S, Bodey GP, Legrand C, Kantarjian H, Abi-Said D, Karl C, Vadhan-Raj S. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. Am J Med 100(1):17-23, 1996.
289. Pollicardo N, O'Brien S, Estey EH, al-Bitar M, Pierce S, Keating M, Kantarjian HM. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia 10(1):27-31, 1996.
290. Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 14(1):196-203, 1996.
291. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15(2):483-90, 2/1997.
292. Gisslinger H, Kurzrock R, Wetzler M, Tucker S, Kantarjian H, Robertson B, Talpaz M. Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. Leuk Lymphoma 25(1-2):121-33, 3/1997.
293. Kantarjian HM, O'Brien SM, Estey E, Giralt S, Beran M, Rios MB, Keating M, de Vos D, Talpaz M. Decitabine studies in chronic and acute myelogenous leukemia. Leukemia 11 Suppl 1:S35-6, 3/1997.
294. Giralt S, Davis M, O'Brien S, van Besien K, Champlin R, de Vos D, Kantarjian H. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia 11 Suppl 1:S32-4, 3/1997.
295. Seong D, Giralt S, Fischer H, Hayes K, Glassman A, Arlinghaus R, Xu J, Kantarjian H, Siciliano M, Champlin R. Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia. Bone Marrow Transplant 19(6):565-70, 3/1997.
296. Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M, Talpaz M. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 11(5):767-71, 5/1997.
297. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15(5):1796-802, 5/1997.
298. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12):4531-6, 6/1997.
299. Cortes J, Kantarjian HM, Giralt S, Talpaz M. Natural history and staging of chronic myelogenous leukaemia. Baillieres Clin Haematol 10(2):277-90, 6/1997.
300. Cortes J, Kantarjian H, Talpaz M, O'Brien S, Beran M, Koller C, Keating M. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Leukemia 11(6):788-91, 6/1997.
301. Cortes J, Kantarjian H, O'Brien S, Beran M, Estey E, Keating M, Talpaz M. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia 11(7):929-32, 7/1997.
302. Bouvet M, Babiera GV, Termuhlen PM, Hester JP, Kantarjian HM, Pollock RE. Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia: a single-institution, 25-year experience. Surgery 122(1):20-5, 7/1997.

303. Rodriguez-Monge EJ, Cortes JE, O'Brien S, Talpaz M, Kantarjian HM. Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. Cancer 80(3):396-400, 8/1997.
304. Bseiso AW, Kantarjian HM, Guo JQ, Cortes J, Talpaz M, Koller C, AlBitar M, Keating M, Arlinghaus R. Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia. Leukemia 11(9):1583-7, 9/1997.
305. Albitar M, Wu WI, Feltz E, Jin G, Hirsch-Ginsberg C, Kantarjian H, Beran M. Simplified Reverse Dot Blot Analyses for Detecting of ras Oncogene Mutations. Mol Diagn 2(3):169-176, 9/1997.
306. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 11(10):1661-4, 10/1997.
307. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90(8):2969-77, 10/1997.
308. O'Brien S, Kantarjian H, Beran M, Koller C, Talpaz M, Lerner S, Keating MJ. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 11(10):1631-5, 10/1997.
309. Sacchi S, Kantarjian HM, O'Brien S, Beran M, Koller C, Pierce S, Kornblau S, Estey E, Keating MJ, Talpaz M. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia 11(10):1610-6, 10/1997.
310. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11(10):1617-20, 10/1997.
311. Dignani MC, Anaissie EJ, Hester JP, O'Brien S, Vartivarian SE, Rex JH, Kantarjian H, Jendiroba DB, Lichtiger B, Andersson BS, Freireich EJ. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 11(10):1621-30, 10/1997.
312. Kantarjian HM, Talpaz M, O'Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ. Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. Clin Cancer Res 3(12 Pt 2):2723-33, 12/1997.
313. de Lima M, Strom SS, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich E, Estey E. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood 90(12):4719-24, 12/1997.
314. Beran M, Jeha S, O'Brien S, Estey E, Vitek L, Zurlo MG, Rios MB, Keating M, Kantarjian H. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. Clin Cancer Res 3(12 Pt 1):2377-84, 12/1997.
315. Koller CA, Kantarjian HM, Thomas D, O'Brien S, Rios MB, Kornblau S, Murphy S, Keating M. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 11(12):2039-44, 12/1997.
316. Sacchi S, Cortes J, Kantarjian H, Talpaz M. Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia. Hematopathol Mol Hematol 11(1):41-7, 1997.
317. Bseiso AW, Kantarjian H, Estey E. Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia. Leukemia 11(1):168-9, 1997.
318. Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 12(1):31-80, 2/1998.
319. DeLima M, Albitar M, O'Brien S, Pierce S, Kantarjian H, Andreeff M, Fayad L, Keating M, Estey E. Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia. Am J Med 104(3):246-51, 3/1998.
320. Sacchi S, Kantarjian HM, Smith TL, O'Brien S, Pierce S, Kornblau S, Beran M, Keating MJ, Talpaz M. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol 16(3):882-9, 3/1998.

321. Cortes J, Fayad L, Kantarjian H, O'Brien S, Lee MS, Talpaz M. Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia 12(4):455-62, 4/1998.
322. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 16(4):1526-31, 4/1998.
323. Seong D, Thall P, Kantarjian HM, Talpaz M, Swantkowski J, Xu J, Shen Y, Glassman A, Ramagli L, Siciliano MJ. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow. Clin Cancer Res 4(4):861-7, 4/1998.
324. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB, Champlin RC, Feinberg AP. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood 91(9):3144-7, 5/1998.
325. Schenk TM, Keyhani A, Bottcher S, Kliche KO, Goodacre A, Guo JQ, Arlinghaus RB, Kantarjian HM, Andreeff M. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia 12(5):666-74, 5/1998.
326. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91(11):3995-4019, 6/1998.
327. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Yousuf H, Regnery H, Klimov AI, Cox NJ, Whimbey E. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 26(6):1418-24, 6/1998.
328. Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia 12(6):860-4, 6/1998.
329. Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol 16(7):2321-31, 7/1998.
330. Kantarjian H. New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction. Semin Hematol 35(3 Suppl 4):1-2, 7/1998.
331. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 4(7):1661-72, 7/1998.
332. Beran M, Kantarjian H. Topotecan in the treatment of hematologic malignancies. Semin Hematol 35(3 Suppl 4):26-31, 7/1998.
333. Jendiroba DB, Lichtiger B, Anaissie E, Reddy V, O'Brien S, Kantarjian H, Freireich EJ. Evaluation and comparison of three mobilization methods for the collection of granulocytes. Transfusion 38(8):722-8, 8/1998.
334. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92(4):1165-71, 8/1998.
335. Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clin Cancer Res 4(8):1955-63, 8/1998.
336. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, Haidar M, Lerner S, Keating M, Albitar M. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 58(20):4552-7, 10/1998.
337. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129(7):559-66, 10/1998.
338. Krainick U, Kantarjian H, Broussard S, Talpaz M. Local cutaneous necrotizing lesions associated with interferon injections. J Interferon Cytokine Res 18(10):823-7, 10/1998.

339. Kantarjian HM, Talpaz M. Questions raised by the Benelux CML Study Group: results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha2b for chronic myeloid leukemia. Blood 92(8):2984-7, 10/1998.
340. Cortes J, Talpaz M, O'Brien S, Rios MB, Majlis A, Keating M, Freireich EJ, Kantarjian H. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol 16(10):3279-85, 10/1998.
341. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 92(9):3090-7, 11/1998.
342. Beran M, Estey E, O'Brien SM, Giles FJ, Koller CA, Kornblau S, Keating M, Kantarjian HM. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 31(5-6):521-31, 11/1998.
343. Jeha S, Kantarjian H, O'Brien S, Vitek L, Beran M. Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia. Leuk Lymphoma 32(1-2):159-64, 12/1998.
344. Rodriguez J, Cortes J, Smith T, O'Brien S, Rios MB, Talpaz M, Kantarjian H. Determinants of prognosis in late chronic-phase chronic myelogenous leukemia. J Clin Oncol 16(12):3782-7, 12/1998.
345. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16(12):3803-9, 12/1998.
346. Kornblau SM, Kantarjian H, O'Brien S, Andreeff M, Koller CA, Beran M, Keating M, Estey E. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leuk Lymphoma 28(3-4):371-5, 1998.
347. Wilhelm M, Bueso-Ramos C, O'Brien S, Pierce S, Keating M, Talpaz M, Kantarjian HM. Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia 12(1):65-70, 1998.
348. Munker R, Kantarjian H, O'Brien S, Keating M, Andreeff M, Estey EH. Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule. Acta Haematol 99(2):106-8, 1998.
349. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology (Williston Park) 13(2):169-80; discussion 181, 184, 2/1999.
350. Issa JP, Kantarjian H, Mohan A, O'Brien S, Cortes J, Pierce S, Talpaz M. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood 93(6):2075-80, 3/1999.
351. Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ, Estey EH. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 85(7):1506-13, 4/1999.
352. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93(8):2478-84, 4/1999.
353. Vey N, Kantarjian H, Tran H, Beran M, O'Brien S, Bivins C, Giles F, Cortes J, Cheson B, Arbuck S, Estey E. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Ann Oncol 10(5):577-83, 5/1999.
354. Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 93(9):2755-9, 5/1999.
355. Aboul-Nasr R, Estey EH, Kantarjian HM, Freireich EJ, Andreeff M, Johnson BJ, Albitar M. Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol 111(6):753-8, 6/1999.

356. Dabaja BS, Faderl S, Thomas D, Cortes J, O'Brien S, Nasr F, Pierce S, Hayes K, Glassman A, Keating M, Kantarjian HM. Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications. Leukemia 13(6):869-72, 6/1999.
357. O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 93(12):4149-53, 6/1999.
358. Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect? Cancer 85(12):2583-8, 6/1999.
359. Estey EH, Thall PF, Reed P, Kantarjian H, Beran M, Pierce S, Keating MJ. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Leukemia 13(6):850-4, 6/1999.
360. Weinkauff R, Estey EH, Starostik P, Hayes K, Huh YO, Hirsch-Ginsberg C, Andreeff M, Keating M, Kantarjian HM, Freireich EJ, Albitar M. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol 111(6):733-40, 6/1999.
361. Patmasiriwat P, Fraizer G, Kantarjian H, Saunders GF. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 13(6):891-900, 6/1999.
362. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 341(3):164-72, 7/1999.
363. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 5(7):1758-66, 7/1999.
364. Faderl S, Kantarjian HM, Manshouri T, Chan CY, Pierce S, Hays KJ, Cortes J, Thomas D, Estrov Z, Albitar M. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res 5(7):1855-61, 7/1999.
365. Seong D, Kantarjian HM, Albitar M, Arlinghaus R, Xu J, Talpaz M, Rios MB, Guo JQ, O'Brien S, Siciliano M. Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. Ann Oncol 10(8):955-9, 8/1999.
366. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 131(3):207-19, 8/1999.
367. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17(8):2461-70, 8/1999.
368. Wilhelm M, O'Brien S, Rios MB, Estey E, Keating MJ, Plunkett W, Sorenson M, Kantarjian HM. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk Lymphoma 34(5-6):511-8, 8/1999.
369. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94(5):1517-36, 9/1999.
370. Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O'Brien S, Markowitz A, Kantarjian H. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 35(1-2):109-18, 9/1999.
371. Giles FJ, Kantarjian HM, Cortes J, Thomas DA, Talpaz M, Manshouri T, Albitar M. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance. Cancer 86(5):805-13, 9/1999.
372. Cortes J, Fayad L, O'Brien S, Keating M, Kantarjian H. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity. Clin Cancer Res 5(9):2491-7, 9/1999.
373. Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T, Chan CC, Hays KJ, Pierce S, Albitar M. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther 5(3):159-63, 9/1999.

374. Starostik P, O'Brien S, Chung CY, Haidar M, Manshouri T, Kantarjian H, Freireich E, Keating M, Albitar M. The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia. Leuk Res 23(9):795-801, 9/1999.
375. Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17(9):2819-30, 9/1999.
376. Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 86(7):1203-9, 10/1999.
377. Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 94(7):2230-5, 10/1999.
378. Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM, Talpaz M, Aggarwal BB. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 94(8):2844-53, 10/1999.
379. Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86(7):1216-30, 10/1999.
380. Beran M, Kantarjian H. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Semin Hematol 36(4 Suppl 8):3-10, 10/1999.
381. Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P, Rodriguez J, von Wolff B, Gajewski J, Cabanillas F, Champlin R. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 10(11):1293-9, 11/1999.
382. Sacchi S, Kantarjian HM, Freireich EJ, O'Brien S, Cortes J, Rios MB, Kornblau S, Giles FJ, Koller C, Gajewski J, Talpaz M. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leuk Lymphoma 35(5-6):483-9, 11/1999.
383. Koller CA, Kantarjian HM, Feldman EJ, O'Brien S, Rios MB, Estey E, Keating M. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer 86(11):2246-51, 12/1999.
384. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res 5(12):4041-7, 12/1999.
385. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94(11):3717-21, 12/1999.
386. Ravandi F, Cortes J, Albitar M, Arlinghaus R, Qiang Guo J, Talpaz M, Kantarjian HM. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol 107(3):581-6, 12/1999.
387. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86(12):2632-41, 12/1999.
388. Lin CW, O'Brien S, Faber J, Manshouri T, Romaguera J, Huh YO, Kantarjian H, Keating M, Albitar M. De novo CD5+ Burkitt lymphoma/leukemia. Am J Clin Pathol 112(6):828-35, 12/1999.
389. Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma 36(1-2):57-65, 12/1999.

390. Kantarjian HM, Talpaz M, O'Brien S, Manshouri T, Cortes J, Giles F, Rios MB, Croce CM, Albitar M. Significance of FHIT expression in chronic myelogenous leukemia. Clin Cancer Res 5(12):4059-64, 12/1999.
391. Partyka S, O'Brien S, Podoloff D, Kantarjian H, Keating MJ. The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter's transformation. Leuk Lymphoma 36(1-2):151-5, 12/1999.
392. Vey N, Kantarjian H, Beran M, O'Brien S, Cortes J, Koller C, Estey E. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Invest New Drugs 17(1):89-95, 1999.
393. Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer 85(1):58-64, 1999.
394. Albitar M, Manshouri T, Kantarjian H, Keating M, Estrov Z, Faber J, Freireich EJ, Pierce S, Estey E. Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res 23(1):63-9, 1999.
395. Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs 17(1):81-7, 1999.
396. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 17(1):284-92, 1999.
397. Cortes J, Estey E, Beran M, O'Brien S, Giles F, Koller C, Keating M, Kantarjian H. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma 36(5-6):479-84, 2/2000.
398. Kaban K, Kantarjian H, Talpaz M, O'Brien S, Cortes J, Giles FJ, Pierce S, Albitar M. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. Cancer 88(3):570-6, 2/2000.
399. Keyhani A, Huh YO, Jendiroba D, Pagliaro L, Cortez J, Pierce S, Pearlman M, Estey E, Kantarjian H, Freireich EJ. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res 24(2):153-9, 2/2000.
400. Cortes J, Kantarjian HM. Promising approaches in acute leukemia. Invest New Drugs 18(1):57-82, 2/2000.
401. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18(3):547-61, 2/2000.
402. Vey N, Giles FJ, Kantarjian H, Smith TL, Beran M, Jeha S. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clin Cancer Res 6(2):731-6, 2/2000.
403. Haidar MA, Kantarjian H, Manshouri T, Chang CY, O'Brien S, Freireich E, Keating M, Albitar M. ATM gene deletion in patients with adult acute lymphoblastic leukemia. Cancer 88(5):1057-62, 3/2000.
404. Chung CY, Kantarjian H, Haidar M, Starostik P, Manshouri T, Gidel C, Freireich E, Keating M, Albitar M. Deletions in the 13q14 locus in adult lymphoblastic leukemia: rate of incidence and relevance. Cancer 88(6):1359-64, 3/2000.
405. Haidar MA, Manshouri T, Keating MJ, Kantarjian HM, Freireich EJ, Mehta K, Albitar M. Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice. Int J Oncol 16(3):561-5, 3/2000.
406. Giles FJ, Wong GC, Clark SJ, Pierce S, Kantarjian HM, Keating MJ. Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia. Leuk Lymphoma 37(1-2):87-95, 3/2000.
407. Keating MJ, Smith TL, Lerner S, O'Brien S, Robertson LE, Kantarjian H, Freireich EJ. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma 37(1-2):71-85, 3/2000.

408. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 6(4):1401-9, 4/2000.
409. Huh YO, Smith TL, Collins P, Bueso-Ramos C, Albitar M, Kantarjian HM, Pierce SA, Freireich EJ. Terminal deoxynucleotidyl transferase expression in acute myelogenous leukemia and myelodysplasia as determined by flow cytometry. Leuk Lymphoma 37(3-4):319-31, 4/2000.
410. Seong CM, Giralt S, Kantarjian H, Xu J, Swantkowski J, Hayes K, Glassman AB, Khouri I, Korbling M, Thall P, Siciliano MJ, Champlin RE. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol 18(9):1831-6, 5/2000.
411. Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian HM, Talpaz M. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Cancer Res 6(5):1671-7, 5/2000.
412. Saad ED, Thomas DA, O'Brien S, Fuller GN, Medeiros LJ, Forman A, Albitar M, Schomer D, Kantarjian HM, Keating MJ. Progressive multifocal leukoencephalopathy with concurrent Richter's syndrome. Leuk Lymphoma 38(1-2):183-90, 6/2000.
413. Ravandi-Kashani F, O'Brien S, Manshouri T, Lerner S, Sim S, Dodd K, Kantarjian H, Freireich E, Keating M, Albitar M. Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. Leuk Res 24(6):469-74, 6/2000.
414. Aguayo A, O'Brien S, Keating M, Manshouri T, Gidel C, Barlogie B, Beran M, Koller C, Kantarjian H, Albitar M. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 96(2):768-70, 7/2000.
415. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96(6):2240-5, 9/2000.
416. Talpaz M, Qiu X, Cheng K, Cortes JE, Kantarjian H, Kurzrock R. Autoantibodies to Abl and Bcr proteins. Leukemia 14(9):1661-6, 9/2000.
417. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6(9):1018-23, 9/2000.
418. Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P, Sarris AH, Younes A, Rodriguez J, Cabanillas F. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 39(1-2):77-85, 9/2000.
419. Kozuch P, Talpaz M, Faderl S, O'Brien S, Freireich EJ, Kantarjian H. Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation? Cancer 89(7):1482-9, 10/2000.
420. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B, O'Brien S. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 18(20):3513-21, 10/2000.
421. Faderl S, Kantarjian HM, Talpaz M, O'Brien S. New treatment approaches for chronic myelogenous leukemia. Semin Oncol 27(5):578-86, 10/2000.
422. Kantarjian HM, Giles FJ, O'Brien S, Giralt S, Talpaz M. Therapeutic choices in younger patients with chronic myelogenous leukemia. Cancer 89(8):1647-58, 10/2000.
423. Ibrahim S, Estey EH, Pierce S, Glassman A, Keating M, O'Brien S, Kantarjian HM, Albitar M. 11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses. Am J Clin Pathol 114(5):793-7, 11/2000.
424. Tannir NM, Talpaz M, Ghazal H, Proothi S, Kantarjian HM. Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. Leuk Lymphoma 39(5-6):647-50, 11/2000.
425. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol 12(6):564-73, 11/2000.
426. Berman E, Clift RA, Copelan EA, Emanuel PD, Erba HP, Glenn MJ, Greenberg PL, Jones RJ, O'Brien S, Saba HI, Schilder R, Snyder DS, Soiffer RJ, Tallman MS, Wetzler M, Ravandi-Kashani F, Kantarjian H, Talpaz M. NCCN Practice Guidelines for Chronic Myelogenous Leukemia. Oncology (Williston Park) 14(11A):229-40, 11/2000.

427. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 89(9):1976-82, 11/2000.
428. Kantarjian HM. Adult acute lymphocytic leukemia. Introduction and questions related to current programs. Hematol Oncol Clin North Am 14(6):1205-8, VII, 12/2000.
429. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of minimal residual disease in leukemia. Int J Oncol 17(6):1277-87, 12/2000.
430. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol 11(12):1551-6, 12/2000.
431. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96(12):3671-4, 12/2000.
432. Garcia-Manero G, Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 14(6):1381-96, x-xi, 12/2000.
433. Kantarjian H, Melo JV, Tura S, Giralt S, Talpaz M. Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. Hematology (Am Soc Hematol Educ Program):90-109, 2000.
434. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 11(1):69-72, 2000.
435. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, Albitar M, Estrov Z. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36(3-4):263-73, 2000.
436. Verstovsek, S, Kantarjian H, Estey E, Aguaryo A, Giles FJ, Manshouri T, Koller C, Estrov Z, Freireich E, Keating M, Albitar M:. Plasma hepatocyte growth factor is prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. . Amer Soc of Hematol 96:104a, 2000.
437. Rodriguez J, Cortes J, Talpaz M, O'Brien S, Smith TL, Rios MB, Kantarjian H. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clin Cancer Res 6(1):147-52, 2000.
438. Faber J, Kantarjian H, Roberts MW, Keating M, Freireich E, Albitar M. Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia. Arch Pathol Lab Med 124(1):92-7, 2000.
439. Beran M, Kantarjian HM. Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies. Ann N Y Acad Sci 922:247-59, 2000.
440. Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, Pierce S, Cortes J, Estey E. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 40:511-20, 2/2001.
441. Nguyen Q, Estey E, Raad I, Rolston K, Kantarjian H, Jacobson K, Konoplev S, Ghosh S, Luna M, Tarrand J, Whimbey E. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis 32(4):539-45, 2/2001.
442. Thomas DA, Kantarjian HM. Lymphoblastic lymphoma. Hematol Oncol Clin North Am 15(1):51-95, vi, 2/2001.
443. Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, Kantarjian HM. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 19(3):762-71, 2/2001.
444. Pachmann K, Zhao S, Schenk T, Kantarjian H, El-Naggar AK, Siciliano MJ, Guo JQ, Arlinghaus RB, Andreeff M. Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification. Br J Haematol 112(3):749-59, 3/2001.
445. Tannir NM, Kantarjian H. Idiopathic thrombocytopenic purpura following successful treatment of acute lymphoblastic leukemia. Leuk Lymphoma 41(1-2):217-20, 3/2001.

446. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19(5):1414-20, 3/2001.
447. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res 61(6):2343-55, 3/2001.
448. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14):1038-42, 4/2001.
449. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 134(7):573-86, 4/2001.
450. Aguayo A, Manshouri T, O'Brien S, Keating M, Beran M, Koller C, Kantarjian H, Rogers A, Albitar M. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res 25(4):279-85, 4/2001.
451. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031-7, 4/2001.
452. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, Beran M, Kantarjian HM, Freireich EJ, Albitar M. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 7(4):795-9, 4/2001.
453. Giles FJ, Kantarjian H, O'Brien S, Rios MB, Cortes J, Beran M, Koller C, Keating M, Talpaz M. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leuk Lymphoma 41(3-4):309-19, 4/2001.
454. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19(8):2165-70, 4/2001.
455. Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 97(9):2846-53, 5/2001.
456. Verstovsek S, Manshouri T, Kantarjian H, Giles FJ, Keating M, Estey E, Albitar M. Highly reproducible detection and semi-quantification of telomerase activity. Biotechniques 30(5):930-4, 5/2001.
457. Rosenfeld C, Kantarjian H. Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies. Leuk Lymphoma 41(5-6):493-500, 5/2001.
458. Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O'Brien S, Kantarjian H, Keating MJ. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol 12(5):621-5, 5/2001.
459. Ravandi F, Hayes K, Cortes J, Albitar M, Glassman A, Talpaz M, Kantarjian HM. Translocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia. Cancer 91(9):1704-8, 5/2001.
460. Kurzrock R, Bueso-Ramos CE, Kantarjian H, Freireich E, Tucker SL, Siciliano M, Pilat S, Talpaz M. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 19(11):2915-26, 6/2001.
461. Kurzrock R, Kantarjian H, Talpaz M. Chronic myelogenous leukemia in chronic phase. Curr Treat Options Oncol 2(3):245-52, 6/2001.
462. Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27(12):1221-5, 6/2001.
463. Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer 91(11):1964-72, 6/2001.

464. Giles FJ, Shen Y, Kantarjian HM, Korbling MJ, O'Brien S, Anderlini P, Donato M, Pierce S, Keating MJ, Freireich EJ, Estey E. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma 42(1-2):67-73, 6/2001.
465. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98(1):181-6, 7/2001.
466. Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, Schlette ES, Faderl S, Sarris A, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma 42(3):329-37, 7/2001.
467. Verstovsek S, Estey E, Manshouri T, Keating M, Kantarjian H, Giles FJ, Albitar M. High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma 42(3):511-6, 7/2001.
468. Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 92(1):7-14, 7/2001.
469. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92(2):406-13, 7/2001.
470. Estey E, Koller C, Cortes J, Reed P, Freireich E, Giles F, Kantarjian H. Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid. Leuk Lymphoma 42(3):309-16, 7/2001.
471. Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, Koller C, Estrov Z, Freireich E, Keating M, Albitar M. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 15(8):1165-70, 8/2001.
472. Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, Estey E, Albitar M. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 114(2):290-5, 8/2001.
473. Aboul-Nasr R, O'Brien S, Freireich EJ, Ginsberg CF, Kantarjian HM, Koller CA, Keating MJ, Albitar M. "T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow. Leuk Lymphoma 42(5):1023-31, 9/2001.
474. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM. Homoharringtonine: history, current research, and future direction. Cancer 92(6):1591-605, 9/2001.
475. Talpaz M, O'Brien S, Rose E, Gupta S, Shan J, Cortes J, Giles FJ, Faderl S, Kantarjian HM. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 98(6):1708-13, 9/2001.
476. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell RP, Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19(18):3852-60, 9/2001.
477. Albitar M, Manshouri T, Gidel C, Croce C, Kornblau S, Pierce S, Kantarjian HM. Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia. Leuk Res 25(10):859-64, 10/2001.
478. Cortes J, O'Brien S, Loscertales J, Kantarjian H, Giles F, Thomas D, Koller C, Keating M. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer 92(8):2016-22, 10/2001.
479. Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, Cortes J, Thomas DA, Faderl S, Despa S, Estey EH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 92(8):1999-2015, 10/2001.
480. Kantarjian HM, Shan J, Smith T, Talpaz M, Kozuch P, Rios MB, Cortes J, Giles FJ, O'Brien S. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer 92(10):2501-7, 11/2001.

481. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 21(6A):3777-84, 11/2001.
482. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 98(13):3575-83, 12/2001.
483. Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin Cancer Res 7(12):3884-93, 12/2001.
484. Thomas DA, Giles FJ, Cortes J, Albitar M, Kantarjian HM. Antiangiogenic therapy in leukemia. Acta Haematol 106(4):190-207, 2001.
485. Sarriera JE, Albitar M, Estrov Z, Gidel C, Aboul-Nasr R, Manshouri T, Kornblau S, Chang KS, Kantarjian H, Estey E. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia 15(1):57-61, 2001.
486. Faderl S, Gidel C, Kantarjian HM, Manshouri T, Keating M, Albitar M. Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia. Leuk Res 25(1):39-43, 2001.
487. Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs 19(1):13-20, 2001.
488. Tsimberidou, A, O'Brien S, Cortes J, Faderl S, Andreeff M, Kantarjian, H, Keating M, Giles F. Phase II study of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) treatment of patients with richter's syndrome (RS), refractory prolymphocytic leukemia (PLL) or refractory non-hodgkin's lymphoma (NHL). Blood 98:250b, 2001.
489. Lai R, Estey E, Shen Y, Despa S, Kantarjian H, Beran M, Maushouri T, Quackenbuch RC, Keating M, Albitar M. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer 94(1):14-7, 1/2002.
490. Weiser MA, O'Brien S, Thomas DA, Pierce SA, Lam TP, Kantarjian HM. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer 94(2):285-91, 1/2002.
491. Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, Faderl S, Kantarjian H. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer 94(3):773-9, 2/2002.
492. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9):645-52, 2/2002.
493. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 20(3):656-64, 2/2002.
494. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, Glassman AB, Albitar M, Kwari MI, Beran M. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99(3):840-9, 2/2002.
495. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94(5):1492-9, 3/2002.
496. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL. Imatinib induces durable hematologic and cytogenetic responses in patients with

accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99(6):1928-37, 3/2002.
497. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A, Albitar M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 99(6):2265-7, 3/2002.
498. Verstovsek S, Kantarjian H, Manshouri T, O'Brien S, Faderl S, Talpaz M, Cortes J, Albitar M. Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer 94(5):1517-21, 3/2002.
499. DiRaimondo F, Albitar M, Huh Y, O'Brien S, Montillo M, Tedeschi A, Kantarjian H, Lerner S, Giustolisi R, Keating M. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer 94(6):1721-30, 3/2002.
500. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 43(4):767-72, 4/2002.
501. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 94(7):2024-32, 4/2002.
502. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99(10):3547-53, 5/2002.
503. Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 94(10):2653-62, 5/2002.
504. Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 94(9):2416-25, 5/2002.
505. Lee WI, Kantarjian H, Glassman A, Talpaz M, Lee MS. Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction. Ann Oncol 13(5):781-8, 5/2002.
506. Dabaja BS, Ha CS, Thomas DA, Wilder RB, Gopal R, Cortes J, Bueso-Ramos C, Hess MA, Cox JD, Kantarjian HM. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer 94(10):2738-44, 5/2002.
507. Atallah E, Talpaz M, O'Brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Cancer 94(11):2996-9, 6/2002.
508. Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JP. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res 8(6):1897-903, 6/2002.
509. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH, Cortes JE, Kantarjian HM. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99(11):4222-4, 6/2002.
510. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia-Manero G, Manshouri T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 16(6):1045-52, 6/2002.
511. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 99(12):4343-9, 6/2002.
512. Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives. Rev Clin Exp Hematol 6(2):142-60; discussion 200-2, 6/2002.

513. Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res 26(6):551-9, 6/2002.
514. Faderl S, Thall PF, Kantarjian HM, Estrov Z. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol 117(4):869-74, 6/2002.
515. Alvarado Y, Kantarjian HM, Cortes JE, Apostolidou E, Bivins C, Giles FJ. Troxacitabine activity in extramedullary myeloid leukemia. Hematology 7(3):179-85, 6/2002.
516. Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HM. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res 26(7):643-9, 7/2002.
517. Verstovsek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H, Albitar M. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 118(1):151-6, 7/2002.
518. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8(7):2217-24, 7/2002.
519. Cortes JE, Kurzrock R, Kantarjian HM. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Semin Hematol 39(3 Suppl 2):26-30, 7/2002.
520. Kantarjian HM, Cortes JE, Rowe JM, Kurzrock R. Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. Semin Hematol 39(3 Suppl 2):36-8, 7/2002.
521. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8(7):2177-87, 7/2002.
522. Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res 8(7):2134-41, 7/2002.
523. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8(7):2167-76, 7/2002.
524. Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica 87(8):804-7, 8/2002.
525. Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian HM, Rogers A, Jilani I, Lin CW, Pierce S, Freireich EJ, Estey EH. Myelodysplastic syndrome is not merely "preleukemia." Blood 100(3):791-8, 8/2002.
526. Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, Talpaz M. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95(4):881-7, 8/2002.
527. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100(5):1590-5, 9/2002.
528. Lai R, O'Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M, Albitar M. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 95(5):1071-5, 9/2002.
529. Tsimberidou AM, Thomas D, O'Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol 50(3):237-42, 9/2002.

530. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26(9):881-4, 9/2002.
531. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, Lerner S, Kantarjian H. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43(9):1755-62, 9/2002.
532. Giles FJ, Kantarjian HM, Bekele BN, Cortes JE, Faderl S, Thomas DA, Manshouri T, Rogers A, Keating MJ, Talpaz M, O'Brien S, Albitar M. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol 119(1):38-45, 10/2002.
533. Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M, Scappini B, Rios MB, Keating MJ, Beran M. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 95(8):1673-84, 10/2002.
534. Kurzrock R, Cortes J, Kantarjian H. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol 39(4 Suppl 3):20-4, 10/2002.
535. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, Giles F, Kantarjian H, Cortes J, Thomas D, Keating M, Freireich E, Albitar M. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 118(4):560-6, 10/2002.
536. Huh YO, Jilani I, Estey E, Giles F, Kantarjian H, Freireich E, Albitar M. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia 16(11):2249-52, 11/2002.
537. Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, Kantarjian HM, Beran M. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 62(21):5995-8, 11/2002.
538. Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T, Gidel C, O'Brien S, Keating MJ, Albitar M. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 95(9):1923-30, 11/2002.
539. Guo JQ, Lin H, Kantarjian H, Talpaz M, Champlin R, Andreeff M, Glassman A, Arlinghaus RB. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 16(12):2447-53, 12/2002.
540. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 50(6):497-500, 12/2002.
541. Foran, J, Wetzler M, Kantarjian HM, Faderl S, Abramson N, Rizzieri DA, Craig A, Weiss J, Douer D. A phase II, open-label study of CLOFAREX™ in adult patients with refractory or relapsed acute myelogenous leukemia. Blood 100:271b, 2002.
542. Ravandi F, Talpaz M, Kantarjian H, Estrov Z. Cellular signalling pathways: new targets in leukaemia therapy. Br J Haematol 116(1):57-77, 2002.
543. Giles F, Garcia-Manero G, O'Brien S, Estey E, Kantarjian H. Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. Acta Haematol 108(3):164-7, 2002.
544. Raad I, Hanna H, Osting C, Hachem R, Umphrey J, Tarrand J, Kantarjian H, Bodey GP. Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction. Infect Control Hosp Epidemiol 23(1):41-3, 2002.
545. Apostolidou, E, Estey, E, Cortes, J, Garcia-Manero, G, Faderl, S, Thomas, D, Tsimberidou, A, Kantarjian, H, Giles, F. Mitroxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. . Leukemia Research 26:1-4, 2002.
546. Faderl S, Gandhi V, Kantarjian H, Plunkett W. New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif 20:37-58, 2002.
547. Garcia-Manero, G, Kantarjian, H. Treatment innovations in chronic myelogenous leukemia. Hematologia Argentina. 2:19-25, 2002.
548. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2):473-5, 1/2003.
549. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M, Kantarjian H. Liposomal amphotericin B versus the combination of fluconazole and

itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97(2):450-6, 1/2003.
550. Lu D, Nounou R, Beran M, Estey E, Manshouri T, Kantarjian H, Keating MJ, Albitar M. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 97(2):441-9, 1/2003.
551. Garcia-Manero G, Jeha S, Daniel J, Williamson J, Albitar M, Kantarjian HM, Issa JP. Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer 97(3):695-702, 2/2003.
552. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97(4):1033-41, 2/2003.
553. Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Lerner S, Keating M, Albitar M. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 120(3):452-6, 2/2003.
554. Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 97(5):1234-41, 3/2003.
555. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13):1201-14, 3/2003.
556. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A, Kantarjian HM. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 9(3):976-80, 3/2003.
557. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101(5):1692-7, 3/2003.
558. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 97(6):1481-7, 3/2003.
559. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994-1004, 3/2003.
560. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Faderl S, Giles FJ, Keating M, Albitar M. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer 97(5):1248-52, 3/2003.
561. de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97(5):1242-7, 3/2003.
562. Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov Z. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res 27(3):259-66, 3/2003.

563. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21(6):1167-73, 3/2003.
564. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 21(6):1050-6, 3/2003.
565. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101(7):2507-13, 4/2003.
566. Ibrahim S, Jilani I, O'Brien S, Rogers A, Manshouri T, Giles F, Faderl S, Thomas D, Kantarjian H, Keating M, Albitar M. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer 97(8):1914-9, 4/2003.
567. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 97(7):1711-20, 4/2003.
568. Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res 27(4):301-4, 4/2003.
569. Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer 97(8):1920-8, 4/2003.
570. Giles FJ, Bekele BN, O'Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P, Albitar M. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol 121(4):578-85, 5/2003.
571. Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101(10):4131-6, 5/2003.
572. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 21(9):1722-7, 5/2003.
573. Thomas MB, Koller C, Yang Y, Shen Y, O'Brien S, Kantarjian H, Davis J, Estey E. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. Leukemia 17(5):990-3, 5/2003.
574. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413-5, 5/2003.
575. Duzkale H, Jilani I, Orsolic N, Zingaro RA, Golemovic M, Giles FJ, Kantarjian H, Albitar M, Freireich EJ, Verstovsek S. In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines. Cancer Chemother Pharmacol 51(5):427-32, 5/2003.
576. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 138(10):819-30, 5/2003.
577. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res 27(5):375-80, 5/2003.

578. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 97(9):2225-8, 5/2003.
579. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101(10):3794-800, 5/2003.
580. Verstovsek S, Manshouri T, Smith FO, Giles FJ, Cortes J, Estey E, Kantarjian H, Keating M, Jeha S, Albitar M. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer 97(9):2212-7, 5/2003.
581. Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 97(9):2218-24, 5/2003.
582. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101(12):4714-6, 6/2003.
583. Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian H. Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. Leuk Res 27(6):475-9, 6/2003.
584. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 17(6):1100-3, 6/2003.
585. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 97(11):2760-6, 6/2003.
586. Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer 97(12):3010-6, 6/2003.
587. Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, Giles F, Albitar M. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res 27(7):661-9, 7/2003.
588. Champlin RE, Kantarjian H. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia. Clin Adv Hematol Oncol 1(7):398-400, 7/2003.
589. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad, II. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98(2):292-9, 7/2003.
590. Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Estrov Z. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood 102(2):630-7, 7/2003.
591. Konopleva M, Cheng SC, Cortes JE, Hayes KJ, Pierce SA, Andreeff M, Giles FJ, O'Brien S, Kantarjian HM, Estey EH. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. Haematologica 88(7):733-6, 7/2003.
592. Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad, II, Kontoyiannis DP. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer 98(1):86-93, 7/2003.
593. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102(1):83-6, 7/2003.

594. Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth Rios M, Keating M, Freireich E, Talpaz M. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer 98(1):81-5, 7/2003.
595. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer 98(3):437-57, 8/2003.
596. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98(3):522-8, 8/2003.
597. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Aggarwal BB. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102(3):987-95, 8/2003.
598. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102(3):795-801, 8/2003.
599. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, Beran M. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88(8):853-63, 8/2003.
600. Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, O'Brien SM. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol 52(3):223-8, 9/2003.
601. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 52(3):229-34, 9/2003.
602. Gatto S, Ball G, Onida F, Kantarjian HM, Estey EH, Beran M. Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood 102(5):1622-5, 9/2003.
603. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98(6):1105-13, 9/2003.
604. Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 102(5):1866-8, 9/2003.
605. Beran M, O'Brien S, Thomas DA, Tran HT, Cortes-Franco JE, Giles F, Estey E, Kantarjian HM. Phase I study of oral topotecan in hematological malignancies. Clin Cancer Res 9(11):4084-91, 9/2003.
606. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98(5):888-93, 9/2003.
607. Raad, II, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, Boktour MR, Whimbey EE, Kontoyiannis D, Jacobson K, Kantarjian H, Levett LM, Rolston KV. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 98(5):1039-47, 9/2003.
608. Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer 98(7):1430-7, 10/2003.
609. Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma 44(10):1719-25, 10/2003.

610. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 27(10):893-7, 10/2003.
611. Lee JN, Giles F, Huh YO, Manshouri T, O'Brien S, Kantarjian HM, Keating MJ, Albitar M. Molecular differences between small and large cells in patients with chronic lymphocytic leukemia. Eur J Haematol 71(4):235-42, 10/2003.
612. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102(7):2379-86, 10/2003.
613. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 27(10):887-91, 10/2003.
614. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 98(7):1337-54, 10/2003.
615. Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA, Kurzrock R. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17(11):2101-6, 11/2003.
616. Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 98(9):1905-11, 11/2003.
617. Estey EH, Thall PF, Wang X, Verstovsek S, Cortes J, Kantarjian HM. Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood 102(9):3097-9, 11/2003.
618. Thomas DA, Estey E, Giles FJ, Faderl S, Cortes J, Keating M, O'Brien S, Albitar M, Kantarjian H. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 123(3):436-41, 11/2003.
619. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F, Keating M, Albitar M. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 102(10):3514-20, 11/2003.
620. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98(12):2657-63, 12/2003.
621. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien SM, Keating MJ, Kantarjian HM, Armitage JO, Albitar M. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol 123(5):850-7, 12/2003.
622. Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs 12(12):1985-93, 12/2003.
623. Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 102(13):4527-34, 12/2003.
624. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 98(11):2483-7, 12/2003.
625. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98(12):2636-42, 12/2003.
626. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 52(6):449-52, 12/2003.

627. Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 9(17):6335-42, 12/2003.
628. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 27(12):1077-83, 12/2003.
629. Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res 27(12):1091-6, 12/2003.
630. Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM. Rituximab in relapsed or refractory hairy cell leukemia. Blood 102(12):3906-11, 12/2003.
631. Cortes J Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol 40(1):79-86, 2003.
632. Jilani I, Estey E, Manshuri T, Caligiuri M, Keating M, Giles F, Thomas D, Kantarjian H, Albitar M. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia 17(1):114-9, 2003.
633. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R, Talpaz M. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101(1):97-100, 2003.
634. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51(1):87-90, 2003.
635. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles FJ. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 51(1):81-6, 2003.
636. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, Giles F, Rios MB, Shan J, Arlinghaus R. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 9(1):160-6, 2003.
637. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64(2):672-7, 1/2004.
638. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100(3):581-9, 2/2004.
639. Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103(3):784-9, 2/2004.
640. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen MH, Aggarwal BB. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol 35(2):246-53, 2/2004.
641. Mattiuzzi GN, Kantarjian H, O'Brien S, Kontoyiannis DP, Giles F, Zhou X, Lim J, Bekele BN, Faderl S, Cortes J, Pierce S, Leitz GJ, Raad I, Estey E. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100(3):568-73, 2/2004.
642. Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer 100(3):441-54, 2/2004.
643. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5):1635-40, 3/2004.

644. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 100(6):1179-85, 3/2004.
645. Orsolic N, Giles FJ, Gourdeau H, Golemovic M, Beran M, Cortes J, Freireich EJ, Kantarjian H, Verstovsek S. Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. Br J Haematol 124(6):727-38, 3/2004.
646. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res 28(4):353-7, 4/2004.
647. Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 100(7):1459-71, 4/2004.
648. Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res 28(4):373-8, 4/2004.
649. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103(8):2873-8, 4/2004.
650. Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100(7):1449-58, 4/2004.
651. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22(7):1287-92, 4/2004.
652. Raad I, Hachem R, Hanna H, Afif C, Escalante C, Kantarjian H, Rolston K. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 53(4):646-9, 4/2004.
653. Rogers A, Joe Y, Manshouri T, Dey A, Jilani I, Giles F, Estey E, Freireich E, Keating M, Kantarjian H, Albitar M. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood 103(7):2799-801, 4/2004.
654. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 125(2):187-95, 4/2004.
655. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10(9):2908-17, 5/2004.
656. Cortes J Kantarjian H. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer 100(10):2064-78, 5/2004.
657. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10(10):3371-6, 5/2004.
658. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103(10):3669-76, 5/2004.
659. Hu Q, Dey AL, Yang Y, Shen Y, Jilani IB, Estey EH, Kantarjian HM, Giles FJ, Albitar M. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 100(9):1884-91, 5/2004.

660. Sanders KE, Ha CS, Cortes-Franco JE, Koller CA, Kantarjian HM, Cox JD. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer 100(10):2176-80, 5/2004.
661. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien SM, Kantarjian HM, Armitage JO, Albitar M. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 28(6):595-604, 6/2004.
662. Cortes J, O'Brien S, Quintas A, Giles F, Shan J, Rios MB, Talpaz M, Kantarjian H. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 100(11):2396-402, 6/2004.
663. Beran M, Luthra R, Kantarjian H, Estey E. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res 28(6):547-50, 6/2004.
664. Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100(12):2583-91, 6/2004.
665. Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 100(12):2592-7, 6/2004.
666. Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. Leuk Res 28(6):613-8, 6/2004.
667. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396-407, 6/2004.
668. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39(2):199-205, 7/2004.
669. Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Medeiros LJ, Kantarjian H. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 101(2):332-6, 7/2004.
670. Faderl S, Kantarjian HM. Novel therapies for myelodysplastic syndromes. Cancer 101(2):226-41, 7/2004.
671. Verstovsek S, Giles FJ, O'Brien S, Faderl S, Kantarjian HM, Keating MJ, Albitar M. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res 28(7):707-11, 7/2004.
672. Hanna H, Benjamin R, Chatzinikolaou I, Alakech B, Richardson D, Mansfield P, Dvorak T, Munsell MF, Darouiche R, Kantarjian H, Raad I. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol 22(15):3163-71, 8/2004.
673. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 101(5):999-1008, 9/2004.
674. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104(6):1624-30, 9/2004.
675. Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP, Chatzinikolaou I, Perego C, Kantarjian HM, Raad, II. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101(7):1594-600, 10/2004.
676. Cooper T, Kantarjian H, Plunkett W, Gandhi V. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids 23(8-9):1417-23, 10/2004.

677. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104(7):1979-88, 10/2004.
678. Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma 45(11):2187-95, 11/2004.
679. Sun X, Amin HM, Freireich EJ, Keating MJ, Kantarjian HM, Koller CA, O'Brien SM, Giles F, Albitar M. Hairy cell leukemia with large cells: long disease course with adequate response to therapy. Leukemia 18(11):1912-4, 11/2004.
680. Hennessy B, Giles F, Cortes J, O'Brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol 77(3):209-14, 11/2004.
681. Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, McQueen T, Monaco G, Munsell M, Belmont J, Kantarjian H, Sporn MB, Andreeff M. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 64(21):7927-35, 11/2004.
682. Jilani I, Keating M, Giles FJ, O'Brien S, Kantarjian HM, Albitar M. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res 28(12):1255-62, 12/2004.
683. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101(12):2788-801, 12/2004.
684. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10(1 Pt 1):88-95, 2004.
685. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 10(1 Pt 1):68-75, 2004.
686. Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, Zhou X, Resta D, Wierda W, Faderl S, Giles F, Cortes JE. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 100(1):116-21, 2004.
687. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian H. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood 105(3):1366-1367, 2/2005. PMCID: PMC15659618.
688. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105(3):940-7, 2/2005.
689. Tefferi A, Dewald GW, Litzow ML, Cortes J, Mauro MJ, Talpaz M, Kantarjian HM. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc 80(3):390-402, 3/2005.
690. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105(6):2281-6, 3/2005.
691. Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine. Nat Rev Drug Discov 4(4):275-6, 4/2005.
692. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23(12):2805-12, 4/2005.

693. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad, II. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191(8):1350-60, 4/2005.
694. Issa JP, Kantarjian H. Azacitidine. Nat Rev Drug Discov Suppl:S6-7, 5/2005.
695. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11(9):3425-32, 5/2005.
696. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer 103(10):2099-108, 5/2005.
697. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer 103(10):1985-95, 5/2005.
698. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 29(6):649-52, 6/2005.
699. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-8, 6/2005.
700. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-88, 6/2005.
701. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer 103(12):2551-7, 6/2005.
702. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23(17):3948-56, 6/2005.
703. Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, Rosner G, Garcia-Manero G. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol 23(17):3932-9, 6/2005.
704. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11(13):4941-7, 7/2005.
705. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res 29(7):739-48, 7/2005.
706. Faderl S, Kantarjian HM. Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes. Nat Clin Pract Oncol 2(7):348-55, 7/2005.
707. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J, Cortes J. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 46(7):993-7, 7/2005.
708. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 104(3):541-6, 8/2005.
709. Canalli AA, Yang H, Jeha S, Hoshino K, Sanchez-Gonzalez B, Brandt M, Pierce S, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA methylation of a cell cycle regulatory pathway

composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leuk Res 29(8):881-5, 8/2005.

710. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 104(3):547-54, 8/2005.
711. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J, Cortes J. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 104(4):777-80, 8/2005.
712. Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104(6):1230-6, 9/2005.
713. Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, Kantarjian HM, O'Brien SM, Jilani I, Albitar M. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia 19(9):1567-72, 9/2005.
714. Cortes J Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 23(26):6316-24, 9/2005.
715. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11(18):6615-24, 9/2005.
716. Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 11(17):6247-55, 9/2005.
717. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc 80(11):1517-27, 11/2005.
718. Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, Reuben JM. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19(11):1905-11, 11/2005.
719. Merzianu M, Medeiros LJ, Cortes J, Yin C, Lin P, Jones D, Glassman A, Kantarjian H, Huh Y. inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. Am J Clin Pathol 124(5):807-14, 11/2005.
720. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106(10):3370-3, 11/2005.
721. Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O'Brien S. Mature T-cell leukemias. Cancer 104(9):1808-18, 11/2005.
722. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 11(21):7817-24, 11/2005.
723. Giles FJ, Cortes JE, Kantarjian HM. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr Mol Med 5(7):615-23, 11/2005.
724. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma 6(3):234-9, 11/2005.
725. Kantarjian H. Trends in the management of chronic myelogenous leukemia. J Natl Compr Canc Netw 3 Suppl 1:S41-5, 11/2005.
726. Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D. A proof-of-principle pharmacokinetic, pharmacodynamic,

and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106(13):4253-60, 12/2005.
727. Faderl S, Do KA, Johnson MM, Keating M, O'Brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar M. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 106(13):4303-7, 12/2005.
728. Yee KW, Jabbour E, Kantarjian HM, Giles FJ. Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Ann Hematol 84 Suppl 13:18-24, 12/2005.
729. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 19(1):34-8, 2005.
730. Patel HS, Kantarjian HM, Bueso-Ramos CE, Medeiros LJ, Haidar MA. Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia. Genes Chromosomes Cancer 42(1):87-94, 2005.
731. Hennessy BT, Thomas DA, Giles FJ, Kantarjian H, Verstovsek S. New approaches in the treatment of myelofibrosis. Cancer 103(1):32-43, 2005.
732. Giles, FJ, Shi, GG, Cortes, JE, Thomas, D, Lerner, S, Keating, A, Kantarjian, HM, Keating, MJ, O'Brien, S. The additional of amifostine to the fludarabine and cyclophosphamide regimen does not reduce toxicity in patients with chronic lymphocytic leukemia. In Press. Cancer Chemotherapy Pharma, 2005.
733. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106(2):337-45, 1/2006.
734. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106:120-7, 1/2006.
735. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106(2):346-52, 1/2006.
736. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107(2):480-2, 1/2006.
737. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107(3):880-4, 2/2006.
738. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc 81(2):247-60, 2/2006.
739. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 132(4):398-409, 2/2006.
740. Giles F, Verstovsek S, Faderl S, Vey N, Karp J, Roboz G, Khan KD, Cooper M, Bilgrami SF, Ferrant A, Daenen S, Karsten V, Cahill A, Albitar M, Kantarjian H, O'Brien S, Feldman E. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res 30:1591-1595, 3/2006.
741. Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 106(5):1099-109, 3/2006.
742. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24(7):1204-8, 3/2006.
743. Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma 47(3):417-23, 3/2006.

744. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106(5):1090-8, 3/2006.
745. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 106(6):1306-15, 3/2006.
746. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569-80, 4/2006.
747. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106(8):1794-803, 4/2006.
748. Albitar M, Potts SJ, Giles FJ, O'Brien S, Keating M, Thomas D, Clarke C, Jilani I, Aguilar C, Estey E, Kantarjian H. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer 106(7):1587-94, 4/2006.
749. Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer 106(8):1730-8, 4/2006.
750. Verstovsek S, Giles FJ, Quintas-Cardama A, Manshouri T, Huynh L, Manley P, Cortes J, Tefferi A, Kantarjian H. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 30:1499-1505, 5/2006.
751. Hock BD, McKenzie JL, Patton NW, Drayson M, Taylor K, Wakeman C, Kantarjian H, Giles F, Albitar M. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 106(10):2148-57, 5/2006.
752. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24(15):2343-51, 5/2006.
753. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 66(10):5495-503, 5/2006.
754. Kantarjian HM, Cortes J. New strategies in chronic myeloid leukemia. Int J Hematol 83(4):289-93, 5/2006.
755. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106(9):1974-84, 5/2006.
756. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107(9):3469-73, 5/2006.
757. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531-41, 6/2006.
758. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood 107(12):4658-62, 6/2006.
759. Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, Rubnitz JE, Ribeiro RC, Rytting M, Pui CH, Kantarjian H, Jeha S. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer 106(11):2495-502, 6/2006.
760. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108:2811-2813, 6/2006.

761. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354(24):2542-51, 6/2006.
762. Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost 32(4 Pt 2):409-16, 6/2006.
763. Ma W, Jilani I, Gorre M, Keating M, Chan H, Tseng R, Kantarjian H, O'Brien S, Giles FJ, Albitar M. Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia. Br J Haematol 133:690-2, 6/2006.
764. Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, Shpall EJ, Raad, II, Kantarjian HM, Champlin RE. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 106(12):2664-71, 6/2006.
765. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma 47(6):1062-8, 6/2006.
766. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108(2):419-25, 7/2006.
767. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108(1):45-51, 7/2006.
768. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20:1767-1773, 7/2006.
769. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 66(13):6468-72, 7/2006.
770. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107(1):125-35, 7/2006.
771. Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, Deangelo D, Galinsky I, Giles F, Estey E, Kantarjian H, Cohen P, Wang Y, Roesel J, Karp JE, Small D. Plasma inhibitory activity (PIA): A pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 108:3477-3483, 7/2006.
772. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'Brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 134(1):58-60, 7/2006.
773. Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, O'Brien S, Giles F, Albitar M. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. Cytometry B Clin Cytom 70(4):270-5, 7/2006.
774. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12(15):4628-35, 8/2006.
775. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108(4):1421-3, 8/2006.

776. Ma W, Kantarjian H, Verstovsek S, Jilani I, Gorre M, Giles F, Cortes J, O'Brien S, Keating M, Albitar M. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br J Haematol 134:341-3, 8/2006.
777. Ma W, Kantarjian H, Jilani I, Gorre M, Bhalla K, Ottmann O, Giles F, Albitar M. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia 20:1989-1991, 8/2006.
778. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-1302, 8/2006.
779. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108(4):1158-64, 8/2006.
780. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 91(8):1147-8, 8/2006.
781. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer 107:1429-1439, 8/2006.
782. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase I/II study of the combination of 5-aza-2' -deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279, 8/2006.
783. Koller C, Bekele BN, Zhou X, Park C, Estrov Z, O'Brien S, Keating M, Jilani I, Giles FJ, Kantarjian HM, Albitar M. Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood 108(3):1001-6, 8/2006.
784. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR, Estey EH. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 135:165-173, 8/2006.
785. Quintas-Cardama A, Abruzzo LV, Giles FJ, Jorgensen J, Cortes J, Sarriera JE, Kantarjian H, Verstovsek S. A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome. Leukemia 20(9):1638-40, 9/2006.
786. Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 107:1525-1529, 9/2006.
787. Orsolic N, Golemovic M, Quintas-Cardama A, Scappini B, Manshouri T, Chandra J, Basic I, Giles F, Kantarjian H, Verstovsek S. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Sci 97(9):952-60, 9/2006.
788. Arana-Yi C, Quintas-Cardama A, Giles F, Thomas D, Carrasco-Yalan A, Cortes J, Kantarjian H, Verstovsek S. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist 11(8):929-43, 9/2006.
789. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108(6):1809-20, 9/2006.
790. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA, Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108(5):1497-503, 9/2006.
791. Onciu M, Schlette E, Zhou Y, Raimondi SC, Giles FJ, Kantarjian HM, Medeiros LJ, Ribeiro RC, Pui CH, Sandlund JT. Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer 107(5):1084-92, 9/2006.

792. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Survival benefit with imatinib mesylate versus interferon-{alpha}-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108(6):1835-40, 9/2006.
793. Thomas DA, Ravandi F, Kantarjian H. Monoclonal antibody therapy for hairy cell leukemia. Hematol Oncol Clin North Am 20:1125-36, 10/2006.
794. Verstovsek S, Akin C, Manshouri T, Quintas-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 30(11):1365-70, 11/2006.
795. Zhao W, Claxton DF, Medeiros LJ, Lu D, Vadhan-Raj S, Kantarjian HM, Nguyen MH, Bueso-Ramos CE. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22). Am J Surg Pathol 30:1436-44, 11/2006.
796. Jabbour E, Cortes J, Kantarjian H. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol 18:578-83, 11/2006.
797. Tsimberidou AM, Kantarjian H, Keating MJ, Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma 47:2282-8, 11/2006.
798. Ahmed B, Estey E, Manning J, David C, Keating MJ, Kantarjian H, Tsimberidou AM. Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia - case report and review of the literature. Haematologica 91:ECR55, 12/2006.
799. Verstovsek S, Giles F, Quintas-Cardama A, Perez N, Ravandi-Kashani F, Beran M, Freireich E, Kantarjian H. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol Oncol 24(4):181-188, 12/2006.
800. Verstovsek S, Quintas-Cardama A, Kantarjian H, Tefferi A. Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs 15:1555-63, 12/2006.
801. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145:913-23, 12/2006.
802. Quintas-Cardama A, Kantarjian H, Cortes J. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol 2:655-65, 12/2006.
803. Cortes J, Guintas-Cardama A, Kantarjian H. Challenges and progress in the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Clinical Leukemia 1:19-27, 2006.
804. Kantarjian H, Jabbour E, Grimley J and Kirkparick P. Dasatinib. Nat Rev Drug Discov 5:717-8, 2006.
805. Verstovsek S, Quintas-Cardama A, Kantarjian H. Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs 15(12):1555-63, 2006.
806. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-17, 2006.
807. Kantarjian H, Cortes J. New strategies in chornic myeloid leukemia. Int J Hematol 83(4):289-293, 2006.
808. Jilani I, Keating M, Day A, William W, Kantarjian H, O'Brien S, Giles FJ, Albitar M. Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies 28:325-31, 2006.
809. Jabbour E, Cortes J, Giles F, O'Brien S and Kantarjian H. The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. Targ Oncol 1:186-196, 2006.
810. Alvarez RH, Kantarjian H, Cortes JE. The role of Src in solid and hematologic malignancies—development of new-generation Src inhibitors. Cancer 107:1918-1929, 2006.
811. Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar

M, Mufti G, O'Brien S. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 25(1):25-31, 1/2007.
812. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109(2):497-9, 1/2007.
813. Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 109(1):315-322, 1/2007.
814. Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 20(1):54-62, 1/2007.
815. Jabbour E, Kantarjian H. Introduction: chronic myelogenous Leukemia (CML). Semin Hematol 44(1 Suppl 1)(1 Suppl 1):S1-3, 1/2007.
816. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109(2):500-2, 1/2007.
817. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol 44(1 Suppl 1):25-31, 1/2007.
818. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109(2):248-55, 1/2007.
819. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-57, 1/2007.
820. Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 44(1 Suppl 1):4-14, 1/2007.
821. Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 8(1):65-73, 1/2007.
822. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109(2):265-73, 1/2007.
823. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 48(2):283-9, 2/2007.
824. Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian H. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 109(4):713-7, 2/2007.
825. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 109:1355-1359, 2/2007.
826. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 109:5143-5150, 2/2007.

827. Kantarjian HM, Cortes J, Guilhot F, Hochhaus A, Baccarani M, Lokey L. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer 109:1365-1374, 2/2007.
828. Safdar A, Rodriguez G, Rolston KV, O'Brien S, Khouri IF, Shpall EJ, Keating MJ, Kantarjian HM, Champlin RE, Raad II, Kontoyiannis DP. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 39(3):157-64, 2/2007.
829. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13:1089-97, 2/2007.
830. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7(2):118-29, 2/2007.
831. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 109:1152-1156, 2/2007.
832. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt S. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109(4):1395-400, 2/2007.
833. Kantarjian HM. Recent experience with decitabine in MDS. Clin Adv Hematol Oncol 5(2):140, 2/2007.
834. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109:1133-1137, 2/2007.
835. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136(4):624-7, 2/2007.
836. Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs 16:381-92, 3/2007.
837. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6):2303-9, 3/2007.
838. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol 136(6):800-5, 3/2007.
839. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'Brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109:899-906, 3/2007.
840. Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer 109(5):907-14, 3/2007.
841. Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. RIL, a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis. Cancer Res 67:1997-2005, 3/2007.
842. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109(8):3214-3218, 4/2007. e-Pub 1/2007.

843. Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes J. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 109(8):1556-60, 4/2007.
844. Quintás-Cardama A, Kantarjian H, Cortes J. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. Leuk Lymphoma 48(4):802-4, 4/2007.
845. Jabbour E, Cortes J, Kantarjian H. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park) 21(6):653-62; discussion 663-4, 667-8, 5/2007.
846. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lynmphocytic leukmeia. Blood 109(11):4679-4685, 6/2007.
847. Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A, Aguilar C, Jitkaroon C, Giles F, O'Brien S, Keating M, Albitar M. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). Leuk Res 31:791-797, 6/2007.
848. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukaemia: a case series. Br J Haematol 138(2):213-6, 7/2007.
849. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia--some topical issues. Leukemia 21(7):1347-52, 7/2007.
850. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarjian H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs 10(7):468-79, 7/2007.
851. Ravandi F, Faderl S, Kebriaei, Kantarjian H. Modern treatment programs for adults with acute lymphoblastic leukemia. Current Hematologic Malignancy Report 2(3):169-175, 2007 Jul, 7/2007.
852. Aribi A, Huh Y, Keating M, O'Brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F. T-cell large granular lymphocytic (T-LGL) leukemia: Experience in a single institution over 8 years. Leuk Res 31:939-945, 7/2007.
853. Plimack E, Kantarjian H, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymph 48:1472-1481, 8/2007.
854. Kalac M, Quintás-Cardama A, Vrhovac R, Kantarjian H, Verstovsek S. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 110:955-964, 9/2007.
855. Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Rohatgi N, Sepulveda CA, Kantarjian HM, Jiang Y, Safdar A, Raad II, Chemaly RF. Characteristics and Outcome of Respiratory syncytial virus infection in patients with leukemia. Haematologica 92(9):1216-23, 9/2007.
856. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110(6):1295-302, 9/2007.
857. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110(8):2991-5, 10/2007.
858. Quintás-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 6(10):834-48, 10/2007.
859. Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 110(7):1509-19, 10/2007.
860. Koschmieder S, D'Alò F, Radomska H, Schöneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, Andreeff M, Sporn MB, Perrotti D, Berdel WE, Müller-Tidow C, Serve H, Tenen DG. CDDO

induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood 110(10):3695-705, 11/2007.
861. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 110(9):2012-8, 11/2007.
862. Cortes J, Quintás-Cardama A, Garcia-Manero G, O'Brien S, Jones D, Faderl S, Ebarb T, Giles F, Thomas D, Kantarjian H. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 110(9):2000-6, 11/2007.
863. Borthakur G, Lin E, Faderl S, Ferrajoli A, Wierda W, Giles F, Browning ML, Kantarjian H, Keating M, O'Brien S. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer 110(11):2478-83, 12/2007.
864. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer 110(12):2756-60, 12/2007.
865. Kantarjian HM. Purine Nucleosidase Phosphorylase (PNP): A novel target in leukemias and lymphomas. Semin Oncol 34(6 Suppl 5):S1-2, 12/2007.
866. Quintás-Cardama A, Kantarjian H, Verstovsek S. Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol 82(12):1124, 12/2007.
867. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 67(23):11291-9, 12/2007.
868. Fenaux P, Raza A, Mufti G, Aul C, Germing U, Kantarjian H, Cripe L, Kerstens R, De Porre P, Kurzrock R. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 109:4158-62, 2007.
869. Bareng J, Jilani I, Gorre M, Kantarjian H, Giles FJ, Hannah A, Albitar M. A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. Leukemia Lymphoma 6:1-7, 2007.
870. Mattiuzzi G, Kantarjian H. Antifungal prophylaxis in patients with hematological cancers. J Invasive Fungal Infect 1(1):10-16, 2007.
871. Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 25(29):4648-4656, 2007.
872. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res 31(1):91-95, 2007.
873. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic Acute Leukemia: a case series. British Journal of Haematol 138:213-6, 2007.
874. Koschmieder S, D'Alo F, Radomska H, Schoneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, Andreeff M, Sporn MB, Perrotti D, Berdel WE, Muller-Tidow C, Serve H, Tenen DG. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational upregulation of p42 CCAAT enhancer binding protein alpha. Blood 110:3695-3705, 2007.
875. Jabbour E, Kantarjian HM, Abruzzo L, O'brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110(8):2991-2995, 2007.
876. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia - some topical issues. Leukemia 21(7):1347-52, 2007.

877. Albitar M, Vose JM, Johnson MM, Do KA, Day A, Jilani I, Kantarjian H, Keating M, O'Brien SM, Verstovsek S, Armitage JO, Giles FJ. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res 31(2):139-45, 2007.
878. Jeha S, Kantarjian H. Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther 7(2)(2):113-8, 2007.
879. Kantarjian H, Jeha S, Gandhi V, Wess M, Faderl S. Clofarabine: past, present and future. Leuk Lymph 48(10):1922-1930, 2007.
880. Sun X, Zhang W, Ramdas L, Stivers D, Jones D, Kantarjian H, Estey E, Vadhan-Raj S, Medeiros L and Bueso-Ramos C. Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. Mod Pathl 20(8):811-20, 2007.
881. Atallah E, Durand JB, Kantarjian HM, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110:1233-1237, 2007.
882. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarjian H. Current and emerging treatment options in chronic myeloid leukemia. Cancer 109:2171-80, 2007.
883. Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer 13:357-365, 2007.
884. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opinion on Investigational Drugs 16(5):679-87, 2007.
885. Cortes J, Jabbour E, Kantarjian H, Yin C, Shan J, O'Brien S, Garcia-Manero G, Gile F, Breeden M, Reeves N, Wierda W, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110:4005-4011, 2007.
886. Yanada M, Huang X, Garcia-Manero G, O'brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey E. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. Br J Haematol 138(4):555-560, 2007.
887. Atallah E, Kantarjian H, Cortes J. Emerging safety issues with imatinib and other abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma 7(S3):S105-12, 2007.
888. Atallah E, Cortes J, O'brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 110:3547-3551, 2007.
889. Quintás-Cardama A, Kantarjian H, Abruzzo LV, Cortes J. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy. Leukemia 21(11):2394-2396, 2007.
890. Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A. 'Idiopathic' eosinophilia with an occult T-cell clone: prevalence and clinical course. Leuk Res 31(5)(5):691-4, 2007.
891. Borthakur G, O'Brien S, Wierda W, Thomas D, Cortes J, Giles F, Kantarjian H, Lerner S, Keating M. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors. British Journal of Haematology 136:800-805, 2007.
892. Albitar M, Johnson M, Do KA, Day A, Jilani I, Pierce S, Estey E, Kantarjian H, Keating M, Verstovsek S, O'Brien S, Giles FJ. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia 21(3):480-8, 2007.
893. Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clinical Lymphoma & Myeloma 7(S2):S51-7, 2007.
894. Chemaly R, Torres H, Aguilera E, Mattiuzzi G, Cabanillas M, Kantarjian H, Gonzalez V, Safdar A, Raad I. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clinical Infectious Diseases 44:964-7, 2007.
895. Kantarjian H, Cortes J. New tyrosine kinase inhibitors in chronic myeloid leukemia (CML). Leukemia Research Suppl 2:S16-19, 2007.

896. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly amn107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540-3546, 2007.
897. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 110:340-4, 2007.
898. Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes J. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post imatinib mesylate failure. Cancer 109:1556-60, 2007.
899. Cortes J, Jabbour E, Daley GQ, O'brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase I study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110:1295-302, 2007.
900. Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curcio TJ, Wilkes MA, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJ. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. J Clin Oncol 25(1)(1):10-5, 2007.
901. Soupir CP, Vergilio JA, Dal Cin P, Muzikansky A, Kantarjian H, Jones D, Hasserjian RP. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 127(4):642-50, 2007.
902. Ma W, Tseng R, Gorre M, Jilani I, Keating M, Kantarjian H, Cortes J, O'Brien S, Giles F, Albitar M. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica 92(2)(2):170-175, 2007.
903. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, and Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914, 2007. e-Pub.
904. Mesa R, Verstovsek S, Cervantes F, Barosi G, Reilly J, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell P, Silver R, Vannucchi A, Deeg H, Gisslinger H, Thomas D, Odenike O, Solberg L, Gotlib J, Hexner E, Nimer S, Kantarjian H, Orazi A, Vardiman J, Thiele J, Tefferi A; On behalf of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 31(6):737-40, 2007.
905. Deininger M, Cortes J, Paquette R, Park B, Niederwieser D, Stone R, Hochhaus A, Reiffers J, Fischer T, Kantarjian H, Baccarani M, Gambacorti-Passerini C, So C, Krahnke T, Gathmann I, Smith D, Druker B, Guilhot F. Prognosis of CML patients who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 110:1509-19, 2007.
906. Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, Giles F, Kantarjian H. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma 48(6):1150-60, 2007.
907. Ravandi F, Burnett A, Agura E, Kantarjian H. Progress in the treatment of acute myeloid leukemia. Cancer 110:1900-1910, 2007.
908. Heidel F, Cortes J, Rucker F, Aulitzky W, Letvak L, Kindler T, Huber C, Dohner H, Kantarjian H, Fischer T. Results of a multicenter phase II trial for older patients with C-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib. Cancer 109:907-914, 2007.
909. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda W, Ouzounian S, Quezada A, Pierce S, Estey E, Issa JP, Kantarjian H. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302-2308, 2007.

910. Pan J, Quintas-Cardama A, Manshouri T, Cortes J, Kantarjian H, Verstovsek S. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Can Sci 98(8):1223-5, 2007.
911. Quintas-Cardama A, Kantarjian H, Cortes J. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. Leuk Lymphoma 48(4):802-4, 2007.
912. Kantarjian H, Giles F, List A, Lyons R, Sekeres M, Pierce S, Deuson R, Leveque J. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 109:1705-14, 2007.
913. Tam C, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou A, Kantarjian H, Wierda W. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymp 48 (10):1931-1939, 2007.
914. Pan J, Quintás-Cardama A, Manshouri T, Giles FJ, Lamb P, Tefferi A, Cortes J, Kantarjian H, Verstovsek S. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia 21(7):1395-404, 2007.
915. Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, Rae P, Weitzman A, Meyer JM, Dugan M, Ottmann OG. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 21:2311-2315, 2007.
916. Ferrajoli, A., Faderl, S., Van, Q., Harris, D., Koch, P., Liu, Z., Hazan-Halevy, I., Wang, Y., Kantarjian, H.M., Priebe, W., Estrov, Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myeloid leukemia cells. Cancer Research 67:11291-11299, 2007.
917. Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 7(1):48-58, 1/2008.
918. Tefferi A, Levine RL, Kantarjian H. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms. Biol Blood Marrow Transplant 15(1 Suppl):114-9, 1/2008.
919. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 1/2008.
920. Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol, 1/2008.
921. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112(4):837-45, 2/2008.
922. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Gambacorti C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111(3):1039-43, 2/2008.
923. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111(4):1834-9, 2/2008.
924. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111(3):1060-6, 2/2008.

925. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res 14(3):721-30, 2/2008.
926. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111(4):1816-9, 2/2008.
927. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3):538-43, 3/2008.
928. Kantarjian H, Cortes J. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw 6(Suppl 2):S37-42; quiz S43-S44, 3/2008.
929. Cortes J, Kantarjian H. Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. J Natl Compr Canc Netw 6(Suppl 2):S22-S30, 3/2008.
930. Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer 112(6):1306-12, 3/2008.
931. Tefferi A, Kantarjian H. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement. Am J Hematol 83(3):175-7, 3/2008.
932. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111(6):3183-9, 3/2008.
933. Jabbour E, Cortés JE, Kantarjian H. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. Clin Lymphoma Myeloma 8 Suppl 3:S75-81, 3/2008.
934. Faderl S, Gandhi V, Kantarjian HM. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol 15(2):101-7, 3/2008.
935. Quintás-Cardama A, Cortés JE, Kantarjian H. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma 8 Suppl 3:S82-8, 3/2008.
936. Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49(4):690-5, 4/2008.
937. Quintás-Cardama A, Gibbons DL, Cortes J, Bobadilla D, Slovak ML, Kantarjian H, Abruzzo LV. Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia. Leukemia 22(4):877-8, 4/2008.
938. Ma W, Kantarjian H, Zhang X, Sun W, Buller AM, Jilani I, Schwartz JG, Giles F, Albitar M. Higher detection rate of JAK2 mutation using plasma. Blood 111(7):3906-7, 4/2008.
939. Lee TS, Potts SJ, Kantarjian H, Cortes J, Giles F, Albitar M. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer 112(8):1744-53, 4/2008.
940. Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res 32(4):643-9, 4/2008.
941. Yu Z, Sun B, Kantarjian HM, Keating MJ, Amin HM, Sun X. Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. Leuk Lymphoma 49(4):751-6, 4/2008.
942. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Relapse and death during first remission in acute myeloid leukemia. Haematologica 93(4):633-4, 4/2008.
943. Quintás-Cardama A, Gibbons DL, Kantarjian H, Talpaz M, Donato N, Cortes J. Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain. Leukemia 22(4):885-8, 4/2008.

944. Quintás-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 22(5):965-70, 5/2008.
945. Samudio I, Kurinna S, Ruvolo P, Korchin B, Kantarjian H, Beran M, Dunner K, Kondo S, Andreeff M, Konopleva M. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther 7(5):1130-9, 5/2008.
946. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 68(9):3413-20, 5/2008.
947. Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer 112(10):2112-8, 5/2008.
948. Quintás-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 22(6):1117-24, 6/2008.
949. Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F, Albitar M. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leuk Res 32(6):936-43, 6/2008.
950. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22(6):1200-6, 6/2008.
951. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112(11):2341-51, 6/2008.
952. El Kinge AR, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H, Bazarbachi A. Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res 33(4):565-6, 6/2008. e-Pub 6/2008.
953. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 22(6):1095-105, 6/2008.
954. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14(12):3906-15, 6/2008.
955. Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia 22(6):1295-8, 6/2008.
956. Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, Rosti G, Apperley JF. The effects of imatinib on pregnancy outcome. Blood 111(12):5505-8, 6/2008.
957. Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 99(6):1265-73, 6/2008.
958. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1):53-5, 7/2008.
959. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26(19):3204-12, 7/2008.

960. Jabbour E, El Ahdab S, Cortes J, Kantarjian H. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs 17(7):1127-36, 7/2008.
961. Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma 49(7):1399-402, 7/2008.
962. Kroeger H, Jelinek J, Estécio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112(4):1366-73, 8/2008.
963. Yeh CH, Tseng R, Zhang Z, Cortes J, O'Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H, Albitar M. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res 33(2):212-7, 8/2008. e-Pub 8/2008.
964. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer, 8/2008.
965. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112(3):516-8, 8/2008.
966. Yanada M, Borthakur G, Ravandi F, Bueso-Ramos C, Kantarjian H, Estey E. Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica 93(8):1263-5, 8/2008.
967. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4):975-80, 8/2008.
968. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4):981-9, 8/2008.
969. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113:6330-6337, 8/2008.
970. O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer, 8/2008.
971. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pilot pharmacokinetic study of oral azacitidine. Leukemia 22(9):1680-4, 9/2008. e-Pub 6/2008.
972. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638-45, 9/2008.
973. Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, Hai S, Ravandi F, Lima MD, Kantarjian H, Jorgensen JL. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood 12(13):5190, 9/2008.
974. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13):4839-42. e-Pub 9/2008.
975. Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W, Kantarjian HM. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 113(5):985-94, 9/2008.
976. Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ, Estey E. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer 113(6):1370-1378, 9/2008.

977. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113(6):1351-61, 9/2008.
978. Vega-Ruiz A, O'Brien S, Cortes J, Kebriaei P, Thomas D, Kantarjian H, Ravandi F. Secondary myelodysplastic syndrome in a patient with philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hypercvad plus imatinib mesylate. Leuk Res 32(9):1468-71, 9/2008.
979. Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 113(6):1338-43, 9/2008.
980. Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 112(5):1628-37, 9/2008.
981. Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey E. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 113(1):28-36. e-Pub 9/2008. PMCID: PMC2614639.
982. Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res 32(10):1505-9, 10/2008.
983. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, Maciejewski JP. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 100(21):1542-51. e-Pub 10/2008.
984. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. Functional proteomic profiling of AML predicts response and survival. Blood 113(1):154-64. e-Pub 10/2008.
985. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 113(7):1605-13, 10/2008.
986. Jain N, Cortes J, Quintás-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res, 11/2008.
987. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-41, 11/2008.
988. Kantarjian H. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O]. Clin Adv Hematol Oncol 6(11):797-9, 11/2008.
989. Yin C, Jones D, Cortes J, Kantarjian H, Merzianu M, Medeiros LJ, Bueso-Ramos C. Type B core binding factor β/smooth muscle myosin heavy chain fusion transcript in myeloid blast phase of chronic myeloid leukemia:correlation with nuclear and cytoplasmic localization of the fusion protein. Clinical Leukemia 2(4):257-260, 11/2008.
990. Schimmer A, O'Brien S, Kantarjian H, Brandwein J, Cheson B, Minden M, Yee K, Ravandi-Kashani F, Giles F, Schuh A, Gupta V, Andreeff M, Koller Ch, Chang H, Kamel-Reid S, Berger M Viallet J, Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14(24):8295-301, 2008 Dec 15, 12/2008.
991. Lee TS, Ma W, Zhang X, Giles F, Cortes J, Kantarjian H, Albitar M. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther, 12/2008.
992. Quintás-Cardama A, Verstovsek S, Freireich E, Kantarjian H, Chen YW, Zingaro R. Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Anticancer Agents Med Chem 8(8):904-9, 12/2008.

993. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. J Clin Oncol. e-Pub 12/2008.
994. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186-91, 12/2008.
995. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 49(12):2246-55, 12/2008.
996. Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 113(11):3181-5, 12/2008.
997. Oki Y, Jelinek J, Shen L, Kantarjian H, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111:2382-2384, 2008.
998. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111:1774-1780, 2008.
999. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 27:904-910, 2008.
1000. Kurzrock R, Kantarjian H, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey E, Giles FJ, Beran M, Sebti SM. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clinical Cancer Research 14(2):509-514, 2008.
1001. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111:1060-1066, 2008.
1002. Jabbour E, Kantarjian H, Koller C, and Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 112:1089-1095, 2008.
1003. Jabbour E, Cortes J, Ghanem H, O'Brien S, Kantarjian H. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Therapy 8(1):99-110, 2008.
1004. Manshouri T, Quintas-Cardama, A, Nussenzveig, R.H., Gaikwad, A., Estrov, Z., Cortes, J.E., Kantarjian, H.M., Verstovsek, S. The Jak kinase inhibitor CP690,550 inhibits the growth of human polycythemia vera cells carrying the Jak2V617F mutation. Cancer Science 99:1265-1273, 2008.
1005. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M. Valganciclovir prevents CMV reactivation in patients receiving alemtuzumab based therapy. Blood 111:1816-1819, 2008.
1006. Verstovsek S, Manshouri T, Quintas-Cardama A, Harris D, Cortes J, Giles F, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 14:788-796, 2008.
1007. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintás-Cardama A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 15(1):368-73, 1/2009.
1008. Tsimberidou AM, Tam C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, Kantarjian HM, Keating MJ. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115(2):373-80, 1/2009.
1009. Ma W, Kantarjian H, Zhang X, Jilani I, Sheikholeslami MR, Donahue AC, Ravandi F, Estey E, O'Brien S, Keating M, Giles FJ, Albitar M. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomarkers 5(1):51-58, 1/2009.

1010. Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, Kantarjian H. Epigenetics of acute lymphocytic leukemia. Semin Hematol 46(1):24-32, 1/2009.
1011. Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S, Albitar M. Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias. J Mol Diagn 11(1):49-53, 1/2009. PMCID: PMC2607565.
1012. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer 115(1):101-6, 1/2009.
1013. Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 4(1):3-10, 1/2009. e-Pub 1/2009.
1014. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115(3):551-560, 2/2009.
1015. Kantarjian HM, O'Brien S. Insurance policies in the United States may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimens. Blood 113(8):1861; author reply 1862, 2/2009.
1016. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome negative acute lymphocytic leukemia. Blood 113(9):1892-1898, 2/2009. e-Pub 12/2008. PMCID: PMC2651008.
1017. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc 84(2):161-9, 2/2009. PMCID: PMC2664587.
1018. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. e-Pub 2/2009.
1019. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41(4):455-9. e-Pub 3/2009.
1020. Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop 2(1):2-8, 3/2009. e-Pub 11/2008. PMCID: PMC2713495.
1021. Ma W, Kantarjian H, Yeh CH, Zhang ZJ, Cortes J, Albitar M. BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors. Acta Haematol 121(1):27-31. e-Pub 3/2009.
1022. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 113(10):2154-2160, 3/2009.
1023. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-1642, 4/2009. e-Pub 2/2009.
1024. Verma D, Fava C, Kantarjian H, Cortes J. Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Am J Hematol 84(4):256-7, 4/2009.
1025. Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H, Ravandi F. Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol. e-Pub 4/2009.

1026. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, Perrotti D, Arlinghaus RB. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 28(14):1669-81, 4/2009. e-Pub 2/2009. PMCID: PMC2841483.
1027. Jabbour E, Garcia-Manero G, Taher A, Kantarjian H. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist 14(5):489-96. e-Pub 4/2009.
1028. Lee TS, Ma W, Zhang X, Giles F, Kantarjian H, Albitar M. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. Cancer 115(8):1692-1700, 4/2009.
1029. Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16(2):122-31, 4/2009.
1030. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 113(14):3168-71, 4/2009.
1031. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood 113:4171-4178, 4/2009.
1032. Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien S. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer 115(10):2147-2154, 5/2009.
1033. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113:5058-5063, 5/2009.
1034. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 84(5):287-93, 5/2009.
1035. Nussenzveig RH, Cortes J, Sever M, Quintás-Cardama A, Ault P, Manshouri T, Bueso-Ramos C, Prchal JT, Kantarjian H, Verstovsek S. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol. e-Pub 5/2009.
1036. Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res 69(9):3910-3917, 5/2009. e-Pub 4/2009.
1037. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, dePadua L, Shpall E, Champlin R, deLima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899-1905, 5/2009.
1038. Albitar M, Potts SJ, Giles FJ, O'Brien S, Jilani I, Donahue AC, Estey EH, Kantarjian H. Proteomics-based prediction of clinical response in acute myeloid leukemia. Exp Hematol. e-Pub 5/2009.
1039. Silver RT, Cortes J, Waltzman R, Mone M, Kantarjian H. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica 94(5):743-4, 5/2009.
1040. Quintás-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115(11):2482-2490, 6/2009.
1041. Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early

chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113:6315-6321, 6/2009.
1042. Quintás-Cardama A, De Souza Santos FP, Kantarjian H, O'Brien S, Faderl S, Awais A, Borthakur G, Cortes J. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 115(17):3935-3943, 6/2009.
1043. DePadua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43(11):839-843, 2009 Jun, 6/2009. e-Pub 1/2009.
1044. Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, Dipersio J, Muller MC, Radich JP, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C, Tallman MS. Phase III study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113:6322-6329, 6/2009.
1045. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage Myelodysplastic Syndrome. Clin Cancer Res 15(11):3820-3826, 6/2009.
1046. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 15(12):3938-3946, 6/2009.
1047. Quintás-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115:2912-2921, 7/2009.
1048. Hochhaus A, Müller MC, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A, Hughes TP. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia:1-6. e-Pub 7/2009.
1049. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114(1):144-147, 7/2009.
1050. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23(7):1297-1302, 7/2009.
1051. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 115(14):3217-3221, 7/2009.
1052. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114:261-263, 7/2009.
1053. Rytting ME, Kantarjian H, Albitar M. Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity. Am J Clin Pathol 132(2):182-5; quiz 306, 8/2009.
1054. Quintás-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 6(9):535-43. e-Pub 8/2009.
1055. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial. J Clin Oncol 27(23):3842-3848, 8/2009.
1056. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM, Jones D. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 27(22):3642-3649, 8/2009.
1057. Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E, Cortes J. Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-

Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response. J Clin Oncol 27(22):3659-3664, 8/2009. e-Pub 6/2009. PMCID: PMC2799063.
1058. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-3718, 8/2009.
1059. Cole S, Kantarjian H, Ault P, Cortés JE. Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma 9(4):324-7, 8/2009.
1060. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa JP, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 9(1605-1613), 9/2009.
1061. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. Chronic myeloid leukemia (CML) with P190BCR-ABL - analysis of characteristics, outcomes and prognostic significance. Blood 114(11):2232-2235, 9/2009. e-Pub 6/2009.
1062. Yeh CH, Tseng R, Hannah A, Estrov Z, Estey E, Kantarjian H, Albitar M. Clinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res, 9/2009. e-Pub 9/2009.
1063. Apostolidou E, Kantarjian HM, Verstovsek S. JAK2 Inhibitors: A Reality? A Hope? Clin Lymphoma Myeloma 9(3):S340-S345, 9/2009.
1064. Freireich EJ, Kantarjian H, Keating MJ. Leukemia Research, 2008. Clin Lymphoma Myeloma 9:S178, 9/2009.
1065. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-2043, 9/2009. e-Pub 6/2009.
1066. Champlin R, Lima MD, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. Clin Lymphoma Myeloma 9(3):S261-S265, 9/2009.
1067. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. J Clin Oncol 27(27):4563-4568, 9/2009. e-Pub 8/2009.
1068. Jabbour E, Cortés JE, Kantarjian H. Second-line Therapy and Beyond Resistance for the Treatment of Patients With Chronic Myeloid Leukemia Post Imatinib Failure. Clin Lymphoma Myeloma 9(3):S272-S279, 9/2009.
1069. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a Phase 2 Trial. Cancer 115(17):3924-3934, 9/2009.
1070. Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 8(9):2509-16, 9/2009. e-Pub 9/2009. PMCID: PMC2754862.
1071. Sampat K, Kantarjian H, Borthakur G. Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs 18(10):1559-64, 10/2009. e-Pub 8/2009.
1072. Konoplev S, Huang X, Drabkin H, Koeppen H, Jones D, Kantarjian H, Garcia-Manero G, Chen W, Medeiros J, Bueso-Ramos C. Cytoplasmic Localization of Nucleophosmin in Bone Marrow Blasts of Acute Myeloid Leukemia Patients is not Completely Concordant With NPM1 Mutation and is not Predictive of Prognosis. Cancer 115:4737-4744, 10/2009.
1073. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J. High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses. J Clin Oncol 27(28):4754-4759, 10/2009. e-Pub 8/2009.

1074. Thomas DA, Ravandi F, Keating M, Kantarjian HM. Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy. Leuk Lymphoma 50 Suppl 1:27-31, 10/2009.
1075. Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia 23(10):1755-62, 10/2009. e-Pub 5/2009.
1076. Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S. Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. J Clin Oncol 27(28):4760-4766, 10/2009. e-Pub 8/2009.
1077. Thomas DA, O'Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23(5):949-71, v, 10/2009.
1078. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. e-Pub 11/2009.
1079. Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, Verstovsek S. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol 90(4):522-5, 11/2009. e-Pub 8/2009.
1080. Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, Keating MJ, Thomas DA, Verstovsek S. Dynamic model for predicting death within twelve months in patients with primary or post-polycythemia vera/essential thromobocythemia myelofibrosis. J Clin Oncol 27(33):5587-5593, 11/2009. e-Pub 9/2009.
1081. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27(32):5418-24, 11/2009.
1082. Ravandi-Kashani F, Ahmed A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27(32):5425-5430, 11/2009.
1083. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33(11):1481-1484, 11/2009.
1084. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey E. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 15(11):1431-8, 11/2009. e-Pub 9/2009.
1085. Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero G. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer 115:5202-09, 11/2009.
1086. Garg RJ, Kantarjian H, O'Brien S, Quintás-Cardama A, Faderl S, Estrov Z, Cortes J. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 114(20):4361-8, 11/2009. e-Pub 9/2009.
1087. Garg R, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z, Cortes J. The use of nilotinib or dasatinib after failure to two prior tyrosine kinase inhibitors (TKI): long-term follow-up. Blood 114(20):4361-4368, 11/2009.
1088. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult Acute Erythroleukemia: An analysis of 91 patients treated at a single institution. Leukemia 23(12):2275-80, 12/2009. e-Pub 9/2009.
1089. Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE. Cuplike nuclei (prominent nuclear invaginations) in

acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer 115(5481-5488), 12/2009. PMCID: PMC3378048.
1090. Quintás-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine, mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 115(23):5382-5394, 12/2009. e-Pub 9/2009.
1091. Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115:5490-5498, 12/2009.
1092. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 115:5746-5751, 12/2009.
1093. Fava C, Kantarjian H, Cortes J, Jabbour E. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Des Devel Ther 2:233-43, 2009. PMCID: PMC2761189.
1094. Fava C, Cortés JE, Kantarjian H, Jabbour E. Standard management of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma 9 Suppl 4:S382-90, 2009.
1095. Lee TS, Ma W, Zhang X, Kantarjian H, Albitar M. Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations. BMC Struct Biol 9:58, 2009. PMCID: PMC2749040.
1096. Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 116(1):93-97, 1/2010. e-Pub 10/2009.
1097. Fullmer A, Cortes J, Kantarjian H, Jabbour E. ASH 2009 meeting report-Top 10 clinically oriented abstracts in acute leukemia. Am J Hematol. e-Pub 1/2010.
1098. Fullmer A, Cortes J, Kantarjian H, Jabbour E. ASH 2009 meeting report-Top 10 clinically oriented abstracts in chronic myeloid leukemia. Am J Hematol. e-Pub 1/2010.
1099. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 24(1):6-12, 1/2010. e-Pub 10/2009.
1100. Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther 10(1):9-22, 1/2010.
1101. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S. Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias. Cancer Res 70(2):447-52, 1/2010. e-Pub 1/2010. PMCID: PMC2947340.
1102. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392-397, 1/2010. e-Pub 12/2009. PMCID: PMC2815701.
1103. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120(1):142-56, 1/2010. e-Pub 12/2009. PMCID: PMC2799198.
1104. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 28(2):285-291, 1/2010. e-Pub 11/2009.
1105. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 116(1):424-430, 1/2010. e-Pub 12/2009.
1106. Dimov ND, Medeiros LJ, Kantarjian HM, Cortes JE, Chang KS, Bueso-Ramos CE, Ravandi F. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining

with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer 116(2):369-376, 1/2010. e-Pub 11/2009.
1107. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51(1):73-8, 1/2010. PMCID: PMC2876330.
1108. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28(3):398-404, 1/2010. e-Pub 12/2009. PMCID: PMC2815702.
1109. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 28(3):437-444, 1/2010. e-Pub 12/2009.
1110. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-93, 2/2010. e-Pub 11/2009.
1111. Bruey JM, Kantarjian H, Estrov Z, Zhang Z, Ma W, Albitar F, Abdool A, Thomas D, Yeh C, O'Brien S, Albitar M. Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leuk Res 34(2):173-6, 2/2010. e-Pub 8/2009.
1112. Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, Galitz L, Schran H. Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib. Clin Pharmacol Ther 87(2):197-203, 2/2010. e-Pub 11/2009.
1113. Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Rev Hematol 3(1):15-22, 2/2010.
1114. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes. J Clin Oncol 28(4):605-614, 2/2010. e-Pub 12/2009. PMCID: PMC2815995.
1115. Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma 51(2):269-74, 2/2010. e-Pub 12/2009.
1116. Jones D, Yao H, Romans A, Dando C, Pierce S, Borthakur G, Hamilton A, Bueso-Ramos C, Ravandi F, Garcia-Manero G, Kantarjian H. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer 49(2):182-91, 2/2010.
1117. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115(6):1131-1136, 2/2010. e-Pub 12/2009.
1118. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28(4):549-555, 2/2010. e-Pub 12/2009.
1119. Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S, O'Brien S, Giles F, Albitar M. Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology. Int J Lab Hematol 32(1 Pt 2):95-102, 2/2010. e-Pub 2/2009.
1120. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95(2):232-40, 2/2010. PMCID: PMC2817025.

1121. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: implications for the treatment of myeloproliferative neoplasms. Blood 115(15). e-Pub 2/2010.
1122. Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, Abruzzo LV, Kantarjian HM, Medeiros LJ, Wang SA. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood 115(10):1985-92, 3/2010. e-Pub 12/2009.
1123. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 116(5):1165-76, 3/2010. e-Pub 1/2010.
1124. Lee TS, Ma W, Zhang X, Albitar M, Giles F, Cortes J, Kantarjian H. BCR-ABL1INS35 Is Not Uncommon in CML Patients and Is Related to Resistance and Sensitivity to Inhibitors in CML Treatment - Response. Mol Cancer Ther 9(3):772, 3/2010. e-Pub 3/2010.
1125. Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs 15(1):1-11, 3/2010. e-Pub 1/2010.
1126. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia 24(3):666-8, 3/2010. e-Pub 1/2010.
1127. Kantarjian HM, Cortes J, La Rosée P, Hochhaus A. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer 116(6):1419-30, 3/2010. e-Pub 1/2010.
1128. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma 51(3):475-480, 3/2010. e-Pub 1/2010.
1129. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. J Clin Oncol. e-Pub 3/2010.
1130. Fullmer A, Kantarjian H, Heiskell T and Jabbour E. The Role of Imatinib in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Clinical Medicine Reviews in Oncology 2010:2, 3/2010.
1131. Quintás-Cardama A, Amin HM, Kantarjian H, Verstovsek S. Treatment of aggressive systemic mastocytosis with daclizumab. Leuk Lymphoma 51(3):540-2, 3/2010. e-Pub 12/2009.
1132. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol. e-Pub 4/2010.
1133. Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EH. Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center Study. J Clin Oncol 28(10):1766-71, 4/2010. e-Pub 2/2010.
1134. Quintás-Cardama A, Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, Kantarjian HM, Verstovsek S. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. e-Pub 4/2010.
1135. Wang SA, Jabbar K, Lu G, Chen SS, Galili N, Vega F, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ. 'Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia 24(4):740-7, 4/2010. e-Pub 1/2010.
1136. Samudio IJ, Duvvuri S, Clise-Dwyer K, Watt JC, Mak D, Kantarjian H, Yang D, Ruvolo V, Borthakur G. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells. Leuk Lymphoma 51(5):911-9, 5/2010.
1137. Chandra P, Luthra R, Zuo A, Yao H, Ravandi F, Reddy N, Garcia-Manero G, Kantarjian H, Jones D. Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. Am J Clin Path 133(5):686-93, 2010 May, 5/2010.

1138. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Cause of death in patients with lower risk myelodysplastic syndrome. Cancer 116:2174-2179, 5/2010. e-Pub 2/2010.
1139. Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 116:2290-300, 5/2010. e-Pub 3/2010.
1140. Sampat K, Rossi A, Garcia-Gutierrez V, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of pericardial effusions in patients with leukemia. Cancer 116:2366-71, 5/2010. e-Pub 3/2010.
1141. Verma D, Kantarjian H, Faderl S, O'Brien S, Pierce S, Vu K, Freireich E, Keating M, Cortes J, Ravandi F. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma 51(5):778-782, 5/2010. e-Pub 3/2010.
1142. Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W, Qiu Y, Coombes KR, Ju Z, Abdelrahim M, Schober W, Ling X, Kardassis D, Meyer C, Schimmer A, Kantarjian H, Andreeff M, Konopleva M. Role of Peroxisome Proliferator-Activated Receptor-{gamma} and Its Coactivator DRIP205 in Cellular Responses to CDDO (RTA-401) in Acute Myelogenous Leukemia. Cancer Res 70(12). e-Pub 5/2010.
1143. Quintas-Cardama A, Kantarjian H, Cortes J. Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia 10(Suppl. 1):S14-S19, 6/2010.
1144. Abdool A, Yeh CH, Kantarjian H, O'Brien S, Bruey J, Giles F, Albitar M. Circulating CD33 and its clinical value in acute leukemia. Exp Hematol 38(6):462-71, 6/2010. e-Pub 4/2010.
1145. Jabbour E, Fullmer A, Cortes J, Kantarjian H. Clinical Algorithms for the treatment of patients with chronic myeloid leukemia: The 2010 perspective. Clinical Lymphoma, Myeloma and Leukemia 10(Suppl. 1):S6-S13, 6/2010.
1146. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. N Engl J Med 362(24):2260-70, 6/2010. e-Pub 6/2010.
1147. Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cortés JE, Ravandi F. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk 10(3):205-10, 6/2010. PMCID: PMC3726276.
1148. Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs. e-Pub 6/2010.
1149. Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Dünzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 24:1299-1301, 6/2010. e-Pub 6/2010.
1150. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251-9, 6/2010. e-Pub 6/2010.
1151. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome. J Clin Oncol 28(16):2755-60, 6/2010. e-Pub 4/2010.
1152. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res 34(6):752-6, 6/2010. e-Pub 10/2009.
1153. Kantarjian H, Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 116(11):2665-72, 6/2010. e-Pub 3/2010. PMCID: PMC2876208.

1154. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116(11):2673-81, 6/2010.
1155. Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. Current and future management options for myelodysplastic syndromes. Drugs 70(11):1381-94, 7/2010.
1156. Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes J. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 116(13):3152-9, 7/2010.
1157. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 7/2010. e-Pub 5/2010.
1158. Bryan J, Jabbour E, Prescott H, Kantarjian H. Thrombocytopenia in patients with myelodysplastic syndromes. Semin Hematol 47(3):274-80, 7/2010.
1159. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. J Clin Oncol 28(24):3880-3889, 8/2010. e-Pub 7/2010. PMCID: PMC2940403.
1160. Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 150(3):303-12, 8/2010. e-Pub 6/2010.
1161. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ. Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 116(15):3750, 8/2010.
1162. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma 51(8):1478-84, 8/2010. e-Pub 7/2010.
1163. Golemovic M, Quintás-Cardama A, Manshouri T, Orsolic N, Duzkale H, Johansen M, Freireich EJ, Kantarjian H, Zingaro RA, Verstovsek S. MER1, a novel organic arsenic derivative, has potent PML-RARalpha- independent cytotoxic activity against leukemia cells. Invest New Drugs 28(4):402-412, 8/2010. e-Pub 5/2009.
1164. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 116(16):3830-4, 8/2010.
1165. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 116(6):886-892, 8/2010. e-Pub 4/2010. PMCID: PMC2924226.
1166. Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K, Winton E, Verstovsek S. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk 10(4):285-9, 8/2010.
1167. Apostolidou E, Kantarjian H, Thomas D, Burger I, Borthakur G, Verstovsek S. Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Clin Lymphoma Myeloma Leuk 10(4):281-4, 8/2010.
1168. Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM, De Lima M. Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors with BCR-ABL Kinase Domain Mutation T315I. Cancer 116(15):3631-7, 8/2010.

1169. Agrawal M, Garg RJ, Kantarjian H, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr Oncol Rep 12(5):302-13, 9/2010.
1170. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-2077, 9/2010. e-Pub 5/2010.
1171. Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the anti-leukemia agent, CNDAC. Blood 116(10):1737-46, 9/2010. e-Pub 5/2010. PMCID: PMC2947394.
1172. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GN. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer 116(17):4063-8, 9/2010.
1173. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117-27, 9/2010.
1174. Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer 116(19):4580-9, 10/2010. e-Pub 6/2010.
1175. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol 47(4):344-53, 10/2010.
1176. Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O'Brien S, Keating M, Albitar M. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res 34(10):1320-4, 10/2010. e-Pub 4/2010.
1177. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 116(17):3163-3170, 10/2010. e-Pub 7/2010.
1178. Quintás-Cardama A, Kantarjian H, Cortes J. Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol 47(4):371-80, 10/2010.
1179. Zuo Z, Jones D, Yao H, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Abruzzo LV, Medeiros LJ, Chen SS, Luthra R. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod Pathol 23(11):1524-34, 11/2010. e-Pub 8/2010.
1180. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22):4422-9, 11/2010. e-Pub 7/2010.
1181. Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S, Kantarjian H. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer 116(22):5272, 11/2010. e-Pub 7/2010.
1182. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 117(9):1800-11. e-Pub 11/2010.
1183. Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H, Borthakur G. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 117(10):2145-2155. e-Pub 11/2010.
1184. Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs 11(12):1450-1465, 12/2010.
1185. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S, Kantarjian H. Characteristics and outcome of patients with acute

myeloid leukemia refractory to one cycle of high dose cytarabine-based induction chemotherapy. Blood 116(26):5818-23; quiz 6153, 12/2010. e-Pub 10/2010.
1186. Al-Kali A, Verstovsek S, Kantarjian H, Luthra R, Cortes J. Competing cell clones in myeloproliferative neoplasm. Blood 116(23):5074-5, 12/2010.
1187. Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 116(24):5659-66, 12/2010.
1188. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O'Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 116(24):5568-74, 12/2010. e-Pub 8/2010.
1189. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother 11(18):3065-3072, 12/2010. e-Pub 11/2010.
1190. Saglio G, Kantarjian H, Holyoake T, Ranganathan A, Cortés JE. Proceedings of the third global workshop on chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 10(6):443-51, 12/2010.
1191. Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JA. The Great Imitator: Systemic Nocardiosis Mimicking Richter's Transformation in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol 28(35):e732-e734, 12/2010. e-Pub 9/2010.
1192. Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, Yeh CH, O'Brien S, Giles F, Bruey JM, Albitar M. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms. PLoS One 5(8):e12165, 2010. e-Pub 8/2010. PMCID: PMC2921382.
1193. Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evid 4:207-13, 2010. PMCID: PMC2899790.
1194. Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O'Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M. Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC Med Genet 11:163, 2010. e-Pub 11/2010. PMCID: PMC2992491.
1195. Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintás-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117(2):327-35, 1/2011. e-Pub 9/2010.
1196. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer 19(1):19-26, 1/2011. e-Pub 12/2009.
1197. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood 117(3):780-7, 1/2011. e-Pub 11/2010. PMCID: PMC3035072.
1198. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood 117(4):1141-5, 1/2011. e-Pub 11/2010.
1199. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 117(1):110-5, 1/2011. e-Pub 8/2010.
1200. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase 1 Study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96(1):62-8, 1/2011. e-Pub 10/2010. PMCID: PMC3012766.
1201. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. Targeting neuropilin-1 in human leukemia and lymphoma. Blood 117(3):920-7, 1/2011. e-Pub 11/2010.

1202. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34(+)38 (-) cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 16(1):67-74, 1/2011. e-Pub 10/2010.
1203. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy. Clin Lymphoma Myeloma Leuk 11(1):54-9, 2/2011.
1204. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood 117(5):1662-9, 2/2011. e-Pub 11/2010.
1205. Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S, Quintas-Cardama A. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer 117(4):662-76, 2/2011. e-Pub 10/2010.
1206. Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia. J Clin Oncol 29(5):524-531, 2/2011. e-Pub 1/2011.
1207. Kantarjian H, Schiffer C, Burnett A. Hematologic Malignancies: Where Do We Stand in 2011? J Clin Oncol 29(5):473-4, 2/2011. e-Pub 1/2011.
1208. Cortes J, Quintás-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 117(3):572-80, 2/2011. e-Pub 9/2010.
1209. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10(2):127-133, 2/2011.
1210. Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM, Garcia-Manero G. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol 86(2):237-8, 2/2011.
1211. Fullmer A, Kantarjian H, Cortes J, Jabbour E. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma 52 Suppl 1:81-91, 2/2011.
1212. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 117(6):1822-1827, 2/2011. e-Pub 10/2010.
1213. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 117(6):1236-44, 3/2011. e-Pub 10/2010.
1214. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases? Curr Hematol Malig Rep 6(1):58-66, 3/2011. e-Pub 12/2010.
1215. Prescott H, Kantarjian H, Cortes J, Ravandi F. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs 16(3). e-Pub 3/2011.
1216. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-3024, 3/2011. e-Pub 1/2011.
1217. Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 117(5):897-906, 3/2011. e-Pub 10/2010.

1218. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 117(5):982-91, 3/2011. e-Pub 10/2010.
1219. Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer 117(6):1113-22, 3/2011. e-Pub 10/2010.
1220. Mathisen MS, Kantarjian HM, Cortes J, Jabbour E. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica 96(3):347-9, 3/2011. PMCID: PMC3046262.
1221. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117(12):3294-3301, 3/2011. e-Pub 1/2011. PMCID: PMC3069671.
1222. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641-3647, 3/2011. e-Pub 12/2010.
1223. Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 117(5):992-1000, 3/2011. e-Pub 10/2010.
1224. Santos FP, Kantarjian H, Garcia-Manero G, Ravandi F. The Search for Better Prognostic Models in Myelodysplastic Syndromes. Curr Hematol Malig Rep 6(1):13-21, 3/2011. e-Pub 12/2010.
1225. Abdel-Karim I, Plunkett WK, O'Brien S, Giles F, Thomas D, Faderl S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ, Kantarjian HM. A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Invest New Drugs 29(2):323-331, 4/2011. e-Pub 1/2010.
1226. Kantarjian H, Cortes J. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol 29(12):1512-6, 4/2011. e-Pub 3/2011.
1227. Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer. e-Pub 4/2011.
1228. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy. Clin Cancer Res 17(7):1674-83, 4/2011. e-Pub 2/2011.
1229. Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Shan J, Pierce S, Cortes J, Kantarjian H. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk 11(2):237-41, 4/2011. e-Pub 4/2011.
1230. Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, Albitar M. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res 35(4):526-33, 4/2011. e-Pub 10/2010.
1231. Fullmer A, Cortes J, Kantarjian H, Jabbour E. ASH 2010 meeting report-Top 10 clinically oriented abstracts in acute leukemia. Am J Hematol 86(5):454-7, 5/2011.
1232. Fullmer A, Cortes J, Kantarjian H, Jabbour E. ASH 2010 meeting report-Top 10 clinically oriented abstracts in chronic myeloid leukemia. Am J Hematol 86(5):450-3, 5/2011.
1233. Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of

myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 29(15):1963-70, 5/2011. e-Pub 4/2011.
1234. Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117(21):5600-5606, 5/2011. e-Pub 4/2011.
1235. Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol 7(5):661-72, 5/2011. e-Pub 4/2011.
1236. Naqvi K, Verstovsek S, Kantarjian H, Ravandi F. A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs 20(8). e-Pub 6/2011.
1237. Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, Lei X, Shan J, Kantarjian HM, Suarez-Almazor ME. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 29(16):2240-6, 6/2011. e-Pub 5/2011. PMCID: PMC3107743.
1238. Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone marrow stroma secreted cytokines protect JAK2V617F-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 71(11):3831-3840, 6/2011. e-Pub 4/2011.
1239. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine R, Neuberg D, Ebert B. Clinical Effect of Point Mutations in Myelodysplastic Syndromes. N Engl J Med 364(26):2496, 6/2011.
1240. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Dasatinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol 4(3):253-60, 6/2011.
1241. Quintás-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes J. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica 96(6):918-24, 6/2011. e-Pub 2/2011.
1242. Cornelison AM, Kantarjian H, Cortes J, Jabbour E. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S101-10, 6/2011. e-Pub 4/2011.
1243. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. J Clin Oncol 29(18):2507-13, 6/2011. e-Pub 5/2011.
1244. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B. Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. J Clin Oncol 29(18):2521-7, 6/2011. e-Pub 5/2011.
1245. Cortés JE, Freireich EJ, Kantarjian H, Verstovsek S. Retrospect of hematologic malignancies 2010. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S1, 6/2011. e-Pub 5/2011.
1246. Mathisen MS, O'Brien S, Thomas D, Cortes J, Kantarjian H, Ravandi F. Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep 6(3). e-Pub 6/2011.
1247. Jabbour E, Saglio G, Hughes, Kantarjian H. Supoptimal Responses in Chronic Myeloid Leukemia. Cancer. e-Pub 6/2011.
1248. Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE, Issa JP. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One 6(7):e22110, 7/2011. PMCID: PMC3132778.
1249. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 118(4):899-902, 7/2011. e-Pub 5/2011.
1250. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Prediction model

for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol 86(7):546-9, 7/2011. e-Pub 4/2011.
1251. Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118(17):4541-4546. e-Pub 7/2011.
1252. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant. e-Pub 7/2011.
1253. Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. e-Pub 8/2011.
1254. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-93, 8/2011. e-Pub 6/2011.
1255. Lee TS, Kantarjian H, Ma W, Yeh CH, Giles F, Albitar M. Effects of Clinically Relevant MPL Mutations in the Transmembrane Domain Revealed at the Atomic Level through Computational Modeling. PLoS One 6(8):e23396, 8/2011. PMCID: PMC3157383.
1256. Pemmaraju N, Kantarjian H, Ravandi F, Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia: The start of an era? Cancer 117:3293-3304, 8/2011. e-Pub 2/2011.
1257. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J of Clin Onc 29(23):3173-3178, 8/2011.
1258. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphological diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118(17). e-Pub 8/2011.
1259. Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, Shu J, He R, Zhang N, Chung W, Kantarjian HM, Issa JP. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 6(8):e23372, 8/2011. PMCID: PMC3157379.
1260. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F. Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 11(4):361-6, 8/2011.
1261. Santos FP, Kantarjian H, McConkey D, O'Brien S, Faderl S, Borthakur G, Ferrajoli A, Wright J, Cortes J. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Clin Lymphoma Myeloma Leuk 11(4):355-60, 8/2011.
1262. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. PLoS One 6(8):e23108, 8/2011. PMCID: PMC3154919.
1263. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12(9):841-51, 9/2011. e-Pub 8/2011.
1264. Jaso J, Thomas DA, Cunningham K, Jorgensen JL, Kantarjian HM, Medeiros LJ, Wang SA. Prognostic significance of immunophenotypic and karyotypic features of philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer 117(17), 9/2011. e-Pub 3/2011.

1265. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603-3612, 9/2011. e-Pub 7/2011.
1266. Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ. Activation of apoptosis signaling eliminates CD34(+) progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia. e-Pub 10/2011.
1267. Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 38(5):682-92, 10/2011.
1268. Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O'Brien S, Cortes J. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118(16):4353-4358, 10/2011. e-Pub 8/2011.
1269. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118(14):3818-3823, 10/2011. e-Pub 8/2011.
1270. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer 117(20):4689-4695, 10/2011. e-Pub 3/2011.
1271. Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17):4567-4576, 10/2011. e-Pub 8/2011. NIHMSID: NIHMS21865346.
1272. Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-manero G, Burton E, Shan J, Kantarjian H. The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients with Chronic Phase Chronic Myeloid Leukemia After Failure to Frontline Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint? Clinical Lymphoma, Myeloma & Leukemia 11(5):421-426, 10/2011. PMCID: PMC3215673.
1273. Wood SM, Meyers CA, Faderl S, Kantarjian HM, Pierce SA, Garcia-Manero G. Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome. Am J Hematol 86(11):950-2, 11/2011. e-Pub 9/2011.
1274. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 117(21):4869-77, 11/2011. e-Pub 4/2011.
1275. Santos FP, Kantarjian H, Quintás-Cardama A, Cortes J. Evolution of Therapies for Chronic Myelogenous Leukemia. Cancer J 17(6):465-476, Nov-Dec, 11/2011. PMCID: PMC3243359.
1276. Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Garcia-Manero G, Rios M, Cortes J. Frontline therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J of Clin Onc 29(32):4260-4265, 11/2011. PMCID: PMC3221527.
1277. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. J Clin Oncol 29(31):4088-4095, 11/2011. e-Pub 10/2011.
1278. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH. Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment. J Clin Oncol 29(33):4417-4429, 11/2011. e-Pub 10/2011. PMCID: PMC3221524.
1279. Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. A phse lb study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia 157:1808-1814, 12/2011.

1280. Quintás-Cardama A, Cortes JE, Kantarjian HM. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: Long-term implications. Cancer 117:5261-5270, 12/2011. e-Pub 5/2011.
1281. Löwenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H. Phase I/II study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 118(23):6030-6036, 12/2011. e-Pub 10/2011.
1282. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs 29(6):1206-1212, 12/2011. e-Pub 6/2010.
1283. Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood 118(6), 2011. e-Pub 6/2011.
1284. Shihadeh F, Reed V, Faderl S, Medeiros LJ, Mazloom A, Hadziahmetovic M, Kantarjian H, Allen P, Ballas L, Pierce S, Dabaja B. Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer 118(1):112-7, 1/2012. e-Pub 6/2011.
1285. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-1987. e-Pub 1/2012.
1286. Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 118(2):418-427, 1/2012. e-Pub 6/2011.
1287. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87(1):127-9, 1/2012. e-Pub 11/2011.
1288. Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quintás-Cardama A. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer 118(2):293-299, 1/2012. e-Pub 7/2011.
1289. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722-728, 2/2012. e-Pub 7/2011.
1290. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Kassack Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119(5):1123-1129, 2/2012. e-Pub 12/2011.
1291. Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley LA, Issa JP. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 7(2):201-7, 2/2012. PMCID: PMC3335912.
1292. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Results of a Randomized Clinical Trial. Cancer 118(3):848-55, 2/2012. e-Pub 7/2011.
1293. Al-Kali A, Konoplev S, Lin E, Kadia T, Faderl S, Ravandi F, Ayoubi M, Brandt M, Cortes JE, Kantarjian H, Borthakur G. Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. Haematologica 97(2):235-40, 2/2012. e-Pub 11/2011. PMCID: PMC3269483.
1294. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian

HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799-807, 3/2012.
1295. Quintás-Cardama A, Kantarjian H, Cortes J. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase. Drugs Today (Barc) 48(3):177-88, 3/2012.
1296. Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol 87(3):317-8, 3/2012. e-Pub 1/2012.
1297. Link MP, Hagerty K, Kantarjian HM. Chemotherapy Drug Shortages in the United States: Genesis and Potential Solutions. J Clin Oncol 30(7):692-4, 3/2012. e-Pub 1/2012.
1298. Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, Gabrilove J, Huebner D, Gandhi PJ, Kantarjian H, CLASSIC II Investigators. Outpatient Consolidation Treatment with Clofarabine in a Phase 2 Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML). Leuk Lymphoma 53(3):435-40, 3/2012. e-Pub 10/2011.
1299. Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: Implications and management strategies. Cancer 118(5):1181-91, 3/2012. e-Pub 10/2011.
1300. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brümmendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119(15):3403-12, 4/2012. e-Pub 2/2012.
1301. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13(4):403-11, 4/2012. e-Pub 2/2012.
1302. Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant 18(4):584-92, 4/2012. e-Pub 8/2011.
1303. Fava C, Kantarjian H, Cortes J. Molecular Resistance: An Early Indicator for Treatment Change? Clin Lymphoma Myeloma Leuk 12(No. 2):79-87, 4/2012. e-Pub 1/2012.
1304. Kantarjian H. Monoclonal antibodies in adult acute lymphoblastic leukemia. Hematology 17 Suppl 1:52-4, 4/2012.
1305. Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian H, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 10(1038):2012-2015. e-Pub 4/2012.
1306. Liu X, Kantarjian H, Plunkett W. Sapacitabine for cancer. Expert Opin Investig Drugs 21(4):541-55, 4/2012. e-Pub 2/2012. PMCID: PMC3366487.
1307. Tanaka MF, Kantarjian H, Cortes J, Ohanian M, Jabbour E. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother 13((6)):815-828; 2012, 4/2012. e-Pub 3/2012.
1308. Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 119(19):4524-6, 5/2012. e-Pub 3/2012. PMCID: PMC3362365.
1309. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 5/2012. e-Pub 2/2012.
1310. Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, Gönen M, Kantarjian H, Levine RL, Abdel-Wahab O, Verstovsek S. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms reveals recurrent SRSF2

mutations which are associated with adverse outcome. Blood 119(19):4480-5, 5/2012. e-Pub 3/2012. PMCID: PMC3362363.
1311. Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE, Gallagher NJ, Gillis K, Goldberg SL, Larson RA, Hochhaus A, Ottmann OG. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26(5):959-62, 5/2012. e-Pub 12/2011.
1312. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 119(20):4614-8, 5/2012. e-Pub 3/2012.
1313. Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol 68(5):723-33, 5/2012. e-Pub 12/2011.
1314. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 118(10):2665-73, 5/2012. e-Pub 10/2011.
1315. Ohanian M, Cortes J, Kantarjian H, Jabbour E. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother 13(7):927-38, 5/2012.
1316. Tang G, Zuo Z, Thomas DA, Lin P, Liu D, Hu Y, Kantarjian HM, Bueso-Ramos C, Medeiros LJ, Wang SA. B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? Haematologica 97(6):919-25, 6/2012. e-Pub 12/2011. PMCID: PMC3366660.
1317. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12):3123-7, 6/2012. e-Pub 1/2012. PMCID: PMC3342429.
1318. Ravandi F, Kantarjian H. Gemtuzumab ozogamicin in acute myeloid leukaemia. Nat Rev Clin Oncol 9(6):310-1, 6/2012. e-Pub 5/2012.
1319. le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26(6):118994, 6/2012. e-Pub 11/2011.
1320. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs 30(3):1107-1115, 6/2012. e-Pub 4/2011.
1321. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol 30(18):2204-10, 6/2012. e-Pub 5/2012.
1322. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II Study of Bendamustine in Patients with Acute Leukemia and High Risk Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 12(3):197-200, 6/2012.
1323. Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Cortes J. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 118(12):3116-22, 6/2012. e-Pub 2/2012. PMCID: PMC3370116.
1324. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H. A Phase 1 Dose-Escalation Study of ARRY-520, a Kinesin Spindle Protein Inhibitor, in Patients with Advanced Myeloid Leukemias. Cancer 118(14):3556-64, 7/2012. e-Pub 12/2011.

1325. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029-35, 7/2012. e-Pub 1/2012. PMCID: PMC3396674.
1326. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. J Clin Oncol 30(20):2492-9, 7/2012. e-Pub 5/2012.
1327. Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, Bisrat T, Ravandi-Kashani F, Cortes JE, Kantarjian HM, Medeiros LJ, Luthra R. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high resolution melting curve analysis. J Mol Diagn 14(4):336-45, 7/2012. e-Pub 5/2012.
1328. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 30(21):2670-2677, 7/2012. e-Pub 6/2012.
1329. Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87(7):687-91, 7/2012. e-Pub 3/2012.
1330. Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O'Brien S, Thomas DA, Kantarjian H, Medeiros LJ, Luthra R, Patel KP. Rapid Detection and Quantitation of BRAF Mutations in Hairy Cell Leukemia Using a Sensitive Pyrosequencing Assay. Am J Clin Pathol 138(1):153-6, 7/2012.
1331. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 120(1):173-80, 7/2012. e-Pub 5/2012. PMCID: PMC3390955.
1332. Cheng X, Quintás-Cardama A, Golemovic M, Zingaro R, Gao MZ, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S. The Organic Arsenic Derivative GMZ27 Induces PML-RARα-Independent Apoptosis in Myeloid Leukemia Cells. Anticancer Res 32(7):2871-80, 7/2012.
1333. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internaltandem duplication (FLT3-ITD) at complete response and relapsein patients with acute myeloid leukemia. Haematologica 97(8):1242-5, 8/2012. e-Pub 4/2012. PMCID: PMC3409823.
1334. Jabbour E, Saglio G, Radich J, Kantarjian H. Adherence to BCR-ABL Inhibitors: Issues for CML Therapy. Clin Lymphoma Myeloma Leuk 12(4):223-9, 8/2012. e-Pub 5/2012.
1335. Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, Hochhaus A, Kantarjian HM, Larson RA. Concurrent Use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 70(2):345-50, 8/2012. e-Pub 5/2012.
1336. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 120(7):1390-7, 8/2012. e-Pub 5/2012.
1337. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long Term Outcomes of 107 Patients with Myelofibrosis Receiving JAK1/JAK2 Inhibitor Ruxolitinib: Survival Advantage in Comparison to Matched Historical Controls. Blood 120(6):1202-9, 8/2012. e-Pub 6/2012.
1338. Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, Kantarjian H, Lock R, Andreeff M, Konopleva M. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther 13(10):858-70, 8/2012. e-Pub 8/2012. PMCID: PMC3414410.

1339. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-51, 8/2012. e-Pub 4/2012.
1340. Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post - Polycythemic myelofibrosis, A rare entity. Leuk Lymphoma 53(9):1839-41, 9/2012. e-Pub 3/2012.
1341. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 9/2012. e-Pub 1/2012.
1342. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H, Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 120(13):2573-2580, 9/2012. e-Pub 8/2012.
1343. Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, Deangelo DJ, Huntsman-Labed A, Dutreix C, Del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 26(9):2061-8, 9/2012. e-Pub 4/2012.
1344. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 118(18):4462-70, 9/2012. e-Pub 1/2012.
1345. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 120(12):2454-65, 9/2012. e-Pub 6/2012.
1346. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML under conditions mimicking the bone marrow microenvironment. Blood 120(13):2679-89, 9/2012. e-Pub 7/2012.
1347. Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood 120(13):2768-9, 9/2012.
1348. Quintás-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res 36(9):1124-7, 9/2012. e-Pub 4/2012.
1349. Mathisen MS, Jabbour E, Kantarjian HM. Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies. Oncology (Williston Park) 26(9):851-9, 9/2012.
1350. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. J Clin Oncol 30(27):3376-82, 9/2012. e-Pub 8/2012. PMCID: PMC3438234.
1351. Chen Y, Kantarjian H, Estrov Z, Faderl S, Ravandi F, Rey K, Cortes J, Borthakur G. A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities. Clin Lymphoma Myeloma Leuk 12(5):341-4, 10/2012. e-Pub 5/2012.
1352. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A Randomized Controlled

Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 12(5):355-62, 10/2012. e-Pub 6/2012.
1353. Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C. Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. J Clin Oncol 30(28):3486-92, 10/2012. e-Pub 9/2012.
1354. Jabbour E, Morris V, Kantarjian H, Yin CC, Burton E, Cortes J. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 120(16):3382-3, 10/2012.
1355. Warren M, Luthra R, Yin CC, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Zuo Z. Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol 25(10):1405-12, 10/2012. e-Pub 6/2012.
1356. Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-Term Follow-up of Patients With Hypereosinophilic Syndrome Treated With Alemtuzumab, an Anti-CD52 Antibody. Clin Lymphoma Myeloma Leuk. e-Pub 10/2012.
1357. Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, Baccarani M, Kantarjian HM. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol. e-Pub 10/2012.
1358. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26(10):2197-203, 10/2012. e-Pub 5/2012.
1359. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-Associated Vascular Events. Clin Lymphoma Myeloma Leuk 12(5):337-40, 10/2012. e-Pub 5/2012.
1360. Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep 14(5):387-94, 10/2012.
1361. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 26(11):2428-31, 11/2012. e-Pub 6/2012.
1362. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Döhner K, Döhner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 22(5):683-697, 11/2012. PMCID: PMC3547667.
1363. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 87(11):1037-45, 11/2012.
1364. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 118(22):5550-9, 11/2012. e-Pub 5/2012. PMCID: PMC3416961.
1365. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM. Gemtuzumab Ozogamicin: Time to Resurrect? J Clin Oncol 30(32):3921-3923, 11/2012. e-Pub 9/2012.
1366. Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia. J Clin Oncol 30(31):3876-3883, 11/2012. e-Pub 8/2012. PMCID: PMC3478578.
1367. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol 13(11):1096-1104, 11/2012. e-Pub 10/2012.

1368. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367(22):2075-88, 11/2012.
1369. Zhou Y, Jorgensen JL, Wang SA, Ravandi F, Cortes J, Kantarjian HM, Medeiros LJ, Konoplev S. Usefulness of CD11a and CD18 in Flow Cytometric Immunophenotypic Analysis for Diagnosis of Acute Promyelocytic Leukemia. Am J Clin Pathol 138(5):744-50, 11/2012.
1370. Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute Promyelocytic Leukemia: A Population-Based Study on Incidence and Survival in the United States, 1975-2008. Cancer 118(23):5811-8, 12/2012. e-Pub 6/2012.
1371. Hoehn D, Medeiros LJ, Kantarjian HM, Cortes JE, Wang X, Bueso-Ramos CE. Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia. Hum Pathol 43(12):2354-9, 12/2012. e-Pub 8/2012.
1372. Quintás-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Cortes J, Kantarjian H. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 120(24):4840-5, 12/2012. e-Pub 10/2012.
1373. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer 118(23):5819-22, 12/2012. e-Pub 5/2012.
1374. Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC. Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib. J Clin Oncol 30(35):4323-9, 12/2012. e-Pub 10/2012.
1375. Quintás-Cardama A, Sever M, Cortes J, Kantarjian H, Verstovsek S. Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. Leuk Lymphoma. e-Pub 1/2013.
1376. Zheng W, Medeiros LJ, Hu Y, Powers L, Cortes JE, Ravandi-Kashani F, Kantarjian HH, Wang SA. CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. e-Pub 1/2013.
1377. Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S, Worth L, O'Brien S, Thomas D, Champlin RE, Kantarjian H. Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk. e-Pub 1/2013.
1378. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 1/2013. e-Pub 10/2012.
1379. Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. Molecular characterization of de novo Ph+ Acute Myeloid Leukemia. Leuk Lymphoma 54(1):138-44, 1/2013. e-Pub 7/2012.
1380. Jain P, Lynn Sargent R, Konoplev SN, Benjamini O, Kantarjian H, Kadia T. Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase. Am J Hematol. e-Pub 1/2013.
1381. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27(1):107-12, 1/2013. e-Pub 7/2012.
1382. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. e-Pub 1/2013.
1383. Becker PS, Kantarjian HM, Appelbaum FR, Storer B, Pierce S, Shan J, Faderl S, Estey EH. Retrospective comparison of clofarabine versus fludarabine in combination with high dose

cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. Haematologica 98(1):114-8, 1/2013. e-Pub 7/2012. PMCID: PMC3533672.
1384. Jabbour E, Kantarjian H, Ghanem H, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J. The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure. Clin Lymphoma Myeloma Leuk. e-Pub 1/2013.
1385. Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F. The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clin Cancer Res 19(2):327-35, 1/2013. e-Pub 12/2012.
1386. Kantarjian HM, Larson RA, Cortés JE, Deering KL, Mauro MJ. Current Practices in the Management of Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(1):48-54, 2/2013. e-Pub 10/2012.
1387. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. e-Pub 2/2013.
1388. O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. J Clin Oncol 31(6):676-83, 2/2013. e-Pub 11/2012.
1389. Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, Andreeff M, Konopleva M. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett 329(1):45-58, 2/2013. e-Pub 10/2012. PMCID: PMC3572533.
1390. Borthakur G, Rosenblum M, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich E, Kadia TM, Garcia-Manero G, Kantarjian HM, Cortes J. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica 98(2):217-221, 2/2013. e-Pub 8/2012.
1391. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. e-Pub 2/2013.
1392. Quintás-Cardama A, Kantarjian H, Pierce S, Cortes J, Verstovsek S. Prognostic Model to Identify Patients With Myelofibrosis at the Highest Risk of Transformation to Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2/2013.
1393. Daver N, Nazha A, Kantarjian HM, Haltom R, Ravandi F. Treatment of Hairy Cell Leukemia During Pregnancy: Are Purine Analogues and Rituximab Viable Therapeutic Options. Clin Lymphoma Myeloma Leuk 13(1):86-9, 2/2013. e-Pub 9/2012.
1394. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. Am J Hematol 88(3):198-200, 3/2013. e-Pub 1/2013.
1395. Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S, Wang H, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Ganan-Gomez I, Ebert B, Levine R, Kantarjian H, Garcia-Manero G. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. e-Pub 3/2013.
1396. Sever M, Quintás-Cardama A, Pierce S, Zhou L, Kantarjian H, Verstovsek S. Signifi cance of Cytogenetic Abnormalities in Patients with Polycythemia Vera. Leuk Lymphoma. e-Pub 3/2013.
1397. Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Significance of FAB

subclassification of "Acute Myeloid Leukemia, NOS" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients. Blood 121(13):2424-31, 3/2013. e-Pub 1/2013. PMCID: PMC3612855.
1398. Mathisen MS, Jabbour E, Thomas D, O'Brien S, Kantarjian H. Acute Lymphoblastic Leukemia (ALL) in Adults: Encouraging Developments on the Way to Higher Cure Rates. Leuk Lymphoma. e-Pub 4/2013.
1399. Jain P, Kantarjian H, Cortes J. Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis. Curr Treat Options Oncol. e-Pub 4/2013.
1400. Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes J, Quintás-Cardama A. Clofarabine Does Not Negatively Impact the Outcomes of Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 13(2):139-143, 4/2013. e-Pub 12/2012.
1401. Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 4(2):103-17, 4/2013. PMCID: PMC3629755.
1402. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia 27(4):907-13, 4/2013. e-Pub 11/2012.
1403. Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk 13(2):131-138, 4/2013. e-Pub 12/2012.
1404. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia 27(4):836-42, 4/2013. e-Pub 11/2012.
1405. Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia 27(4):977-80, 4/2013. e-Pub 9/2012.
1406. Agrawal V, Woo JH, Borthakur G, Kantarjian H, Frankel AE. Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein Pept Lett 20(4):392-402, 4/2013.
1407. Farroni JS, Zwelling L, Cortes J, Kantarjian H. Saving Medicare through Patient-Centered Changes-The Case of Injectables. N Engl J Med 368(17):1572-1573, 4/2013.
1408. Ghanem H, Kantarjian H, Ohanian M, Jabbour E. The Role of Clofarabine in Acute Myeloid Leukemia. Leuk Lymphoma 54(4):688-98, 4/2013. e-Pub 9/2012.
1409. Bhatt VR, Kantarjian H, Cortes J, Ravandi F, Borthakur G. Therapy of Core Binding Factor Acute Myeloid Leukemia: Incremental Improvements Toward Better Long-Term Results. Clin Lymphoma Myeloma Leuk 13(2):153-158, 4/2013. e-Pub 12/2012.
1410. Cortes J, Feldman E, Yee K, Rizzieri D, Advani AS, Charman A, Spruyt R, Toal M, Kantarjian H. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol 14(4):354-62, 4/2013. e-Pub 2/2013.
1411. Takahashi K, Cortes J, Pierce S, Abruzzo L, Kantarjian H, Verstovsek S. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res 37(5):552-5, 5/2013. e-Pub 2/2013.
1412. Kantarjian H, Wilson W, Ravandi F, Estey E. Decitabine in Older Adults With Acute Myeloid Leukemia: Why Was the Dream Broken? J Clin Oncol 31(14):1795-6, 5/2013. e-Pub 4/2013.
1413. Wang X, Roy A, Hochhaus A, Kantarjian H, Chen T, Shah N. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clinical Pharmacology: Advances and Applications(5):1-13, 5/2013.

1414. Attieh Y, Geng QR, Dinardo CD, Zheng H, Jia Y, Fang ZH, Gañán-Gómez I, Yang H, Wei Y, Kantarjian H, Garcia-Manero G. Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood 121(19):4009-11, 5/2013.
1415. Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP. Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 121(18):3703-8, 5/2013. e-Pub 3/2013.
1416. Murphy DM, Bejar R, Stevenson K, Neuberg D, Shi Y, Cubrich C, Richardson K, Eastlake P, Garcia-Manero G, Kantarjian H, Ebert BL, Mike Makrigiorgos G. NRAS Mutations with Low Allele Burden have Independent Prognostic Significance for Patients with Lower Risk Myelodysplastic Syndromes. Leukemia. e-Pub 5/2013.
1417. Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE, Kantarjian HM, Omacetaxine 203 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol 88(5):350-4, 5/2013. e-Pub 3/2013.
1418. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 121(20):4166-74, 5/2013. e-Pub 4/2013. PMCID: PMC3656451.
1419. Santos FP, Tam CS, Kantarjian H, Cortes J, Thomas D, Pollock R, Verstovsek S. Splenectomy in patients with Myeloproliferative Neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. e-Pub 5/2013.
1420. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 161(4):508-16, 5/2013. e-Pub 3/2013.
1421. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121(22):4439-42, 5/2013. e-Pub 4/2013.
1422. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of Cytogenetic Abnormalities in Patients with IPSS defined Lower-Risk Myelodysplastic Syndrome Is Associated with Poor Prognosis and Transformation to Acute Myelogenous Leukemia. Am J Hematol. e-Pub 6/2013.
1423. Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol 71(6):1599-607, 6/2013. e-Pub 4/2013. PMCID: PMC3668123.
1424. Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. e-Pub 6/2013.
1425. Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey E. Declining rates of Treatment-Related mortality in patients with Newly-diagnosed AML given 'Intense' induction regimens: A report from SWOG and MD Anderson. Leukemia. e-Pub 6/2013.
1426. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. e-Pub 6/2013.
1427. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predicts for better outcomes in patients with newly diagnosed CML-results with four TKI modalities. Blood 121(24):4867-74, 6/2013. e-Pub 4/2013. PMCID: PMC3743466.

1428. Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H. Expectations of Serious Adverse Events at the End of Life of Patients With Acute Myeloid Leukemia Who Receive Salvage Therapy. Clin Lymphoma Myeloma Leuk. e-Pub 6/2013.
1429. Kantarjian HM, O'Brien S, Cortes J. Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval. Clin Lymphoma Myeloma Leuk. e-Pub 6/2013.
1430. Ravandi F, Cortes J, Kantarjian H. Is there a standard induction regimen for patients with AML? Lancet Oncol 14(7):565-6, 6/2013. e-Pub 5/2013.
1431. Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, Owen K, Stockman PK, Oliver SD. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk. e-Pub 6/2013.
1432. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655-62, 6/2013. e-Pub 4/2013. PMCID: PMC3674666.
1433. Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A, Kim DW, Fan X, Novick S, Giles FJ. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia. Leukemia 27(6):1411-3, 6/2013. e-Pub 11/2012.
1434. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Chronic Lymphocytic Leukemia Research Consortium. Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome. Clin Lymphoma Myeloma Leuk. e-Pub 6/2013.
1435. Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. Clin Lymphoma Myeloma Leuk. e-Pub 6/2013.
1436. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol 161(5):659-66, 6/2013. e-Pub 3/2013.
1437. Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM. Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib. Clin Lymphoma Myeloma Leuk. e-Pub 6/2013.
1438. Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. e-Pub 6/2013.
1439. Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. Br J Haematol. e-Pub 7/2013.
1440. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia (AML). Am J Hematol. e-Pub 7/2013.

1441. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. e-Pub 7/2013.
1442. Nazha A, Kantarjian H, Cortes J, Quintás-Cardama A. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. Expert Opin Pharmacother. e-Pub 7/2013.
1443. Nicolini FE, Khoury HJ, Akard L, Rea D, Kantarjian H, Baccarani M, Leonoudakis J, Craig A, Benichou AC, Cortes J. Omacetaxine mepesuccinate for patients with accelerated-phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica 98(7):e78-9, 7/2013. e-Pub 6/2013. PMCID: PMC3696599.
1444. Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. J Clin Oncol 31(20):2548-53, 7/2013. e-Pub 6/2013.
1445. Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options. Clin Lymphoma Myeloma Leuk. e-Pub 7/2013.
1446. Kantarjian HM, Martinelli G, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A, SPARK-AML1 Investigators. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 119(14):2611-9, 7/2013. e-Pub 4/2013.
1447. Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma 54(7):1411-7, 7/2013. e-Pub 12/2012.
1448. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 8/2013.
1449. Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, Thomas DA, Cortes JE, Wang SA. CD30 Expression in Acute Lymphoblastic Leukemia as Assessed by Flow Cytometry Analysis. Leuk Lymphoma. e-Pub 8/2013.
1450. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib JR, Gisslinger H, Levy RS, Siulnik A, Gupta V, Khan M, Dipersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. e-Pub 8/2013.
1451. Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. e-Pub 8/2013.
1452. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia-chromosome positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122(7):1214-21, 8/2013. e-Pub 7/2013.
1453. Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy. Clin Lymphoma Myeloma Leuk 13(4):435-40, 8/2013. e-Pub 6/2013.
1454. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872-84, 8/2013. e-Pub 6/2013.

1455. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122(5):734-7, 8/2013. e-Pub 6/2013.
1456. Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha A, Kantarjian HM, Cleeland CS, Cortes JE. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122(5):641-7, 8/2013. e-Pub 6/2013. PMCID: PMC3731927.
1457. Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular Analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 122(6):893-901, 8/2013. e-Pub 6/2013. PMCID: PMC3739035.
1458. Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 13(4):485-92, 8/2013. e-Pub 6/2013.
1459. Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J. Patient-driven discontinuation of tyrosine kinase inhibitors - single institution experience. Leuk Lymphoma. e-Pub 8/2013.
1460. Cherry M, Cardenas-Turanzas M, Pham H, Kantarjian H, Cortes J, Pierce S, Zhou L, Verstovsek S. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. e-Pub 8/2013.
1461. Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. e-Pub 8/2013.
1462. Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S, Kantarjian HM. Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 13(4):430-4, 8/2013. e-Pub 6/2013.
1463. Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol 162(4):548-52, 8/2013. e-Pub 5/2013.
1464. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S. Results of Inotuzumab Ozogamicin, a CD22 Monoclonal Antibody, in Refractory and Relapsed Acute Lymphocytic Leukemia. Cancer 119(15):2728-36, 8/2013. e-Pub 4/2013. PMCID: PMC3720844.
1465. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. e-Pub 8/2013.
1466. Hochhaus A, Kantarjian H. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol. e-Pub 8/2013.
1467. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl) 22(5):605-11, 9/2013. e-Pub 5/2013. PMCID: PMC3745781.
1468. Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M. Case series of AML patients receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma. e-Pub 9/2013.

1469. Chakhachiro ZI, Zuo Z, Aladily TN, Kantarjian HM, Cortes JE, Alayed K, Nguyen MH, Medeiros LJ, Bueso-Ramos C. CD105 (Endoglin) Is Highly Overexpressed in a Subset of Cases of Acute Myeloid Leukemias. Am J Clin Pathol 140(3):370-8, 9/2013.
1470. Konoplev S, Lin P, Yin CC, Lin E, Nogueras González GM, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. CXC Chemokine Receptor 4 Expression, CXC Chemokine Receptor 4 Activation, and Wild-Type Nucleophosmin Are Independently Associated With Unfavorable Prognosis in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 9/2013.
1471. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. e-Pub 9/2013.
1472. DiNardo CD, Gharibyan V, Yang H, Wei Y, Pierce S, Kantarjian HM, Garcia-Manero G, Rytting M. Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol 88(9):784-9, 9/2013. e-Pub 7/2013.
1473. Rytting M, Triche L, Thomas D, O'Brien S, Kantarjian H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. e-Pub 9/2013.
1474. Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer. e-Pub 9/2013.
1475. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated Nucleophosmin-1 (NPM1) in patients with Acute Myeloid Leukemia (AML) in remission and relapse. Leuk Lymphoma. e-Pub 9/2013.
1476. Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. e-Pub 9/2013.
1477. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer Drugs in the United States: Justum Pretium-The Just Price. J Clin Oncol 31(28):3600-4, 10/2013. e-Pub 5/2013. PMCID: PMC3782152.
1478. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 122(16):2807-11, 10/2013. e-Pub 7/2013. PMCID: PMC3798995.
1479. Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. e-Pub 10/2013.
1480. Talpaz M, Paquette R, Afrin L, Hamburg S, Prchal J, Jamieson K, Terebelo H, Ortega G, Lyons R, Tiu R, Winton E, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Vitanen S, Leopold L, Sandor V, Levy R, Kantarjian H, Verstovsek S. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. Journal of Hematology Oncology. e-Pub 10/2013.
1481. Dinardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents. Leuk Lymphoma. e-Pub 10/2013.
1482. Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Singh RR. Next generation sequencing based multi-gene mutational screen foracute myeloid leukemia using miseq: applicability for diagnostics anddisease monitoring. Haematologica. e-Pub 10/2013.
1483. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status. J Clin Oncol 31(29):3681-7, 10/2013. e-Pub 9/2013.

1484. Jain P, Kantarjian H, Estey E, Pierce S, Cortes J, Lopez-Berestein G, Ravandi F. Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data. Clin Lymphoma Myeloma Leuk. e-Pub 10/2013.
1485. Lu H, Kojima K, Battula VL, Korchin B, Shi Y, Chen Y, Spong S, Thomas DA, Kantarjian H, Lock RB, Andreeff M, Konopleva M. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Ann Hematol. e-Pub 10/2013.
1486. Nazha A, Romo CG, Kantarjian H, Cortes J. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. Haematologica 98(10):e131, 10/2013.
1487. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369(19):1783-96, 11/2013. e-Pub 11/2013.
1488. Kantarjian H, Zwelling L. Cancer drug prices and the free-market forces. Cancer:3903-3905, 11/2013. e-Pub 8/2013.
1489. Kantarjian H, Stewart DJ, Zwelling L. Cancer research in the United States: Dying by a thousand paper cuts. Cancer 119(21):3742-3745, 11/2013. e-Pub 6/2013.
1490. Jain P, Romo CG, Khoury HJ, Kantarjian H, Cortes J. Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. Haematologica 98(11):e141-2, 11/2013.
1491. Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. Blood 122(19):3387-8, 11/2013.
1492. Kantarjian H, Silver R, Komrokji R, Mesa R, Tacke R, Harrison C. Ruxolitinib for Myelofibrosis--An Update of its Clinical Effects. Clinical Lymphoma, Myeloma & Leukemia 13(6):638-45, 12/2013.
1493. Heinrichs S, Conover LF, Bueso-Ramos CE, Kilpivaara O, Stevenson K, Neuberg D, Loh ML, Wu WS, Rodig SJ, Garcia-Manero G, Kantarjian HM, Look AT. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife 2:e00825, 2013. e-Pub 7/2013. PMCID: PMC3713455.
1494. Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F. The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia. Front Oncol 3(Article 218):1-5, 2013. e-Pub 9/2013. PMCID: PMC3764477.
1495. Vannucchi A, Verstovsek S, Kiladjian JJ, Gotlib J, Cervantes F, Mesa R, Barosi G, Sarlis N, Peng W, Sandor V, Sirulnik A, Hmissi A, Stalbovskaya V, Harrison C, Kantarjian H. A Pooled Overall Survival Analysis of the COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib for the Treatment of Myelofibrosis. Haematologica. In Press.
1496. Thomas XG, Arthur C, Delaunay J, Jones M, Berrak E, Kantarjian HM. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Clinical Lymphoma Myeloma and Leukemia. In Press.
1497. Kurzrock R, Kantarjian H, Stewart D, Segall V. A Scandal and Its Aftermath: Escalating Regulatory Burden for Genomic Diagnostic Tests in Cancer Clinical Trials. Nature Biotechnology. In Press.
1498. Karjalainen K, Pasqualini R, Arap W, Cortes J, Kornblau S, Lichtiger B, O'Brien S, Kantarjian H Sidman R. Design, development, and validation of a high-throughput drug screening assay for targeting of human leukemia. Cancer. In Press.
1499. Daver N, Dumlao T, Ravandi F, Pemmaraju N, Nazha A, Pierce S, Borthakur G, Faderl S, Garcia-Maner0 G, Cortes J, Kantarjian H, Quintas-Cardama A. Impact of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia Receiving Standard Chemotherapy. Clinical Lymphoma Myeloma & Leukemia. In Press.
1500. Pemmaraju N, Tanaka M, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt S,Chen J, Pierce S, Cortes J, Kantarjian H, Champlin R, DeLima M, Qazukbash M. Outcomes in Relapsed

or Refractory Acute Promyelocytic Leukemia (APL) Patients Treated With or Without Autologous (Auto) or Allogeneic (Allo) Hematopoietic Stem Cell Transplantation (HCT). Clinical Lymphoma, Myeloma & Leukemia. In Press.

1501. Frolova O, Samudio I, Benito J, Jacamo R, Kornblau S, Markovic A, Schober W, Lu H, Qiu Y, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, Kantarjian H, Lock R, Andreeff M, Konopleva M. Regulation of HIF-1 signaling and chemoresistance in Acute Lymphocytic Leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biology & Therapy. In Press.
1502. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes JE, Kantarjian HM, Andreeff M, Kornblau SM. Survivin is highly expressed in leukemic stem cells and predicts poor clinical outcomes in AML. Blood. In Press.
1503. Mesa R, Verstovsek S, Kantarjian H, et. al. The Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reportted Outcomes in COMFORT-1: a Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology. In Press.
1504. Ohanian M, Kantarjian H, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi-Kashani F, Garcia-Manero G, Champlin R, Pierce S, Alattar M, Trinh L, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes J. Tyrosine Kinase Inhibitors as Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase. Clinical Lymphoma, Myeloma & Leukemia. In Press.
1505. Zhou Y, Jorgensen J, Wang SA, Ravandi F, Cortes J, Kantarjian H, Medeiros J, Konoplev S. Utility of CD11a and CD18 in Flow Cytometic Immunophenotypic Analysis for Diagnosis of Acute Promyelocytic Leukemia. American Journal of Clinical Pathology. In Press.

Invited Articles

1. Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters R, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich EJ. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol 12(2 Suppl 3):98-104, 6/1985.
2. Talpaz, M, Gutterman, JU, Kantarjian, H, Trujillo, JM. Development of secondary Ph1 clone in patients wtih chronic myelogenous leukemia and its suppression with alpha interferon therapy. . The Cancer Bulletin 38(5):267-268, 1986.
3. McCredie KB, Talpaz M, Kantarjian H, Rosenblum M, Keating M, Gutterman J. Biologic agents for the management of hematological disorders: chronic myeloid leukemia. Haematol Blood Transfus 31:120-2, 1987.
4. Keating MJ, Estey E, Kantarjian HM, Walters R, Smith T, McCredie KB, Freireich EJ. Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol 78 Suppl 1:120-6, 1987.
5. Anaisie, EKantarjian, HM et al. Fusarium infection. Yearabook infection diseases 1987, 1987.
6. Keating, MJ, Kantarjian HM, Redman JR:. Fludarabine treatment of chronic lymphocytic leukemia and indolent lymphomas. Cancer Bulletin 42:136-144, 1990.
7. Deisseroth, AB, Herst, CV, Wedrychowski, A, Sims, SH, Seong, DC, Johnson, EB, Yuan, T, Romine, ME, Paslidis, N, Gao, P-q, Huston, LJ, Claxton, DF, Kornblau, SM, Kantarjian, HM, Talpaz, M, Reading, CL:. Future directions in molecular and genetic therapy for leukemias and solid tumors. . Cancer Bulletin 42(3):173, 1990.
8. Keating MJ, Kantarjian H, Estey E, Plunkett W, Trujillo J, McCredie KB. Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia. Haematol Blood Transfus 33:593-603, 1990.
9. Kantarjian, HM, Deisseroth, AB, Gutterman, JU, Talpaz, M:. Novel therapeutic approaches for chronic myelogenous leukemia. . Cancer Bulletin 42(3):149, 1990.
10. Estey, E, McCredie, K, Keating, MJ, Kantarjian, HM, Kurzrock, R, Talpaz, M, Gutterman, JU, Deisseroth, AB:. Treatment of acute myelogenous leukemia with chemotherapy and hematopoietic growth factors. . Cancer Bull 42:156-62, 1990.
11. Estey EH, Kantarjian HM, Beran M, McCredie KB, Keating MJ, Deisseroth A, Gutterman JU. Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF. Haematol Blood Transfus 33:732-6, 1990.

12. Estey, E, Kurzrock R, Kantarjian H, Koller C, O'Brien S, Beran M, Keating M, McCredie K, Freireich E:. 2-chlorodeoxyadenosine: A new anticancer agent in lymphoid malignancies. . Cancer Bulletin 43(3):253-58, 1991.
13. Keating MJ, O'Brien S, Robertson L, Plunkett W, Kantarjian H, Koller C. New drugs in the treatment of chronic lymphocytic leukemia. Leukemia 6 Suppl 4:140-1, 11/1992.
14. Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukemia 6 Suppl 2:78-80, 1992.
15. Keating, M, Kantarjian, H, O'Brien, S, Estey, E, Koller, C, Beran, M, McCredie, K, Freireich, E:. Patterns of failure in salvage therapy for acute myelogenous leukemia. Haematology and Blood Transfusion 34:379-387, 1992.
16. Estey, E, Kantarjian, H, O'Brien, S, Beran, M, McCredie, K, Koller, C, Schachne,r J, Keating, M:. Use of granulocyte-macrophage colony-stimulating factor prior to chemotherapy of newly-diagnosed AML. . Haematology and Blood Transfusion 34:97-101, 1992.
17. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol 20(5 Suppl 7):13-20, 10/1993.
18. Estey EH, Kantarjian H, Keating M. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Semin Oncol 20(6 Suppl 8):1-5, 12/1993.
19. Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, Escudier S, Koller C, Kornblau S, Robertson L, et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma 11 Suppl 2:59-63, 1993.
20. Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leuk Lymphoma 10 Suppl:115-21, 1993.
21. Keating MJ, Estey E, O'Brien S, Kantarjian H, Robertson LE, Plunkett W. Clinical experience with fludarabine in leukaemia. Drugs 47 Suppl 6:39-49, 1994.
22. Keating MJ, O'Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol 31(1):28-39, 1994.
23. Cortes, J, Kantarjian, H. Leukemia in the Elderly. Cancer Bulletin 47:203-211, 1995.
24. Keating MJ, O'Brien S, McLaughlin P, Dimopoulos M, Gandhi V, Plunkett W, Lerner S, Kantarjian H, Estey E. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther 38 Suppl 2:S83-91, 12/1996.
25. O'Brien S, Kantarjian H, Keating MJ. Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. Ann Oncol 7 Suppl 6:S27-33, 1996.
26. Ravandi-Kashani, FCortes, J, Kantarjian, H, Talpaz, M. Chronic myeloid leukemia: Current guidelines for diagnosis and management. Hemotology 3:263-276, 1998.
27. Kantarjian H. New developments in the treatment of acute myeloid leukemia: focus on topotecan. Semin Hematol 36(4 Suppl 8):16-25, 10/1999.
28. Kantarjian H. Introduction: Hematologic Malignancies: Is there a role for topoisomerase-I inhibitors? . Seminars in Hematology 36(4,Suppl 8):1-2, 1999.
29. Kantarjian, HM, Hoelzer, D, Larson, RA,. Advances in the treatment of adult acute lymphocytic leukemia, part I -Preface. Hematology - Oncology Clinics of North America. 14(6):XIII, 2000.
30. Giles ,FJ, Cortes, JE, Thomas, DA, O'Brien, S, Proulx, L, Jolivet, J, Kantarjian, HM. BCH-4556 (troxacitabine), a novel nucleoside analog, is an active anti-leukemia agent. . Cancer Investigation 18:112-114, 2000.
31. Kantarjian, HM, Talpaz, M:. Interferon alpha and low-dose cytarabine: a new standard of care in frontline therapy of chronic myelogenous leukemia. . Cancer Investigation 18:5-8, 2000.
32. Thomas DA, Kantarjian HM. The revitalization of thalidomide. Ann Oncol 12(7):885-6, 7/2001.
33. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. Jama 286(8):895-8, 8/2001.
34. Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol 28(5 Suppl 17):9-18, 10/2001.
35. Kantarjian, HM, Hoelzer D, Larson RA. Advances in the treatment of adult acute lymphocytic leukemia, part II -Preface. . . Hematology - Oncology Clinics of North America. 15(1):XI, 2001.

36. Garcia-Manero G, Talpaz M, Kantarjian HM. Current therapy of chronic myelogenous leukemia. Intern Med 41(4):254-64, 4/2002.
37. Kantarjian HM. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience. J Clin Oncol 20(10):2415-6, 5/2002.
38. Kantarjian, H, Issa, J-P. Decitabine studies in leukemia and myelodysplastic syndrome. Cancer Investigation 20(1):6-8, 2002.
39. Thomas DA, Cortes J, Kantarjian HM. New agents in the treatment of acute lymphocytic leukaemia. Best Pract Res Clin Haematol 15(4):771-90, 12/2003.
40. Garcia-Manero, G, Kantarjian H. Treatment innovations in chronic myelogenous leukemia. Oncology Special Ed 6:25-30, 2003.
41. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am 18(3):753-74, xii, 6/2004.
42. Cortes JE, O'Brien SM, Giles F, Alvarez RH, Talpaz M, Kantarjian HM. Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am 18(3):619-39, ix, 6/2004.
43. Kantarjian, HM, Talpaz M. Chronic myelogenous leukemia. Hematol Oncol Clin North Am 18(3):XV-XVI, 2004.
44. Kantarjian H. Discussion: Selected abstracts on Myeloma and Leukemia from the American Socitey of Hematology Annual Meeting, 2003. Guest Editors Rajkumar SV, Kantarjian H. . Oncology 18(Supplemeent 2):37-42, 2004.
45. Kantarjian HM, Issa JP. Decitabine dosing schedules. Semin Hematol 42:S17-22, 7/2005.
46. Kantarjian H, Cortes J. Imatinib-resistant chronic myeloid leukemia. Definitions and management. Haematologica 5(1):127-131, 6/2011.

Editorials

1. Kantarjian HM. Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions. Cancer 109:1007-1010, 2/2007.
2. Kantarjian H, O'Brien S. Questions Regarding Frontline Therapy of Acute Myeloid Leukemia. Cancer 116(21):4896-4901, 11/2010.
3. Kantarjian HM. Chemotherapy Drug Shortages: A Preventable Human Disaster. The ASCO Post 2(17), 11/2011.
4. Kantarjian H, Zwelling L. Doctor still knows best. The Houston Chronicle, 11/2012.
5. Kantarjian H, Zwelling L. Allowing patients to self-inject drugs could lower health care costs. The Houston Chronicle, 12/2012.
6. Kantarjian H, Zwelling L. It's time to price dugs by their value to patients. Houston Chronicle, 1/2013.
7. Kantarjian H, Fojo T, Zwelling L. Making cancer drugs less expensive. The Washington Post, 2/2013.
8. Kantarjian H, O'Brien S, Cortes J. Homoharringtonine/Omacetaxine: The Little Drug that Could. The ASCO POST 4(6):58-63, 4/2013.
9. Kantarjian H, Estey E. Drug Approvals in Acute Myeloid Leukemia: Can We Do Better? The ASCO Post 4(8):137-138, 5/2013.
10. Leonard Zwelling, Hagop Kantarjian. U.S. needs universal health care. Houston Chronicle(Outlook, Government Section):B9, 6/2013.

Other Articles

N/A

Abstracts (past 5 years)

1. 13th Congress of the European Haematology Association. 12 abstracts. Please refer to. Haematogica 93(S1), 2008.
2. ASCO 44th Annual Meeting. 26 abstracts. Please refer to. JCO 26(15S), 2008.
3. ASH 50th Annual Meeting. 85 abstracts. Please refer to. Blood 112(11), 2008.
4. ASH 51st Annual Meeting. 104 abstract. Please refer to. Blood 114(S1), 2009.
5. 14th Congress of the European Haematology Association. 2 abstracts. Please refer to. Haematologica 94(S1), 2009.
6. ASCO 45th Annual Meeting. 27 abstracts. Please refer to. JCO 27(15S), 2009.
7. ASH 52nd Annual Meeting. 95 abstracts. Please refer to. Blood 116(S1), 1/2010.

8. 15th Congress of the European Haematology Association. 1 abstract. Please refer to. Haematologica 95(S1), 2010.
9. ASCO 46th Annual Meeting. 28 abstracts. Please refer to. JCO 28(15S), 2010.
10. ASCO 47th Annual Meeting. 26 abstracts. Please refer to. JCO 29(15S), 5/2011.
11. 16th Congress of the European Haematology Association. 13 abstracts. Please refer to. Haematologica, 6/2011.
12. ASH 53rd Annual Meeting. 104 abstracts. Please refer to. Blood 118(21), 11/2011.
13. ASCO 48th Annual Meeting. 32 abstracts. Please refer to http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_category_abstracts_view&confID=114&subCatID=114, 6/2012.
14. ASH 54th Annual Meeting. 122 Abstracts. Please refer to. Blood 120(21), 11/2012.
15. ASCO 49th Annual Meeting. 22 Abstracts. Please refer to: JCO 31(15S):737 (Index), 6/2013.

Book Chapters

1. McLaughlin, P, Velasquez W, Rodgers R, Kantarjian H, Butler J, Fuller L. Management of patients with nodular lymphoma . In: U.T. M.D.Anderson Clinical Conference on Cancer. 27. Raven Press, 301 312, 1984.
2. Barlogie, B, Hittelman WN, Davis FM, Kantarjian H:. Nucleic acid cytometry, interphase chromosome and nucleolar antigen in the detection of residual leukemia in morphologic remission. . In: Minimal Residual Disease in Acute Leukemia. Martinus Nijhoff Publishers, 1 18, 1984.
3. Talpaz, M, Kantarjian H, McCredie K, Keating M, Gutterman JU. Chronic myelogenous leukemia: Hematologic remissions with recombinant alpha-A-interferon. . In: The Biology of the Interferon System. Elsevier Science Publishers, 1985.
4. McCredie, KB, Talpaz M, Kantarjian H, Rosenblum M, Keating M, Gutterman JU. Biologic agents for the management of hematological dosorders: Chronic myeloid leukemia. In: Modern Trends in Human Leukemia VII. . In: Haematology and Blood Transfusion. 31. Springer-Verlag., 120-122, 1987.
5. Kantarjian, HM, Talpaz M, Gutterman J. Biological therapy of chronic myelogenous leukemia. In: Oncology. 1, 35-40, 1987.
6. Kantarjian HM, Talpaz M, Kurzrock R, Keating MJ, McCredie KB, Gutterman J, Freireich EJ. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. In: Acta Haematol. 78 Suppl 1, 70-4, 1987.
7. Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. In: Semin Oncol. 14, 435-43, 1987.
8. Kantarjian HM, Talpaz M, Gutterman JU. Chronic myelogenous leukemia--past, present, and future. In: Hematol Pathol. 2, 91-120, 1988.
9. Talpaz, M, Kurzrock R, Kantarjian HM, Gutterman JU. Clinical studies of alpha and gamma interferons in chronic myelogenous leukemia. . In: Clinical Aspects of Interferon, 127 139, 1988.
10. Talpaz M, Kurzrock R, Kantarjian HM, Gutterman JU. Recent advances in the therapy of chronic myelogenous leukemia. In: Important Adv Oncol, 297-321, 1988.
11. Talpaz, M, Kantarjian HM, Kurzrock R, Gutterman J. Therapy of chronic myelogenous leukemia Chemotherapy and interferons. In: Seminars in Hematology. 25, 62 73, 1988.
12. Keating, M, Kantarjian H, Estey E, Plunkett W, Trujillo J, McCredie K. Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in ANL. . In: Hematology and Blood Transfusion. Vol 33, Acute Leukemias II: Prognostic Factors and. Springer-Verlag, 593-604, 1990.
13. Kantarjian, H, Kurzrock R, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. In: Hematology/ Oncology Clinics of North America. Vol 4. W.B. Saunders Co., 389-404, 1990.
14. Estey, E, Kantarjian H, Beran M, McCredie K, Freireich E, Keating M, Gutterman J:. Treatment of Poor Prognosis, Newly-Diagnosed AML with High-Dose Ara-C and GM-CSF. In: Haematology and Blood Transfusion Vol. 33, Acute Leukemias II: Prognostic Factors and Treatment Strategies. Springer-Verlag, 732-736, 1990.

15. Estey, E, Kurzrock R, Talpaz M, McCredie K, Keating M, Kantarjian H, Freireich E, Gutterman J, Deisseroth A. Use of CSFs in AML. In: Acute Myelogenous Leukemia: Progress and Controversies. Wiley-Liss, 441-446, 1990.
16. Kantarjian, H, Talpaz M, Keating M:. Chronic myelogenous leukemia in accelerated and blastic phases - Present status and future prospects. . In: Chronic Myelogenous Leukemia - Hematology. Vol. 13. Marcel Dekker, 387-416., 1991.
17. Talpaz, M, Kantarjian H, Kurzrock R, Gutterman JU:. Interferons in the therapy of CML and myeloproliferative disorders. . In: Biological Therapy of Cancer: Principles and Practice. DeVita. J.B. Lippincott Co, 289-298, 1991.
18. Deisseroth, AB, Herst CV, Wedrychowski A, Sims S, Seong D, Johnson E, Yuan T, Romine M, Paslidis N, Emerson S, Feinberg A, Gao P, Huston L, Claxton D, Kornblau S, LeMaistre F, Kantarjian H, Talpaz M, Reading C, Spitzer G. Novel Approaches to the Therapy of CML. . In: New Strategies in Bone Marrow Transplantation. Wiley-Liss, Inc, 163-169, 1991.
19. Kantarjian, H, Talpaz M:. Treatment of Chronic Myelogenous Leukemia. . In: Therapy of Hematopoietic Neoplasia. 14. Marcel Dekker, Inc, 105-174, 1991.
20. Deisseroth, AB, Zhang W, Cha Y, Yuan T, Chen H, Sims S, Wedrychowski A, Gao P-Q, Huston L, Fillaccio M, Claxton D, Kornblau S, Johnson E, Howard OMZ, Andersson B, delGiglio A, Gressot L, Kantarjian H, Talpaz M, Khouri I, Champlin R, Andreeff M, Gaozza E, Seong D, Suh S-P, Ellerson D, Hu G, Chou M. In: Leukemia and Lymphoma. 6. Howard Academic Publishers, 89-95, 1992.
21. Bloomfield, CD, Kantarjian HM, Schiffer CA. Acute leukemia: Recent Advances in management. . In: Hematology, Education Program American Society of Hematology, 17-28, 1992.
22. Keating, MJ, Kantarjian H, O'Brien S, Estey E, Koller C, Beran M, McCredie KB, Freireich EJ:. Acute Leukemias - Pharmacokinetics. In: Haematology and Blood Transfusions. Vol. 34. Springer-Verlag, 379-387., 1992.
23. Kantarjian, HM, Talpaz M, Wetzler M, O'Brien S, Estey E, Plunkett W, Zhang W, Keating MJ, Deisseroth A. Chronic myelogenous leukemia in blastic phase: A model of heterogeneity and resistance in acute leukemia. In: Haematology and Blood Transfusion. Vol. 34, Acute Leukemias - Pharmacokinetics. Springer-Verlag, 214-221, 1992.
24. Deisseroth, A, Kantarjian H, Talpaz M, Wedrychowski A, Seong D, Sims S, Paslidis N, Romine M, Howard OMZ, Claxton D, Kornblau S, Herst CV, Yuan TY, Fu M, Hu M, Johnson E, Gao PQ, Huston L, O'Brien S, Liang J, Emerson S, Feinberg A, Hester J, Guba S, Zhang W, Champlin R, Spencer V, Andersson B, Yau J, Spitzer G, LeMaistre F, Wallerstein R, Huan S, Eilerson D, Luttrell R, Wu K, Herrick M, Gooch G, Reading C. Integration of molecular biology and genetics with biological and chemotherapeutic approaches to the rearrangement of chronic myelogenous leukemia. . In: Proceedings of the Fifth Annual Symposium on Autologous Bone Marrow Transplantation. 1992.
25. Talpaz, M, Kantarjian H, Kurzrock R, GUtterman JU. Therapy of CML and myeloproliferative disorders with interferons. In: Biological Response Modifiers In the Treatment of Hematopoietic Neoplasia. Vol 15. Marcel Dekker, Inc., 27-42, 1992.
26. Keating, MJ, Estey E, Kantarjian H. Acute Leukemia. In: Principles and Practice of Oncology, 1938-1964, 1993.
27. del Giglio, A, O'Brien S, Kantarjian H:. Chronic lymphocytic leukemia. In: Medical Oncology - A Comprehensive Review. University of Texas M.D. Anderson Cancer Center, 29-36, 1993.
28. del Giglio, A, O'Brien S, Talpaz M, Kantarjian H:. Chronic myelogenous leukemia. . In: Medical Oncology - A Comprehensive Review. University of Texas M.D. Anderson Cancer Center, 37-45, 1993.
29. Deisseroth, A, Andreeff M, Champlin R, Keating M, Kantarjian H, Khouri I, Talpaz M. Therapy for Chronic Phase CML. In: Cancer: Principles and Practice of Oncology, 1965-1983, 1993.
30. Kantarjian, HM, Estey EH, Keating MJ:. Treatment of therapy-related leukemia and myelodysplastic syndrome. . 7, 81, 1993.
31. Kantarjian HM, Deisseroth A, Talpaz M. Chronic myelogenous leukemia--update and future directions. In: Rev Invest Clin. Suppl, 118-24, 1994.
32. Kantarjian H. Acute and Chronic Leukemias. In: MKSAP in the Subspecialty of Hematology, pp121-129, pp142-147, pp157-161, 1995.

33. Khouri, I, Kantarjian H, Talpaz M, Andreeff M, Lee M-S, Champlin R, Deisseroth AB:. Chronic Myelogenous Leukemia. In: Clinical Oncology, 2035-2051, 1995.
34. Khouri, I, Kantarjian H, Talpaz M, Claxton D, Kornblau S, Deisseroth AB. Molecular Diagnosis and therapy of hematopoietic neoplasms. In: The Molecular Basis of Cancer. W.B. Saunders Co, 280-293, 1995.
35. Deisseroth, A, Fu Siqing, Hanania EG, Talpaz M, Kantarjian H, Champlin RP. Section 25.3 gene therapy using stem cell modification. In: Biologic Therapy of Cancer. J.B. Lippincott Company, 1995.
36. Estey, E, Kantarjian H, Keating MJ:. Therapy for acute myeloid leukemia. In: Hematology Basic Principles and Practice, 1014-1028, 1995.
37. Cortes, JE, Kantarjian H, Freireich EJ. Acute lymphocytic leukemia: A comprehensive review with emphasis on biology and therapy. In: Molecular genetics and therapy of leukemia. Kluwer Academic Publishers, 291-323, 1996.
38. Cortes, J, Kantarjian H, O'Brien S, Keating MJ. Clinical trials with nucleoside analogs in other hematologic malignancies. In: Nucleoside analogs in cancer therapy, 289-314, 1997.
39. Cortes, J, Kantarjian HM, Giralt S, Talpaz M:. Natural history and staging of chronic myelogenous leukemia. In: Clinical Haematology, 277-290, 1997.
40. Talpaz M, Kantarjian HM, O'Brien S, Kurzrock R. The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. In: Baillieres Clin Haematol. 10, 291-305, 1997.
41. Kantarjian, HM, Giles FJ, O'Brien SM, Talpaz M:. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. . In: Hematology/Oncology Clinics of North America. 12, 31-80, 1998.
42. Larson, RA, Stock W, Hoelzer DF, Kantarjian H. Acute Lymphoblastic Leukemia in Adults. In: American Society of Hematology Education Program Book, 44-62, 1998.
43. Cortes, JE, Kantarjian, HM:. Chronic leukemias. In: Cancer Management: A Multidisciplinary Approach, 306-328, 1998.
44. O'Brien, S, Kantarjian H, Talpaz M. Practical management of interferon therapy and side effects. In: Medical Management of Chronic Myelogenous Leukemia. Marcel Dekker, 161-170, 1998.
45. Cortes, J, Kantarjian H, Estey EH, O'Brien S, Beran M, Keating MJ, Freireich EJ:. Promising approaches in acute leukemia: Novel and revisited strategies. . In: Medical Management of Hematological Malignant Diseases. 507-538. Marcel Dekker, Inc., 1998.
46. Kantarjian H. Acute and Chronic Leukemias. . In: Primary Care Oncology. 318-337, 1999.
47. Cortes, JE, Aguayo A, Kantarjian H. Chronic leukemias . In: Cancer Management: A Multidisciplinary Approach. 657-680, 1999.
48. Kantarjian, HM, Talpaz M. Chronic myelogenous leukemia - A brief review. In: Medical Management of Chronic Myelogenous Leukemia. 1-41, 1999.
49. Zhao, Y, Ramagli L, Seong D, Kantarjian H, Siciliano MJ. Inter-ALU-PCR generated fluorescence in situ hybridization probes for the analysis of leukemia. In: Principles and Clinical Applications, 325-328, 1999.
50. Talpaz, M, Kantarjian HM. Medical Management of Chronic Myelogenous Leukemia., 1999.
51. Seong, C-M, Kantarjian HM, Talpaz M, Champlin R, Siciliano M. Monitoring the course of chronic myelogenous leukemia by fluorescence in situ hybridization., 317-339, 1999.
52. Aguayo, A, Cortes JE, Kantarjian H. Myelodysplastic syndromes. In: Cancer Management: A Multidisciplinary Approach. 681-694, 1999.
53. Estey, EH, Kantarjian H, Keating MJ. Therapy for acute myeloid leukemia. . In: Hematology - Basic Principles and Practice, 1025-1042, 1999.
54. Giles, FJ, Kantarjian HM. Therapy of chronic myelogenous leukemia. . In: Oncologic Therapies, 326-381, 1999.
55. Kantarjian HM. Adult acute lymphocytic leukemia - Introduction and questions related to current programs. In: Hematology - Oncology Clinics of North America. 14(6), 1205-8, 2000.
56. Kantarjian, H, Melo JV, Tura S, Giralt S, Talpaz M:. Chronic myelogenous leukemia: Disease biology and current and future therapeutic strategies. In: American Society of Hematology Education Program Book. Editors of Hematology, 90-109, 2000.

57. Talpaz, M, Ravandi F, Kurzrock R, Estrov Z, Kantarjian, H:. Interferon-a and -b: clinical applications. Leukemias, Lymphoma, and Multiple Myeloma. . In: Principles and Practice of the Biologic Therapy of Cancer, 209-224, 2000.
58. Garcia-Manero, G, Kantarjian, HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. In: Hematology/Oncology Clinics of North America. Advances in the Treatment of Adult Acute Lymphocytic Leukemia, Part I. 14, 1381-1396, 2000.
59. Kantarjian HM. Adult acute lymphocytic leukemia - Future research directions. . In: Hematology – Oncology Clinics of North America. 15(1), 207-11, 2001.
60. Thomas, DA, Cortes J, Kantarjian HM, Bueso-Ramos C, Hagemeister F. High-grade non-Hodgkin's lymphomas. . In: American Cancer Society Atlas of Malignant Lymphomas. bc decker, 2001.
61. Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantarjian HM. Acute myeloid leukemia. In: Hematology Am Soc Hematol Educ Program, 73-110, 2002.
62. Cortes, J, O'Brien S, Weiss M, Kantarjian H. Chronic lymphocytic leukemia. . In: Cancer Management: A multidisciplinary approach. 721-733, 2002.
63. Cortes, J, Silver R, Kantarjian H, Aguayo A. Chronic myelogenous leukemia. . In: Cancer Management: A multidisciplinary approach. 709-720, 2002.
64. Cortes, J, Kantarjian H, List A, Aguayo A. Myelodysplastic syndromes. . In: Cancer Management: A multidisciplinary approach. 735-749, 2002.
65. Garcia-Manero, G, Kantarjian, H. New investigational strategies in patients with myelodysplastic syndromes. In. In: The Myelosysplastic Syndromes: Pathobiology and Clinical Management, 399-420, 2002.
66. Jeha, S, Kantarjian H. Treatment of acute lymphoblastic leukemia in adolescents and young adults: Lessons learned and future directions. . In: Treatment of Acute Leukemias. New Directions for Clinical Research. 113-120, 2002.
67. Faderl, S, Kantarjian H. XVII Chronic myelogenous leukemia and other myeloproliferative disorders. . In: 12 Oncology. WebMD Scientific American® Medicine. WebMD, inc., 2002.
68. Garcia-Manero, G, Kantarjian H, Schiffer C. Adult acute lymphocytic leukemia. . In: Cancer medicine. 2. American Cancer Society, B.C. Deckner, Inc., 2125-2134, 2003.
69. Garcia-Manero, G, Talpaz M, Faderl S, Kantarjian H. Chronic myelogenous leukemia. . In: Blood: Principles and practices of hematology. Lippincott Williams & Wilkins, 433-454, 2003.
70. Cortes, JE, Silver RT, Kantarjian ,HM. Chronic myelogenous leukemia. . In: Cancer management: a multidisciplinary approach. The Oncology Group, a division of SCP Communications, 759-770, 2003.
71. Faderl, S, Talpaz M, Kantarjian, H. Molecular biology and cytogenetics of chronic myeloid leukemia. . In: Neoplastic diseases of the blood. Cambridge University Press, 36-52, 2003.
72. Cortes, JE, List A, Kantarjian HM. Myelodysplastic syndromes. . In: Cancer management: a multidisciplinary approach,. The Oncology Group, a division of SCP Communications, 785-800,., 2003.
73. Weidner ,DA, Wang RY, Zhao S, Kuehnle I, Kantarjian, H, Brenner MK, Goodell MA, Andreeff M. Reduced level of Philadelphia chromosome positive (Ph+) cells in lineage negative side population bone marrow progenitor cells from patients with chronic myeloid leukemia (CML). . In: Acute Leukemias IX. Springer, 239-251, 2003.
74. Kantarjian, H, Faderl S. 17 Chronic myelogenous leukemia and other myeloproliferative disorders. 12 Oncology. . In: ACP Medicine Online (http://acpmedicine.com). WebMD Inc., 2004.
75. Giles, F, Cortes J, Kantarjian H, O'Brien S. Accelerated and blastic phases of chronic myelogenous leukemia. (www.TheClinics.com) . In: Hematology/Oncology clinics of North America (Chronic Myelogenous Leukemia. 18. W. B. Saunders Company, a Division of Elsevier Inc., 753-774, 2004.
76. Kantarjian, H, Faderl S. Acute lymphoid leukemia in adults. In: Clinical Oncology. Elsevier Inc., 2793-2823, 2004.
77. Cortes, J, Silver R, Kantarjian H. Chronic myelogenous leukemia. In: Cancer Management: A Multidisciplinary Approach (Medical Surgial, & Radiation Oncology),. CMP Healthcare Media, 773-786, 2004.
78. Cortes, J, O'Brien S, Giles F, Alvarez R, Tallpaz, Kantarjian H. Investigational strategies in chronic myelogenous leukemia. . In: Hematology/Oncology clinics of North America (Chronic

Myelogenous Leukemia). (www.TheClinics.com). 18. W. B. Saunders Company, a Division of Elsevier Inc., 619-640, 2004.
79. Cortes, J, List A, Kantarjian H. Myelodysplastic syndromes. . In: Cancer Management: A Multidisciplinary Approach (Medical Surgial, & Radiation Oncology), 801-818, 2004.
80. Giles, F, Kantarjian H, Cortes J. Novel therapies for patients with chronic myeloid leukemia. In: Expert Rev Anticancer Ther. 4, 271-82, 2004.
81. Keating, M, Kantarjian, H. The Chronic Leukemias. Chronic myelogenous leukemia (chronic myeloid leukemia, chronic myelocytic leukemia, chronic granulocytic leukemia). . In: Cecil Textbook of Medicine. Saunders, 1150-1161, 2004.
82. Issa JP, Kantarjian HM. Introduction: emerging role of epigenetic therapy: focus on decitabine. In: Semin Hematol. 42, 3 Suppl 2, S1-2, 7/2005.
83. Cortes, J, Silver R, Kantarjian H. Chronic myelogenous leukemia. . In: Cancer management: a multidisciplinary approach - medical, surgical & radiation oncology. 9. CMP Healthcare Media, 797-810, 2005.
84. Cortes, J, List A, Kantarjian H. Myelodysplastic syndromes. . In: Cancer management: a multidisciplinary approach - medical, surgical & radiation oncology. 9, 825-8842, 2005.
85. Faderl S, Kantarjian H. Myelodysplastic syndromes. . In: Cancer: Principles & Practice of. 7. Lippincott Williams & Wilkins, 2144-2154, 2005.
86. Estey, E, Kantarjian, H. Therapy for acute myeloid leukemia. . In: Hematology: Basic Principles and Practice. 4. Elsevier, Inc., 1099-1120, 2005.
87. Quintas-Cardama A, Kantarjian H, and Cortes J. Dasatinib: a dual ABL and SRC inhibitor. In: In: Chronic Myeloid Leukemia. Ed(s) Cortes J and Deininger M. Informa Healthcare USA, Inc.: New York, NY, 59-68, 2007.
88. Jabbour E, Giles F, Cortes J, O'Brien S, and Kantarjian H. Nilotinib (AMN 107) for the treatment of chronic myelogenous Leukemia. In: Informa Healthcare USA, Inc. Ed(s) Cortes J and Deininger M: New York, NY, 69-77, 2007.
89. Kantarjian H and O'Brien S. The Chronic Leukemias. In: In: Cecil Medicine, 23. Ed(s) Goldman L, Ausiello E. Saunders Elsevier: Philadelphia, PA, 1397-1408, 2007.
90. Kantarjian H, Cortes J. Chronic myeloid leukemia. In: Abeloff's Clinical Oncology. Ed(s) Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG. Churchill Livingstone, an imprint of Elsevier Inc: Philadelphia, PA, 2279-2291, 2008.
91. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, Cortes J. Targeted therapy in myelodysplastic syndrome. In: Targeted Cancer Therapy. Ed(s) Kurzrock R, Markman M. Humana Press, a part of Springer Science+Business Media, LLC,: Totowa, NJ, 237-260, 2008.
92. Kantarjian HM. Introduction:targeting different pathways to prevent tumor cell development. In: Semin Oncol. 36 (2), Suppl 1, 2 Suppl 1, S1-S5, 4/2009.
93. Jabbour E, Fava C, Kantarjian H. Advances in the biology and therapy of patients with chronic myeloid leukaemia. In: Best Pract Res Clin Haematol. 22, 3. Ed(s) J Rowe. Elsevier Ltd: Oxford, UK, 395-407, 9/2009.
94. Cortes J, Silver RT, Kantarjian H. Chronic myeloid leukemia. In: Cancer Management: A Multidisciplinary Approach, 12th. Ed(s) Pazdur R, Wagman L, Camphausen K, Hoskins W. The Oncology Group of CMPMedia: Norwalk, CT, 807-822, 2009.
95. Thomas D, O'Brien S, Kantarjian H. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. In: Hematol Oncol Clin N Am. 23, 5. Ed(s) Stock W, Wetzler M. Saunders and imprint of Elsevier, Inc: Philadelphia, PA, 949-971, 2009.
96. Garcia-Manero G, List A, Kantarjian H, Cortes J. Myelodysplastic syndromes. In: Cancer Management: A Multidisciplinary Approach, 12. Ed(s) Pazdur R, Wagman L, Camphausen k, Hoskins W. The Oncology Group of CMPMedica: Norwalk, CT, 841-858, 2009.
97. Mattiuzzi G, Kantarjian H. Prophylactic antifungal therapy in neutropenic onco-hematology patients. In: Antifungal strategies and complications in high-risk patients. Remedica: London, 18-36, 2009.
98. Faderl S, Pui C, O'Brien S, Kantarjian H. Acute Lymphoblastic Leukemia. In: Cancer Medicine, 8th. Ed(s) Hong W, Bast R, Hait W, Kufe D, Pollock R, Weichselbaum R, Holland J, Frei E. People's Medical Publishing House-USA: Shelton, Connecticut, 1591-1603, 2010.

99. Cortes J, Silver R, Kantarjian H. Chronic Myeloid Leukemia. In: Cancer Medicine, 8th. Ed(s) Hong W, Bast R, Hait W, Kufe D, Pollack R, Weichselbaum R, Holland J, Frei E. People's Medical Publishing House-USA: Shelton, Connecticut, 1582-1590, 2010.
100. O'Brien S, Faderl S, Thomas D, Kantarjian H. Acute Lymphoblastic Leukemia. In: Advances in Malignant Hematology, 1st. Wiley-Blackwell: West Sussex UK, 228-244, 2011.
101. Jabbour E. Fullmer A, Faderl S, Parikh S, Koller S, Kantarjian H. Chronic Myeloid Leukemia. In: The MD Anderson Manual of Medical Oncology, 2nd. Ed(s) Kantarjian H, Wolff R, Koller C. McGraw-Hill: China, 53, 2011.
102. Jabbour E, Parikh S, Kantarjian H, Cortes J. Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment. In: Hematology / Oncology Clinics of North America: Chronic Myelogenous Leukemia. 25, 5. Ed(s) DJ De Angelo, GP Canellos, N Berliner. W.B. Saunders Company: Philadelphia, PA, USA, 981-995, 2011.
103. Jabbour E, Kantarjian H, Cortes J. Chronoic Myeloid Leukemia. In: Management of Hematologic Malignancies. January 2011, 1st. Ed(s) O'Brien S, Vose J, Kantarjian H. Cambridge University Press: New York, 68-80, 2011.
104. Kantarjian H. Myelodysplastic Syndromes. In: Cancer - Principles & Practice of Oncology, 9th. Ed(s) DeVita V, Lawrence T, Rosenbert S. Lippincott Williams & Wilkins: Philadelphia, PA USA, 1988 - 1996, 2011.
105. Faderl S, Garcia-Manero G, Kantarjian H. Myelodysplastic Syndromes (MDS). In: Management of Hematologic Malignancies. January 2011, 1st. Ed(s) O'Brien S, Vose J, Kantarjian H. Cambridge University Press: New York, 103-115, 2011.
106. Jabbour E, Cortes J, Kantarjian H. Standard Management of Patients with Chronic Myeloid Leukemia. In: Advances in Malignant Hematology, 1st. Ed(s) Saba H, Mufti G. Wiley-Blackwell: West Sussex UK, 71-86, 2011.
107. Faderl S, Kantarjian H. Clinical Manifestations and Treatment of Acute Myeloid Leukemia. In: Hematology Basic Principles and Practice, Sixth. Ed(s) R Hoffman, E Benz, L Silberstein, H Heslop, J Weitz, J Anastasi. Elsevier Saunders: Philadelphia, PA, 863-881, 2012.
108. Kantarjiah H, O'Brien S. The Chronic Leukemias. In: Goldman's Cecil Medicine. 1, 24th. Ed(s) Goldman L, Schaffer A. Elsevier Saunders: Philadelphia, PA, 1209-1217, 2012.
109. Nachman, J, Kantarjian, HM. Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia in the Modern Era. In: Hematologic Malignancies in Childre, Adolescents and Young Adults. Ed(s) Cairo MS, Perkins, SL. World Scientific Publishing: Singapore, Japan, 253-, 2012.
110. Nachman J, Kantarjian H. Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia in the Modern Era. In: Hematological Malignancies in Children, Adolescents and Young Adults. 1. Ed(s) Cairo MS, Perkins SL. World Scientific Publishing: New Jersey, 225-235, 2012.
111. Kantarjian H, Cortes J. Chronic Myeloid Leukemia. In: Abeloff's Clinical Oncology, 5. Ed(s) JE Niederhuber, JO Armitage, JH Doroshow, MB Kastan, JE Tepper. Elsevier Churchill Livingstone: Philadelphia, PA, 1944-1957, 2013.

Books (edited and written)

1. Kantarjian H Talpaz M. Treatment of Chronic Myelogenous Leukemia. . In: Therapy of Hematopoietic Neoplasia. Vol. 14. Marcel Dekker, Inc., 1991.
2. Freireich, Emil J, Kantarjian Hagop M. Leukemia: Advances in Research and Treatment. In: Cancer Treatment and Research. Kluwer Academic Publishers, 1993.
3. Freireich, Emil J, Kantarjian Hagop M. Molecular Genetics and Therapy in Leukemia. . In: Cancer Treatment and Research. Kluwer Academic Publishers, 1996.
4. Kantarjian, HM, Talpaz M. Treatment of Chronic Myelogenous Leukemia. In: Medical Management of Hematological Malignant Diseases. Marcel Dekker, Inc, 1998.
5. Talpaz, Moshe, Kantarjian Hagop M. Medical Management of Chronic Myelogenous Leukemia. Marcel Dekker, Inc, 1999.
6. Kantarjian, HM, Hoelzer, Dieter, Larson. Hematology/Oncology Clinics of North America. Advances in the Treatment of Adult Acute Lymphocytic Leukemia, Part I. ., 2000.
7. Kantarjian, HM, Hoelzer, Dieter, Larson. Hematology/Oncology Clinics of North America Advances in the Treatment of Adult Acute Lymphocytic Leukemia, Part II. ., 2001.

8. Kantarjian H, Talpaz M. Hematology/Oncology clinics of North America Chronic Myelogenous Leukemia. (www.TheClinics.com) . June, 2004. W. B. Saunders Company, a Division of Elsevier Inc., 2004.
9. Jabbour E, Borthakur G, Bueso-Ramos C, et al. Ed(s) Kantarjian H, Wolff R, Koller C. MD Anderson Manual of Medical Oncology, 1st. McGraw Hill Professional: New York, NY USA, 2006.
10. Zeidan A, Wetzler M, Fletcher A, Whittle A, Bowen D, Koeppen H, Bueso-Ramos C, Konoplev S, Albitar M, Schafer E, Small D. Ed(s) Faderl S, Kantarjian H. Leukemias: Principles and Practice of Therapy, 1st. Wiley-Blackwell: West Sussex, UK, 2010.
11. Jabbour E, Kantarjian H, Cortes J, O'Brien S, Faderl S. Ed(s) Susan O'Brien, Julie M. Vose and Hagop Kantarjian. Management of Hematologic Malignancies. January 2011, 1st. Cambridge University Press: New York, 2011.
12. Kantarjian H, Wolff R, Koller C. Ed(s) Kantarjian H, Wolff R, Koller C. MD Anderson Manual of Medical Oncology, 2nd. McGraw Hill Professional: New York, NY USA, 2011.

Letters to the Editor

1. Kantarjian HM, Bledin AG, Kim EE, Gutierrez CR, Haynie TP. Uptake of 99mTc-methylene disphosphonate in calcinosis cutis. J Am Acad Dermatol 7(6):804-6, 12/1982.
2. Kantarjian HM, Saad MF, Estey EH, Sellin RV, Samaan NA. Hypercalcemia in disseminated candidiasis. Am J Med 74(4):721-4, 4/1983.
3. Jadeja L, Kantarjian H, Bolivar R. Streptococcus bovis septicemia and meningitis associated with chronic radiation enterocolitis. South Med J 76(12):1588-9, 12/1983.
4. Quesada, JR, Kantarjian H, Keating M:. Hairy cell leukemia: Successful treatment with interferon alpha. Cancer Bulletin 37:88 90, 1985.
5. Ventura GJ, Kantarjian HM, Anaissie E, Hopfer RL, Fainstein V. Pneumonia with Cunninghamella species in patients with hematologic malignancies. A case report and review of the literature. Cancer 58(7):1534-6, 10/1986.
6. Kantarjian HM, Keating MJ. The eosinophilic variant of acute myelomonocytic leukemia developing as a secondary leukemia in a patient with mycosis fungoides. Hematol Pathol 1(3):191-2, 1987.
7. Kantarjian HM, Talpaz M. Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol 6(1):180-2, 1988.
8. Kurzrock, R, Talpaz M, Kantarjian H, Saks S, Gutterman JU:. Recombinant interferon-gamma therapy of chronic myelogenous leukemia. . Blood 74(4):1437-1438, 1988.
9. Seymour JF, Kantarjian HM. Hypercalcemia in acute lymphoblastic leukemia. Leuk Res 18(3):231-2, 3/1994.
10. Kantarjian HM, Talpaz M. Interferon-alpha therapy in chronic myelogenous leukemia: questions related to the German randomized trial. Blood 85(10):2998-9, 3000-2, 5/1995.
11. Talpaz M, Kantarjian H. Low-dose interferon-alpha in chronic myeloid leukemia. Ann Intern Med 122(9):728-9, 5/1995.
12. Albitar M, Chang KS, Pierce S, Kantarjian H, Estey E. The short form of PML-RARalpha fusion transcript is associated with poor survival. Leuk Res 23(1):89-92, 1999.
13. Albitar M, Beran M, O'Brien S, Kantarjian H, Frieriech E, Keating M, Estey E. Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Blood 96(1):372-3, 7/2000.
14. Cheson BD, Bennett JM, Kantarjian H, Schiffer CA, Nimer SD, Lowenberg B, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Greenberg PL. Myelodysplastic syndromes standardized response criteria: further definition. Blood 98(6):1985, 9/2001.
15. Kantarjian, HMHoelze,r DLarson, RA. Advances in the treatment of adult acute lymphocytic leukemia, part II -Preface. . Hematology - Oncology Clinics of North America. 15(1):XI, 2001.
16. Rex JH, Anaissie EJ, Boutati E, Estey E, Kantarjian H. Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults. Leukemia 16(6):1197-9, 6/2002.
17. Garcia-Manero G, Kantarjian HM, Kornblau S, Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia 16(9):1888, 9/2002.

18. Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica 87(10):1114-6, 10/2002.
19. Onida, F, Estey E, Ball G, Kantarjian H, Beran M. Value of peripheral blood lymphocytes and MDAPS in CMML. Blood 100:732-733, 2002.
20. Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation." Science 302(5648):1153; author reply 1153, 11/2003.
21. Kantarjian HM. Author reply, Prediction of Initial Cytogenetic Response for Subsequent Major and Complete Cytogenetic Response to Imatinib Mesylate Therapy in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia. Cancer 98(8):1777-1778, 2003.
22. Cortes, J, Kantarjian, H. Dose escalation of imatinib may improve responses in patients with CML who fail standard-dose imatinib. . Blood. 102:2703, 2003.
23. Kantarjian H, Cortes J. Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group. Leukemia 18(3):650, 3/2004.
24. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res 28(6):657-60, 6/2004.
25. Esmaeli B, Diba R, Ahmadi MA, Saadati HG, Faustina MM, Shepler TR, Talpaz M, Fraunfelder R, Rios MB, Kantarjian H. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye 18(7):760-2, 7/2004.
26. Tsimberidou AM, Estey E, Whitman GJ, Dryden MJ, Ratnam S, Pierce S, Faderl S, Giles F, Kantarjian HM, Garcia-Manero G. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 28(9):991-4, 9/2004.
27. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104(7):2204-5, 10/2004.
28. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian H. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood 105(3):1366-7, 2/2005.
29. Patel SP, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovek S, Kantarjian H, Estey E. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. Leuk Res 30(3):362-3, 3/2006.
30. Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G. Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia 20(8):1452-3, 8/2006.
31. Chen W, Rassidakis GZ, Li J, Routbort M, Jones D, Kantarjian H, Medeiros LJ, Bueso-Ramos CE. High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). Blood 108(5):1783-4, 9/2006.
32. Atallah E, Kantarjian H, Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.' Nat Med 13(1)(1):14, 2007.
33. Quintas-Cardama A, Kantarjian H, Cortes J. Tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 357:1557, 2007.
34. Yanada M, Borthakur G, Ravandi R, Bueso-Ramos C, Kantarjian H, Estey E. Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica 93(8):1263-1265, 8/2008.
35. Kantarjian H, O'Brien S. Insurance policies in the united states may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimens. Blood 113(8):1861, 7/2009.
36. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood 115(26):5428, 7/2010.

37. Kantarjian H. Reply to M. Keyhani and N. Mahmoudi. J of Clin Onc 30(2):220-221, 1/2012. e-Pub 11/2011.
38. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of Hyper-CVAD plus nelarabine as frontline therapy in adult T cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (LL)-MD Anderson cancer center experience. Leukemia. e-Pub 10/2013.
39. Kantarjian H, Zwellilng L. Cost of Cancer Drugs: What Price for What Benefit? The ASCO Post. In Press.

Manuals, Teaching Aids, Other Teaching Publications

1. Kantarjian H, Cortes J. Imatinib-resistant chronic myeloid leukemia. Definitions and management. Hematology Education: the education program for the annual congress of the European Hematology Association 2011. European Hematology Association: London, United Kingdom, 6/2011.

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Journal of Clinical Oncology, 1990−1994

Bone Marrow Transplantation, 1990

Forum, 1990

Hematologic Pathology, 1993

Editorial Board, Leukemia and Lymphoma, 1995−2011

Associate Editor, Investigational New Drugs Journal, 1998−2001

Associate Editor, Hematology, 1998−present

Editor, Journal of Clinical Oncology, 1998−present

Editorial Board, Cancer, 2001−present

Editorial Board, Clinical Advances in Hematology & Oncology, 2002

Editorial Board, Investigational New Drugs Journal, 2002

Editorial Board, Clinical Cancer Research, 2007−2015

Supplement Editor, Clinica Lymphoma, Myeloma and Leukemia, CIG Media Group, LP, 2009

Associate Editor, InPractice Hodgkin Lymphoma, 2009−present

Member of Editorial Review Board

N/A

Journal Reviewer

Reviewer-CML Abstracts, ASH 2002, 2002

Other Editorial and Review Activities

N/A

TEACHING

Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching
N/A

Supervisory Teaching
Committees
Advisory Committees
N/A

Supervisory Committees
N/A

Examining Committees
N/A

Direct Supervision
Undergraduate and Allied Health Students
N/A

Medical Students
N/A

Graduate Students
N/A

Postdoctoral Research Fellows
N/A

Clinical Residents and Fellows
N/A

Other Supervisory Teaching
N/A

Teaching Outside of Current Institution
Formal Teaching
Courses Taught
N/A

Training Programs
N/A

Other Formal Teaching
N/A

Supervisory Teaching
Committees
Advisory Committees
N/A

Supervisory Committees
N/A

Examining Committees
N/A

Direct Supervision
Undergraduate and Allied Health Students
N/A

Medical Students
N/A

Graduate Students

N/A

Postdoctoral Research Fellows
N/A

Clinical Residents and Fellows
N/A

Other Supervisory Teaching
N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

American Society of Hematology, American Society of Hematology Annual Meeting, Miami Beach, FL, Chair and Lecturer , 12/1999

American Society of Hematology, American Society of Hematology Annual Meeting, San Francisco, CA, Chair and Lecturer , 12/2000

American Association for Cancer Research, 93rd Annual Meeting, San Francisco, CA, 4/2002

Leukemia 2002: Towards the Cure, Miami, FL, Chair and Lecturer, 9/2002

Leukemia 2002: Towards the Cure, Miami, FL, Chair, 9/2002

Global Organization Against Leukemia (GOAL), Leukemia 2002: Towards the Cure, Miami, FL, Co-Chairman and Organizer, 9/2002

American Society of Hematology, 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, Chair, 12/2002

NCI, State of the Science (SOTS) Symposium on Acute Lymphoblastic Leukemia, Arlington, VA, Organizer and Chair, 5/2003

European Haematology Association, 8th Congress of the European Haematology Association, Lyon, France, Chair and speaker, 6/2003

Leukemia and Lymphoma Society, East and West Together, Dubrovnik, Croatia, Chair and Co-Organizer, 9/2007

Middle East Medical Assembly, In conjuction with MD. Anderson Cancer Center, Beirut, Lebanon, Co-Organizer, 4/2009

American Society of Clinical Oncology (ASCO), 45th ASCO Annual Meeting, Orlando, FL, Organizing Chair of Educational Sessions, 5/2009

Leukemia and Lymphoma; East and West are Together, Dubrovnik, Croatia, Co-Chair, 9/2011

Onco Services, Hematologic Malignancies Demystified Prime Oncology, Atlanta, GA, Chair, 1/2012

Onco Services, Hematologic Malignancies Demystified: The Series 2012 Prime Oncology, New York, NY, Chair, 1/2012

Onco Services, Hematologic Malignancies Demystified-A Critical Appraisal of Data from 2011 Prime Oncology, Houston, TX, Chair, 2/2012

Onco Services, Hematologic Malignancies Demystified: The Series 2012 Prime Oncology, Hollywood, FL, Chair, 2/2012

MD Anderson Cancer Center, Hematologic Malignancies 2012, Houston, TX, Chair and Organizer, 10/2012

MD Anderson Cancer Center, Medical Oncology and Hematology 2012: Clinical and Scientific Approaches that Enhance Patient Outcomes, Houston, TX, Chair and Organizer, 10/2012

Presentations at National or International Conferences

Invited

Discuss with FDA pivotal phase II-III studies with decitabine in MDS, FDA Pharmachemie, Bethesda, MD, 8/4/1998

Update of the treatment of acute myeloid leukemia and myelodysplastic syndrome, Ninth Alabama Cancer Congress, Destin, FL, 10/10/1998

Leukemia Company, Immunex Meeting – Discussion: common studies in leukemia, Seattle, WA, 10/28/1998

Treatment of relapsed and refractory ALL, American Society of Hematology Annual Meeting, Education Program, Miami Beach, FL, 12/1/1998

To discuss the development of ribonucleotide reductase inhibitor, FMdC Advisory, Dallas, TX, 1/22/1999

ALL-Hyper CVAD regimen and molecular pathophysiology, M.D. Anderson Leukemia Symposium - Middle East Medical Association (MEMA), Beirut, Lebanon, 4/25/1999

CML – post IFN-a novel strategies, American University of Beirut Alumin Club-Gold Medal Award Congres Oncologie du Moyen-Orient (COMO), Beirut, Lebanon, 4/25/1999

Developing TPO, Pharmacia & UpJohn, Chicago, IL, 6/3/1999

New strategies in the management of acute leukaemias and myelodysplastic syndromes, Global Pharmaceuticals-Myeloid Leukemia Global Advisory Board- Fourth Congress of the European Haematology Association, Barcelona, Spain, 6/7/1999

ALL Treatment; Treatment of CML, 25th Anniversary of the Hematology Department, Mexico City, Mexico, 8/25/1999

CML, Chemotherapy Foundation Symposium XVI, New York City, NY, 11/11/1999

Current Trends in the Management of CML, Including Treatment with Intron-A, Grand Rounds, Newark, NJ, 1/27/2000

AML/CML – ASH Update, Latest Progess, Update on Hematological Malignancies and Multiple Myeloma, Little Rock, AR, 3/17/2000

Current Approaches and Novel Strategies in Acute and Chronic Leukemias, 3rd Pan Arab Cancer Congress, Beirut, Lebanon, 4/25/2000

Victories, deceptions and hopes, 5th Middle East Oncology Congress, Beirut, Lebanon, 4/1/2001

Novel molecularly targeted anti-leukemic agents in Oncohematology, Seminar Oncologia Ed Ematologia, Milan, Italy, 4/6/2001

Views on research, progress and hopes for the future of blood cancers, Special Hearing of the Subcommittee on Labor, Health and Human Services, Education and Related Agencies, of the Committee on Appropriations, 6/19/2001

Gleevec (imatinib mesylate) induced Hematologic and Cytogenetic Responses Confirmed and Expanded in Patients with Chronic Myeloid Leukemia (CML) – A Phase II Study Update, American Society of Hematology Annual Meeting, Orlando, FL, 12/6/2001

Understanding Myelodysplastic Syndromes: A Primer for the Practicing Hematologist, The Myelodysplastic Syndromes Foundation. ASH Satellite, 12/7/2001

Tyrosine Kinase Inhibitors: CML as a Successful Model, Southern Illinois University, Cancer 2002: Advances in Research, Diagnosis, Prevention & Treatment, 1/1/2002

Pre-Application Consultation Specialized Programs of Research Excellence (SPOREs), Washington, DC, 2/8/2002

Controversies in the Management of CML, Newport Beach, CA, 2/21/2002

Chronic Myelogenous Leukemia, Second Annual Rush Review, Chicago, IL, 2/23/2002

Acute Leukemias: Current Recommendations, The 37th Middle East Medical Assembly, Beirut, Lebanon, 5/4/2002

Chronic Myeloid Leukemia: Present and Future Directions, The 37th Middle East Medical Assembly, Beirut, Lebanon, 5/4/2002

New Agents in Myeloid Leukemia, 7th Annual Meeting of the European Haematology Association, Florence, Italy, 6/6/2002

Innovations in Adult ALL, Palazzo dei Congress, Lugano, Switzerland, 6/11/2002

State-of-the-Art Treatment of the Adult Patient with AML, 12th Annual Hematology/Oncology Reviews, Mayo Clinic, Amelia Island, FL, 8/7/2002

Decitabine in Myeloid Leukemias, Leukemia 2002: Towards the Cure, Miami, FL, 9/19/2002

Innovations in Adult Acute Lymphocytic Leukemia (ALL), Leukemia 2002: Towards the Cure, Miami, FL, 9/20/2002

AML, 44th Annual Meeting of the American Society of Hematology, Education Program Session, Philadelphia, PA, 12/7/2002

New Agents in AML, 44th Annual Meeting of the American Society of Hematology, Education Program Session, Philadelphia, PA, 4/29/2003

Update on ALL, First Mediterranean CML Forum, Beirut, Lebanon, 4/29/2003

Update on AML, First Mediterranean CML Forum, Beirut, Lebanon, 4/29/2003

Clinical studies with clofarabine in adult acute leukemia, 8th Congress of the European Haematology Association, Lyon, France, 6/12/2003

Innovation in the Management of AML and ALL, 9th Congress of the European Hematology Association, Satellite Symposium: The M.D. Anderson Cancer Center approach to patients with hematologic malignancies, Geneva, Switzerland, 6/10/2004

Novel strategies in CML, including high-dose Imatinib and combinations, 9th Congress of the European Hematology Association, Targeted Therapies in Hematology – CML and New Areas, Geneva, Switzerland, 6/10/2004

High dose imatinib, Imatinib combinations, New SCT approaches, New agents (AML107, BMS35428), 2nd Mediterranean CML Forum, Beirut, Lebanon, 7/3/2004

Philadelphia chromosome positive ALL. M. D. Anderson experience and review of the world experience, 2nd Mediterranean CML Forum, Beirut, Lebanon, 11/19/2004

“Presidential Symposium” and Session: Chronic myeloid leukemia – therapy with TKI,” and Speaker “AML – Risk adapted therapy II”, East and West Together, Leukemia and Lymphoma Society, Dubrovnik, Croatia, 9/15/2007

Kantarjian H, Cortes J. Imatinib-resistant chronic myeloid leukemia. Definitions and management, 16th Congress of the European Hematology Association, London, United Kingdom, 6/10/2011

"Symposium AML." Developmental Therapeutics in AML, Leukemia and Lymphoma; East and West are Together, MD Anderson Cancer Center and Clinical Hospital Center Zagreb, Dubrovnik, Croatia, 9/17/2011

"Symposium MDS." Developmental Therapeutics in MDS, Leukemia and Lymphoma; East and West are Together, MD Anderson Cancer Center and Clinical Hospital Center Zagreb, Dubrovnik, Croatia, 9/17/2011

The Cure of Chronic Myelogenous Leukemia..Almost, Scripps Clinical Hematology & Oncology 2012, San Diego, CA, 2/19/2012

What is New in Acute Lymphoblastic Leukemia, Scripps Clinical Hematology & Oncology 2012, San Diego, CA, 2/19/2012

Elderly AML: A continuous challenge, 2012 Hematology Forum: Improving Patient Outcomes Across the Spectrum of Hematologicc Malignancies, Prime Oncology, Beirut, Lebanon, 4/20/2012

Treatment of high risk MDS, 2012 Hematology Forum: Improving Patient Outcomes Across the Spectrum of Hematologicc Malignancies, Prime Oncology, Beirut, Lebanon, 4/20/2012

Front line therapy for CML, 2012 Hematology Forum: Improving Patient Outcomes Across the Spectrum of Hematologicc Malignancies, Prime Oncology, Beirut, Lebanon, 4/21/2012

New approaches in acute lymphoblastic leukemia therapy, 2012 World Congress of Hematology, International Society of Hematology and Agrupacion Mexicana para el Estudio de la Hematologia, Cancun, Mexico, 4/28/2012

Chair and Lecturer. Drug Shortages: Why Is This Happening and How Can We Treat Our Patients?, 47th Annual Meeting of the American Society of Clinical Oncology, American Society of Clinical Oncology, Chicago, IL, 6/3/2012

Update on the Satus of Drug Shortages, Causes, and Trends, 47th Annual Meeting of the American Society of Clinical Oncology, American Society of Clinical Oncology, Chicago, IL, 6/3/2012

Lessons from CML: How Applying Targeted Therapy to Newly Diagnosed Disease Transformed Outcomes, 47th Annual Meeting of the American Society of Clinical Oncology, American Society of Clinical Oncology, Chicago, IL, 6/4/2012

CML:Making a Choice Between Imatinib, Nilotinib and Dasatinib? Update on their Relative Advantages and Toxicities, Innovative Cancer Therapy for Tomorrrow; The Greenspan Meeting XXX, Chemotherapy Foundation Symposium, New York City, NY, 11/7/2012

Other, Including Scientific Exhibitions

Intensified Cyclophosphamide in Adult ALL, Medical Programs Inc., Memorial-Sloan Kettering, San Juan, PR, 4/15/1999

Medical Oncology – State of the Art II, Network for Medical Communication & Research, Atlanta, GA, 9/22/2000

Challenging Cases in Patient Management, Network for Medical Communication and Research, Atlanta, GA, 10/21/2000

Seminar Invitations from Other Institutions

CLL, ALL, CLL, George Washington University, Washington, DC, 10/16/1998

Investigational Strategies in Leukemia: How do we make progress?, St. Elizabeth's Medical Center, 1/1/1999

Adult Acute Lymphocytic Leukemia: Current Status and New Approaches, Mt Sinai Hospital, New York, NY, 1/27/1999

28th Annual Dr. William Dameshek Symposium, Update on Acute Leukemia, Christi Regional Medical Center, Wichita, KS, 5/20/1999

Decitabine development by NCI/FDA, Pharmachemie-Netherlands, Bethesda, MD, 6/13/1999

CML-Recent Advances, Christus St. John Hospital and Shoreline, Corpus Christi, TX, 6/23/1999

Acute Myeloid Leukemia -Victories, Deceptions, and Hopes. Fifth Middle East Oncology Congress, Unesco Palace, Beirut, Lebanon, 4/25/2001

STI571 – Clinical results in Ph+ leukemias, Signal Transductions Inhibition (STI571): A New Standard in Oncology, Wayne State University, San Francisco, CA, 5/11/2001

Challenging Cases in Malignant Lymphoma and Leukemia, Maui, HI, 6/10/2001

Myelodysplasia, Challenging cases in hematology Pan Pacific Lymphoma Conference, The University of Nebraska, Maui, HI, 6/19/2001

State of the art treatment in CML, May Clinic, 8/15/2001

Gleevec for CML, University of Oklahoma Health Science Center, 8/22/2001

Hematology/Medical Oncology Board Review, Chronic Myeloid Leukemia & Acute Lymphocytic Leukemia, The George Washington University, Arlington, VA, 10/10/2001

CML a New Treatment Paradigm, B-Cell Malignancies and Chronic Leukemias: Adances in Biology, The Fox Chase Cancer Center, Philadelphia, PA, 10/26/2001

Controversies in the Management of CML. Is Imatinib Mesylate or SCT the Therapy of Choice for De Novo CML Patients?, Wayne State University, Orlando, FL, 12/7/2001

Understanding Myeloplastic Syndromes: A Primer for the Practicing Hematologist, Wayne State University, Orlando, FL, 12/7/2001

A New Paradigm in the Treatment of CML, Advances in the Treatment of Hematological Malignancies, Hackensack University Medical Center, Hackensack, NJ, 4/26/2002

CML State of the Art, Mt. Sinai Medical Center, New York City, NY, 6/24/2004

Novel approaches in AML and MDS, Memorial Sloan Kettering Cancer Center, New York City, NY, 6/25/2004

Update on AML and MDS, NYU Medical Center, New York City, NY, 6/25/2004

Chronic myelogenous leukemia – what's new., The Winship Cancer Institute of Emory University S, 7/17/2004

What is new in AML, MDS and CML, Cleveland Cancer Center, Cleveland, OH, 2/16/2005

Insights into the molecular biology of acute leukemia & the implications for treatment, San Diego, CA, 2/19/2005

Is CML a curable malignancy without transplantation?, San Diego, CA, 2/19/2005

Lectureships and Visiting Professorships

N/A

Other Presentations at State and Local Conferences

Foundations of Clinical Cancer Research Symposium, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 3/1/2001

The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/7/2001

Department of Nuclear Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 5/20/2003

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American Medical Association
Member, 1/1985−present

American Association for Cancer Research
Member, 1/1990−present

American Association for the Advancement of Sciences

Member, 1/1991−present

American Society for Hematology
member, 1/1992−present

American Society for Clinical Oncology
member, 1/1995−present

Association of American Physicians
Member, 2004

American Society of Clinical Oncology, Alexandria, VA
Member - Leukemia, Myelodysplasia and Transplantation Track on the Cancer Education Committee, 6/2008−6/2011

International Association for Comparative Research on Leukemia and Related Diseases, Mannheim, Germany
Member of the Nominating Committee, 2/2010−present

Local/State
Texas Medical Association

UNIQUE ACTIVITIES

1. First report of high-dose ara-C clinical and cellular pharmacokinetics in AML (AJM 81: 387, 1986).
2. First report of the efficacy of high-dose ara-C in lymphoma (JCO 1: 689, 1983)
3. First report of in vivo differentiation of APL with chemotherapy (JCO 3: 793, 1985)
4. Co-discovery (with Dr. Moshe Talpaz) of the activity of interferon alpha in CML and of the independent association of complete cytogenetic response with improved survival (NEJM 314: 1065, 1986; Ann Int Med 122: 254, 1995; Cancer 97: 1033, 2003).
5. First studies of IFN + ara-C combinations in CML (JCO 10: 772, 1992)
6. First report of the efficiency of adenosine nucleoside analogues in Waldenstrom disease (Blood 75: 1988; 1990; Ann Int Med 118: 195, 1993)
7. Major participation in original fludarabine studies in CLL and other lymphoproliferative disorders, with Dr. Michael Keating (Blood 74:19, 1989; Sem in Onc 17:66, 1990; AM J Med 90: 223, 1991; Blood 92: 1165, 1998.
8. Discovery of the efficacy of topotecan in AML/MDS, and development of topotecan + ara-C regimens (Blood 81: 1146, 1993; JCO 17: 2819, 1999; Blood 88: 2473, 1996)
9. Discovery of the activity of homoharringtonine and decitabine in CML (Cancer 63: 813, 1989; Leukemia 11:1617, 1997; Blood 93: 4149, 1999)
10. Development of a new adenosine nucleoside analogue, clofarabine, and discovery of its activity in AML {JCO 21: 1167, 2003; Blood 102 (7): 2379-86, 10/2003; Clin Cancer Res 9 (17): 6335-42, 12/2003; Blood 103 (3): 784-9, 2/2004; Blood 105 (3): 940-7, 2/2005; Blood 108 (1): 45-51, 7/2006; Blood 112 (5): 1638-45, 9/2008; JCO 28 (4): 549-555, 2/2010} Through these research efforts, clofarabine received FDA approval for the treatment of pediatric leukemia in 2006. Continued development in AML and MDS.
11. Major participation in the phase I-II studies of imatinib in CML. First report of the phaase II activity of imatinib in CML post IFN failure (NEJM 344: 1038, 2001; NEJM 344: 1031, 2001; NEJM 346: 645, 2002; Clin Can Res 8: 2177, 2002; Clin Can Res 8: 2167, 2002; Blood 101: 97, 2003. Imatinib received FDA approval for CML treatment post interferon failure based on these studies. It also received frontline CML therapy approval.
12. Contribution to the discovery of the activity of imatinib in hypererosinophilic syndrome, and of the pathophysiologic of HES (NEJM 348: 1201, 2003; Leuk Res 26: 881, 2002).
13. Development of the “Hyper CVAD” regimen which is now one of the standards of cure in adult ALL, and has shown activity in lymphoblastic lymphoma, mantle cell lymphoma and multiple

myeloma (JCO 18:547, 2000).

14. Discovery of the activity of decitabine in AML and MDS. {Blood 103 (5): 1635-40, 3/2004; Cancer 106 (8): 1794-803, 4/2006; Blood 109 (1): 52-57, 1/2007; Cancer 109: 1133-1137, 2/2007} Decitabine received FDA approval for the treatment of MDS in 2006 based on the work led by Dr. Kantarjian.
15. Leading and championing the studies with second generation TKIs (dasatinib; nilotinib) {N Engl J Med 354 (24): 2531-41, 6/2006; N Engl J Med 354 (24): 2542-51, 6/2006; Blood 109: 5143-5150, 2/2007; Blood 109 (6): 2303-9, 3/2007; Through these efforts both agents were approved for the treatment of CML post imatinib failure. Leading randomized trials in frontline CML therapy resulted in their FDA approval for frontline CML therapy. {Blood 110 (10) 3540-3546, 2007; JCO 26 (19): 3204-12, 7/2008; Cancer 115 (18): 4136 - 4147, 9/2009; JCO 28 (3): 392-397; JCO 28 (3): 398-404, 1/2010; N Engl J Med 362 (24): 2260 - 70, 6/2010; N Engl J Med 362 (24): 2251 - 9, 6/2010}

DATE OF LAST CV UPDATE

11/11/2013